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Discovery of prognostic biomarkers from the prostate cancer 
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The link between aberrant glycosylation and cancer progression has formed the basis for 
detection of cell surface glycans and glycoproteins in the clinical management of cancer. 
However, the utility of biomarkers has been challenged in recent years due to low cancer 
specificity and high false-positive rates. The aim of this study was to use synthetic precursors 
of sialic acid and N-acetylgalactosamine that had been labelled with an azide group (N-
azidoacetylmannosamine (Ac4ManNAz) and N-azidoacetylgalactosamine (Ac4GalNAz)), and 
which are incorporated biosynthetically into cell surface glycans, to monitor changes in cell 
surface glycosylation in models of prostate and breast cancer progression, in order to 
identify novel biomarkers. 
 
A panel of human prostate, breast and pancreatic cancer cell lines was used, which 
represented the stages of cancer progression. The metastatic potential of the established 
prostate and breast cancer cell lines used in the study was confirmed in the scratch wound 
and Boyden chamber assays and by demonstrating a correlation with increased expression 
of vimentin, loss of PTEN expression, and decreased E-cadherin expression. Collectively, the 
data validated the panels as suitable in vitro models of prostate and breast cancer 
progression.  
 
Global azidosugar labelling of glycoproteins and glycolipids was detected by NeutrAvidinTM 
DyLightTM 650 (NA650) fluorescence using flow cytometry. Azidosugar labelling of 
glycoproteins was detected by Alkyne-Alexa Fluor 488 fluorescence using 1D gel 
electrophoresis, and Streptavidin 800 fluorescence using 2D gel electrophoresis. An increase 
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in the overall NA650 fluorescence was seen across the breast cancer cell lines using flow 
cytometry. An increase in the overall Alexa-488 fluorescence on 1D gels and Streptavidin-
800 fluorescence on 2D gels was seen across the prostate, breast, and pancreatic cancer cell 
lines. A general increase in azidosugar-specific sialylation (Ac4ManNAz) and N-
acetylgalactosamine (Ac4GalNAz) glycosylation was associated with an increase in metastatic 
potential. Proteomic analysis of the prostate cancer cell lines revealed that Basigin (CD147) 
glycosylation, which showed a strong increase in Ac4ManNAz and Ac4GalNAz labelling, 
correlated with an increase in metastatic potential, despite its total expression decreasing 
across the panel of prostate cancer cell lines. 
 
In summary, we have demonstrated the use of bioorthogonal chemistry for detecting 
differential sialyation and N-acetylgalactosamine glycosylation of proteins from human cell 
lines that represent the progression of cancer. Our data suggest that differential 
glycosylation may be a more sensitive and specific marker for monitoring prostate and 
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Ac4GalNAz Peracetylated N-azidoacetylgalactosamine 
Ac4ManNAz Peracetylated N-azidoacetylmannosamine 
AFP Alpha fetoprotein 
AFP-L3 Abberantly fucosylated alpha fetoprotein 
Asn Asparagine 
CA15-3 Cancer antigen 15-3  
CEA Carcinoembryonic antigen  
CT Computerised tomography   
EBL Elderberry bark lectin 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
FBS Foetal bovine serum  
Fuc Fucose  
Gal Galactose  
GalNAc N-acetyl-galactosamine 
Glc Glucose 
GlcA Glucuronic acid 
GlcNAc N-acetyl-glucosamine 
H&E Hematoxylin and eosin  
HER 2 Human epidermal growth factor receptor 2  
HPA Helix pomatia agglutinin   
HRP Horseradish peroxidase  
KC p48Cre; LSL-KrasG12D 
LCA 
LCMS 
Lens culinaris agglutinin lectin  






MAL I Maackia amurensis lectin 
Man Mannose  
MRI Magnetic resonance imaging 
MUC1 Mucin 1, cell surface associated 
NA650 NeutrAvidinTM DyLightTM 650  
NeuAc N-acetylneuraminic acid 
NSAF Normalised Spectral Abundance Factor 
PanIN Intraepithelial neoplasia  
PBS Phosphate Buffered Saline  
PDA Pancreatic ductal adenocarcinoma  
PET Positron-emission tomography  
PNGase F Peptide N-glycosidase F 
PSA Prostate specific antigen 
PSMA Prostate-specific membrane antigen  
PTEN Phosphatase and tensin homolog  
Ser Serine 
SLeA Sialyl Lewis A antigen 
SLeX Sialyl Lewis X antigen 
SNA Sambucus Nigra Lectin 
SPECT Single-photon emission imaging  
STI Soybean trypsin inhibitor  
T Thomsen-Friedenreich antigen  
Thr Threonine 
TMDIBO Tetramethoxydibenzocyclooctyne 
Tn Thomsen-nouveau antigen  
TRIS-HCL Tris hydrochloride 
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Chapter 1: Glycans and cancer 
 
 
1.1 The global burden of cancer 
 
1.1.1 The global burden of cancer 
 
Trends in cancer-related morbidity (Fitzmaurice et. al. 2015) and mortality worldwide, 
highlight cancer as a threat to public health. Neoplasms were the third leading cause of 
deaths globally in 1990, after cardiovascular disorders, infections, and parasitic diseases 
(Murray et. al. 1997). Neoplasms accounted for 5.7 million deaths in 1990, 8.2 million deaths 
in 2013, and 9.9 million deaths in 2016 (Naghavi et. al. 2015; Foreman et. al. 2018). The 
number of global cancer deaths is forecasted to rise to 14.9 million by 2040 (Foreman et. al. 
2018). A surge in the incidence of age-related cancers, such as prostate and breast cancers, 
is also anticipated due to increasing life expectancy, an aging population, and the association 
between cancer risk and age (Cook et. al 1969). For example, the global incidence of 
prostate cancer increased by 217% between 1990-2013 (Fitzmaurice et. al. 2015; Drudge-
Coates et. al. 2018), although this trend has been associated with increases in the use of 
prostate specific antigen (PSA) testing and the incidental detection of tumours in patients 
undergoing a transurethral prostatectomy for the treatment of benign prostatic hyperplasia 
(Potosky et. al. 1990, Zhou et. al. 2016). In the UK alone, prostate and breast cancers account 
for the greatest proportion of cancer cases in males and females, respectively (Smittenaar 




Figure 1.1: Total number of cancer cases recorded in the UK in 1993, 2014 and forecasted 
for 2035, divided by organ site, and gender. (Figure taken from Smittenaar et. al. 2016).  
 
 
Several epidemiology studies have identified a link between unhealthy dietary patterns and 
cancer risk (Grosso et. al. 2017). Therefore, the projected increases in global cancer 
incidence and mortality, have been attributed to the prevalence of cancer-associated risk 
factors. Without intervention, high blood pressure is forecast to be the leading risk factor 
contributing to poor health outcomes in 2040, followed by a high body mass index, high 
fasting plasma glucose, tobacco, alcohol use, ambient particulate matter, and high total 
cholesterol (Foreman et. al. 2018). In response to the rising incidence of cancer in Europe 
(Quinn et. al. 2003; Naghavi et. al. 2015), the European Code Against Cancer was created to 
influence dietary habits across the EU and minimise population exposure to avoidable risk 
factors (Boyle et. al. 2003) (Figure 1.2). In the UK alone, tobacco smoking and obesity have 
been identified as the most preventable causes of cancer (Brown et. al. 2018). 
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Figure 1.2: The European code against cancer. (Figure taken from The World Health 
Organization, 2019, and Boyle et. al. 2003). 
 
 
Overall, cancer incidence and mortality continue to increase worldwide, a trend accelerated 
by rising life expectancy, an ageing population, and exposure to cancer-associated risk 
factors (Smittenaar et. al. 2016). 
 
 
1.1.2 Reducing the burden of cancer with precision oncology and glycomics 
 
Screening in disease prevention remains a priority for policymakers, to improve the early 
detection of cancer, and offset the grave increases in cancer incidence observed worldwide 
(Shieh et. al. 2016; Schröder et. al. 2009; Foreman et. al. 2018) (Figure 1.3). Furthermore, 
non-imaging-based screening programmes have reduced the incidence of colorectal cancer, 
such as the faecal occult blood test, which screens healthy individuals aged over 50 for blood 
in the faeces (Duffy 2012). Prevention with the Human Papilloma Virus vaccine has also been 




Figure 1.3. The impact of population-based screening on cancer incidence in the USA. 
Annual incidence rates of selected cancers in individuals aged over 50, between 1975-2012, 
were collated from the Surveillance, Epidemiology, and End Results registry. The 
implementation of routine screening programmes associated with each cancer type is 
represented (black lines). A reduction in the incidence of cervical and colorectal cancers are 
associated with the implementation of cervical cytology and the faecal occult blood test, 
respectively (Figure taken from Shieh et. al. 2016). 
  
 
Whilst public health interventions have improved cancer detection and prevention, 
advancements in precision molecular oncology are furthering improvements in cancer 
outcomes. Molecular medicine is “a branch of medicine that develops ways to diagnose and 
treat disease by understanding the way genes, proteins, and other cellular molecules work” 
(National Cancer Institute Dictionary of Cancer Terms, 2019). Precision oncology, involves 
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using patients biological, genetic and clinical information, to individualise clinical 
interventions, and treatment regimens (Biankin 2017). The rise of the “omics” revolution has 
expanded the field of precision oncology by exploiting our understanding of the role of 
biomolecules in cancer such as DNA (genomics), gene expression (transcriptomics), 
epigenetic mutations (epigenomics), protein expression (proteomics), and metabolism 
(metabolomics) (Epstein and Lin 2017). 
 
The impact of “omics” research on precision oncology and disease outcomes can be 
illustrated through the development of immunotherapy, which specifically targets molecules 
unique to cancer cells to block or slow their proliferation and spread (Lee et. al. 2018). 
Trastuzumab is a monoclonal antibody, which targets human epidermal growth factor 
receptor 2 (HER2), a protein receptor overexpressed in breast cancers (Lee et. al. 2018). 
Breast cancer patients receiving anti-HER2 trastuzumab, are first tested for the presence of 
HER2 overexpression or HER2 gene amplification using a Food and Drug Administration 
(FDA)-approved multiple gene expression diagnostic assay called Oncotype DX (Schmidt et. 
al. 2016). Administering trastuzumab specifically in HER2 positive patients has been shown 
to provide optimal treatment response, reduce time to disease progression, and improve 
survival (Schmidt et. al. 2016). Next-generation sequencing has also been used to improve 
drug prescription guidelines by identifying gene mutations associated with drug toxicity. For 
example, leukaemia patients being treated with thiopurine based chemotherapies, receive 
up to a 90% dose reduction if they express a mutant thiopurine-S-methyl transferase, which 
has reduced thiopurine metabolism activity (Bainkin 2017). 
 
Glycomics is the study of glycans, carbohydrates covalently attached to proteins or lipids, 
within cells and tissues, and their variation during biological events such as development and 
disease (Bertozzi and Sasisekharan 2009; Bennun et. al. 2016). Cancer glycomics involves the 
use of technologies such as mass spectrometry, glycan-binding lectin and antibody arrays, 
carbohydrate stains, enzymatic cleavage, metabolic labelling techniques, and genetic 
mutation models, to study the structure, distribution, abundance, and function of glycans in 
cancer (Springer and Gagneux 2016). This field of research has contributed towards a 
growing body of evidence implicating glycosylation as a vital driver in tumourigenesis 
(Christiansen et. al. 2014). Collaborative organisations such as the Consortium for Functional 
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Glycomics (CFG), and the National Cancer Institute’s (NCI) Alliance of Glycobiologists, have 
been created to advance our understanding of glycan biology to improve precision oncology 
(Hart and Copeland 2010). 
 
This chapter will review the role of glycans in cancer, and their utility in promoting precision 
oncology through biomarker discovery, and molecular imaging. 
 
 
1.2 Glycans in health and disease 
 
1.2.1 Glycan structure, diversity and biosynthesis 
 
Glycans are the complex carbohydrate structures formed when monosaccharides link 
together via glycosidic bonds. These monosaccharides are glucose (Glc), N-acetyl-
glucosamine (GlcNAc), Galactose (Gal), N-acetyl-galactosamine (GalNAc), Mannose (Man), 
Xylose (Xyl), Glucuronic acid (GlcA), Fucose (Fuc) and N-acetylneuraminic acid (NeuAc), also 
known as sialic acid (Prestegard and Widmalm, 2017).  As with proteins and nucleic acids, 
diversity in carbohydrate structures is conferred by the composition of monosaccharide 
units and their sequences. However, monosaccharides, unlike amino acids and nucleotides, 
are unique due to their ability to bond at different carbon positions, and in linear or 
branched forms (Seeberger 2017; Prestegard and Widmalm, 2017). D-sugars can link via α-
glycosidic bonds where the OH group on the anomeric carbon is below the plane of the 
monosaccharide ring, or via β-glycosidic bonds where the OH group on the anomeric carbon 
is above the plane of the monosaccharide ring (Seeberger 2017; Prestegard and Widmalm, 
2017). Additional layers of complexity exist by the covalent attachment of chemical groups 
to glycan structures such as sulphates, phosphates, and acetyl groups (Seeberger 2017). 
Furthermore, monosaccharides can conjugate to acyl (non-sugar) groups within proteins or 
lipids that are embedded in the cell membrane or secreted. This gives rise to the different 
classes of glycoconjugates, which are the glycoproteins, glycolipids, glycosphingolipids, 





Figure 1.4: Common classes of glycoconjugates in mammalian cells. Schematic 
representations of the structures of proteoglycans, N-glycans, O-glycans, glycosphingolipids, 
and proteoglycans. Within the glycoproteins, subclasses are defined by the amino acid upon 
which the glycan structures are installed. The synthesis of the N-glycans involves the binding 
of N-acetylglucosamine to asparagine residues within the target polypeptide chain via an 
amide side chain. The synthesis of the O-glycans involves the covalent addition of carbon 1 in 
N-acetylglucosamine to serine or threonine residues via a hydroxyl group. Core structures 
conserved within each class of glycoconjugates are highlighted (red perforated box). 
Abbreviations: serine (Ser), asparagine (Asn), and threonine (Thr). (Author diagram). 
 
 
The majority of mammalian glycoconjugates are synthesised de novo by assembly through 
the Endoplasmic reticulum (ER)-Golgi secretory pathway. The enzymes responsible for 
processing the glycosidic linkages between monosaccharides and target conjugates include 
the glycosyltransferases and glycosidases (Ghazarian et. al. 2011). By segregating the 
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location of glycoenzymes in different cell compartments, glycosylation occurs in a 
sequential, and non-templated fashion (St. Amand et. al. 2014). 
 
The synthesis of the N-glycan's (Stanley et. al. 2017) is initiated by the ER-resident enzyme 
UDP-GlcNAc dolichol phosphate N-acetylglucosamine-1-phosphate transferase, which 
transfers N-acetylglucosamine-phosphate (GlcNAc-1-P) to dolichol phosphate (Dol-P), to 
generate dolichol pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc). Thirteen 
monosaccharides are transferred sequentially to Dol-P-P-GlcNAc by glycosyltransferases, to 
generate a mature 14-sugar (Glc3Man9GlcNAc2) dolichol pyrophosphate precursor (Stanley 
et. al. 2017; Lowe and Marth 2003) (Figure 1.5a). The oligosaccharyltransferase complex 
embedded within the ER membrane facilitates the transfer of Glc3Man9GlcNAc2 from the 
dolichol pyrophosphate precursor to select asparagine (Asn) residues within growing 
polypeptide chains (Schedin-Weiss et. al. 2014). Glucose is trimmed from Glc3Man9GlcNAc2-
Asn by ER-resident glucosidases, generating the high mannose N-glycans (class I) (Nagae and 
Yamaguchi, 2012) (Figure 1.5b). Sequential trimming and monosaccharide extension events 
throughout the medial and trans Golgi, generate the hybrid (class II) and complex 
multiantenna N-glycan's (class III) (Nagae and Yamaguchi, 2012) (Figure 1.5b). The trimming 
and re-addition processing events are vital for protein folding in the ER and quality control in 
















Figure 1.5. The synthesis of the N-glycans. Schematic representations of key structures 
generated during N-glycan synthesis. (a) Glc3Man9GlcNAc2 from the mature 14-sugar dolichol 
pyrophosphate precursor is transferred (dotted lines) to select asparagine residue within 
growing polypeptide chains translocating into the ER lumen from the cytoplasm. This transfer 
is facilitated by the oligosaccharyltransferase complex embedded within the ER 




pathway generate the three types of N-glycan. A core structure, composed of two N-
acetylglucosamine and three mannose residues, is conserved across all N-glycans. 
Abbreviations: Ser = Serine, Asn = Asparagine, Thr = Threonine. (Author diagram). 
 
 
The synthesis of the O-glycan's (Brockhausen and Stanley, 2017) can occur through multiple 
pathways, which can be initiated by modification of serine and threonine residues with N-
acetylgalactosamine, fucose, glucose or mannose. The pathway responsible for generating 
the most highly abundant subset of O-glycan’s called the Core 2 O-glycan’s (Figure 1.4, red 
perforated box), involves the installation of N-acetylgalactosamine onto specific serine and 
threonine residues, by one of several polypeptide N-acetylgalactosamine transferases (Lowe 
and Marth 2003). In the Golgi, the polypeptide chains are extensively modified by branch-
specific glycosyltransferases and sulfotransferases, which is distinct from the glycoside-
mediated modifications that occur with the N-glycans (Lowe and Marth 2003). The synthesis 
of the mucin-type-O-glycans is predominantly localized to the Golgi, which enables their 
synthesis without the need for glycosidase-dependent trimming events (Haltiwanger and 
Lowe 2004). 
 
The synthesis of the glycolipids involves the addition of glucose or galactose to ceramide 
embedded in the plasma membrane, which is mediated by glucosylceramide synthase or 
galactosylceramide synthase, respectively (Lowe and Marth 2003). In contrast to the 
microheterogeneity of glycoproteins, the glycosphingolipids carry only one single glycan 
chain (Kopitz 2017). Glucosylceramide or galactosylceramide synthesised in the cytosol are 
then elongated by glycosyltransferases throughout the Golgi. 
 
The terminal ends of the glycoconjugates are further modified in the trans Golgi with the 
addition of other monosaccharides such as sialic acid by sialyltransferases, and fucose by 
fucosidases (Schedin-Weiss et. al. 2014). After release from the Golgi, glycoconjugates are 
embedded within the cell membrane, packaged into lysosomes or packaged into secretory 
granules for secretion (Colley et. al. 2017). Such diversity in localisation and structure is 
incredible given that this co-translational and post-translational modification is not genome 
encoded and based on only ten monosaccharides (Ghazarian et. al. 2011). For example, 
 11 
within a single polypeptide, multiple asparagine, serine, and threonine residues are available 
for glycan installation. This can occur at different positions, across different polypeptides, at 
any given time, illustrating the complexity of glycoproteins. The glycome remains the most 
diverse universal characteristic of all living cells (Varki et. al. 2017). 
 
 
1.2.2 Glycan function 
 
Glycan structures are widely distributed at the cell surface and within the extracellular 
matrix, making them abundant contact sites for inter and intraspecies cellular recognition 
and communication (Varki et. al. 2017).  
 
Intrinsically, glycan structures can be recognised by glycan-binding proteins called galectins 
(Cummings et. al. 2017). These interactions are vital for mammalian carbohydrate-
dependent regulation of intracellular signalling, glycoprotein endocytosis, quality control in 
the ER, and targeting of glycoconjugates to intracellular compartments through the 
secretory pathway (Moremen et. al. 2012). For example, galectin 4-dependent recognition of 
N-glycosylated neural adhesion molecule L1, causes its sorting to and clustering at the axon 
membrane, a process vital for polarisation, elongation, and branching of mammalian 





Figure 1.6: N-glycosylation of neural adhesion molecule L1 is required for galectin-4 
mediated targeting to the axon membrane. In the Golgi, galectin 4 binds the N-glycosylated 
C-terminus of NCAM-L1. Galectin-4 then binds to glycosylated sphingolipids in the axon 
membrane, facilitating NCAM-L1 axon delivery. (a) Mammalian neurons expressing galectin 4 
exhibited NCAM-L1 (red) clustering throughout the axon membrane (blue). (b) siRNA 
knockdown of galectin-4 severally impaired NCAM-L1 sorting to the axon membrane. 
Abbreviations: neural adhesion molecule L1 (NCAM-L1, in red), and acetylated tubulin (Ac. 
tubulin, in blue) (Figure taken from Higuero et. al. 2017). 
 
 
Differential glycosylation of glycoconjugates at any given time is required for regulating cell 
differentiation and development (Moremen et. al. 2012). For example, glycan-dependent 
variation amongst the ABO blood groups and stage-specific embryonic antigens (SSEAs) has 
been identified and extensively characterised using immunohistochemistry (Haltiwanger and 
Lowe 2004). Differentiation of plasmalemmal glycoconjugates has also been correlated with 
a.       b. 
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the development of epithelial cell types in the embryonic rat pancreas (Maylié-Pfenninger 
et. al. 1980). Furthermore, it is believed that extensive a1,2-fucosylation of pluripotent stem 
cells is the principal feature distinguishing them from differentiated cells (Berger et. al. 
2016).  
 
Sialic acid has been shown to have a specific role in the survival and regulation of hormones 
in the circulation. Enzymatically de-sialylated gonadotrophic hormones injected into mice 
were rapidly removed from circulation and recovered in the liver (Morell et. al. 1971). 
Subsequent studies attributed this to exposure of galactose residues following 
neuraminidase mediated de-sialyation, specific recognition of the exposed galactose 
residues by asialoglycoprotein receptors in the hepatocyte cell membranes, and endocytosis 
of the hormones for lysosomal degradation in the liver (Ashwell and Harford 1982). De-
sialylated hormones were also removed from the circulation by secretion into the bile 
(Ashwell and Harford 1982).  
 
Glycosphingolipids can regulate signal transduction by spontaneously forming lipid rafts, 
which complex with galectins and facilitate the topological organisation of proteins within 
the plasma membrane (Kopitz 2017) (Figure 1.6). Furthermore, studies have suggested that 
sialylated glycosphingolipids such as ganglioside 3, regulate epidermal growth factor 
receptor (EGFR)-tyrosine kinase signalling pathways by binding to N-acetylglucosamine 
resides decorating the extracellular face of EGFR (Todeschini and Hakomori 2008).  
 
Glycolipids and O-linked proteins at the surface of leukocytes, glycosylated with fucose and 
sialic acid, interact with glycan-binding selectins on the vascular endothelium, facilitating the 
migration of immune cells to sites of inflammation (Schnaar 2015). These interactions are 
exploited by some pathogens, notably viruses, through “molecular mimicry”, which enables 
pathogens to highjack mobile immune cells for the dissemination of infection, and immune 
evasion (Krasnova and Wong 2016; Varki et. al. 2017). 
 
Glycans also facilitate extrinsic interactions with chemical compounds, which has been 
studied extensively using clones of Chinese hamster ovary cell lines exhibiting defects in the 
pathways governing protein glycosylation. The 15B clone was isolated based its acquired 
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resistance to ricin, a cytotoxic galactose-binding lectin, and showed reduced plasma 
membrane glycosylation, and plant-lectin binding capacity (Gottlieb et. al. 1974). This 
phenotype was attributed to the absence of N-acetylglucosaminyltransferase, and its 
associated glycan structures, resulting in less of the galactose epitopes usually responsible 
for ricin sensitivity (Stanley et. al. 1975). 
 
In all, glycans act as cellular decorations with roles in intracellular signalling, hormone 
regulation, cell migration, plasma membrane structuring, immunity, host-pathogen 
recognition, and drug sensitivity (Pinho and Reis 2015; Varki 2017). 
 
 
1.2.3 Glycosylation in disease 
 
The synthesis of glycans and their associated functions are dependent on the dynamic 
interactions between glycoenzymes within a specific cell type. These dynamic interactions 
are sensitive to physiological and pathological changes (Reily et.al. 2019; Krasnova and Wong 
2016; Mariño et. al. 2010). Abnormal changes in the expression and degradation of 
glycoconjugates have been implicated in a variety of human diseases (Ohtsubo and Marth 
2006; Varki et. al. 2017). 
 
Aberrant N-glycosylation of Tau protein has been shown to increase its susceptibility to 
phosphorylation, generating the hyperphosphorylated variant responsible for the 
neurofibrillary tangles observed in Alzheimer pathology (Schedin-Weiss et. al. 2014). 
Decreased glycosylation of the anti-apoptotic protein a1 antitrypsin (AAT), which is secreted 
by hepatocytes and immune cells, is known to reduce its half-life, and anti-inflammatory 
properties in the circulation, leading to some chronic inflammatory conditions (McCarthy et. 
al. 2014). Altered N-glycosylation of scavenger receptor class BI (SR-BI) decreases its 
insertion within the plasma membrane of hepatocytes, subsequently reducing SR-BI 
mediated uptake of high-density lipoprotein cholesterol from the circulation (van den 
Boogert et. al. 2017). Therefore, aberrant glycosylation has been associated with an 
increased risk of cardiovascular disease. A rare paediatric Lysosomal Storage disease called 
Hurler syndrome is caused by a deficiency in α-L-iduronidase, leading to accumulation of 
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glycosaminoglycans in the lysosomes (Bie et. al. 2013). Osteoarthritis can result from 
degradation of aggrecan, a cartilage proteoglycan normally responsible for resisting 
compressive pressure (Huang and Wu 2008). Deficiencies in particular glycoenzymes have 
also been associated with the human congenital disorders of glycosylation (Freeze et. al. 
2015; Marques-da-Silva et. al. 2017).  
 
 
1.2.4 Aberrant glycosylation in cancer 
 
Aberrant glycosylation has been identified in several cancers (Stowell et. al. 2015). Changes 
in glycan expression can occur as a result of cancer-associated alterations in the expression 
of glycoenzymes and their location within the Golgi compartments, alterations to the 
tertiary conformation of peptide backbones and nascent glycan chains, as well as 
fluctuations in the abundance of acceptor substrates, sugar nucleotide donors and cofactors 
(Pinho and Reis 2015; Adamczyk et. al. 2012). Aberrant glycosylation can also be caused by 
incomplete synthesis of glycan structures, and neo-synthesis of glycan structures due to 
changes in the gene expression of carbohydrate determinants (Pinho and Reis 2015). The 
overall consequence is the generation of tumour-associated glycan patterns such as 
hypersialylation, aberrant fucosylation, glycan truncation, hyperbranching, and 





Figure 1.7: Cancer-associated glycans. Schematic representation of a subset of glycans 
found on tumour cells. Tumour-associated glycan patterns include hypersialylation, aberrant 
fucosylation, glycan truncation, hyperbranching, and overexpression of glycosphingolipids. 
Tumour-specific modifications within the glycoproteins are highlighted (grey perforated box). 
Abbreviations: serine (Ser), asparagine (Asn), and threonine (Thr) (Author diagram). 
 
 
Sialyl Lewis X (SLeX) and sialyl Lewis A (SLeA) are a set of Lewis type blood group antigens, 
which are overexpressed in cancer (Natoni et. al. 2016; Pinho and Reis 2015) (Figure 1.8a). 
Under normal conditions, glycoconjugates containing SLeX and SLeA act as ligands for 
calcium-dependent receptors called selectins, which are present on the cell surface of 
endothelial cells, red blood cells and leukocytes. The interaction of selectins with the Lewis 
antigens facilitates adhesion and migration of activated platelets to physiologically 
perturbed sites in inflammation (Pinho and Reis 2015). Expression de novo of SLeX and SLeA 
on mucins and glycosphingolipids at the tumour cell surface enhances the ability of tumour 
cells to adhere to the vasculature (Figure 1.8b). This process is vital for tumour dissemination 
through the bloodstream, formation of emboli at distant endothelial sites and metastasis 






Figure 1.8: The Sialyl Lewis antigens promote tumour progression. (a) Schematic 
representation of the Sialyl Lewis X (SLeX) and sialyl Lewis A (SLeA) antigens. (b) Selectins 
expressed on endothelial cells (E-selectin), activated platelets (P-selectin) and host leukocytes 
(L-selectin) specifically bind glycan receptors on the surface of tumour cells containing SLeX 
and SLeA. These glycan specific interactions facilitate dissemination of the tumour cells 
through the bloodstream. Tumour-specific modifications are highlighted (grey perforated 
box). Abbreviations: serine (Ser), and threonine (Thr) (Author diagram). 
 
 
Cancer-associated mutations in the Golgi enzyme T synthase or Cosmc, the molecular 
chaperone responsible for correct folding of T synthase, leads to the abnormal generation of 
the Thomsen-nouveau (Tn) antigen (Ju et. al. 2011) (Figure 1.9). The overexpression of Tn 
antigen, a mucin-type O-glycan, has been correlated with poor prognosis in several cancers 
(Ju et. al. 2011). The interaction between Tn antigen on colorectal cancer cells, and 
macrophage galactose type lectins (MGLs) expressed on macrophages and dendritic cells, 
are believed to facilitate immunosuppression and immunoevasion (Ju et. al. 2011). Aberrant 
a.                                     b. 
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sialyation of the Fas receptor-Fas ligand has been shown to block the induction of apoptosis 
in cancer cells, promoting their resistance to cell death (Vajaria and Patel et. al. 2017). 
Overexpression of glycosphingolipid GM1 causes ganglioside-dependent heterodimerisation 
and activation of the receptor tyrosine kinases ERBB2–ERBB3, within lipid rafts (Fuster and 
Esko 2005). More recently, differential glycosylation of cell surface markers present on 





Figure 1.9: The Thomsen-nouveau (Tn) antigen.  Schematic representation of the the 
Thomsen-nouveau (Tn) antigen. Tumour-specific modifications are highlighted (grey 
perforated box). Abbreviations: serine (Ser), and threonine (Thr) (Author diagram). 
 
 
Overall, aberrant glycosylation can affect growth factor signalling, cell proliferation, 
adhesion, and migration, and promote tumour progression through enhanced cell-matrix 




1.2.5 The functional role of aberrant glycosylation in cancer progression 
 
Observing changes in glycosylation during physiological and pathological processes does not 
necessarily provide evidence for its function in normal development and cancer progression. 
Therefore, probing the function of sialyltransferases using gene editing has provided an 
avenue to begin to understand the biological mechanisms of glycosylation and cancer 
progression. 
 
Murugaesu and colleagues identified the sialyltransferase ST6GalNAc2 as a suppressor of 
late breast cancer metastasis. Knockdown of ST6GalNAc2 in mouse mammary 4T1 tumour 
cells resulted in increased tumour burden in the lungs and the liver, and seeding of tumour 
cells at secondary sites (Murugaesu et. al. 2014). This phenotype was correlated with 
increases in the binding of recombinant galectin 3 due to enhanced presentation of its 
ligand, unmodified core 1 O-glycan called the Thomsen-Friedenreich (T) antigen (Figure 
1.10). In a complementary study, Reticker-Flynn and colleagues showed that knockdown of 
ST6GalNAc4 could drive lung cancer metastasis, which correlated with disrupted branching 
and elongation of the T-antigen, increased presentation of T-antigen on the surface of 
metastatic cells and an increase in galectin-3 binding to leukocytes (Reticker-Flynn and 
Bhatia 2015). Collectively, these studies provided a mechanism where patients with low 
expression of particular sialyltransferases would have increased levels of T antigen at the 
tumour cell surface, enhancing galectin 3 binding. Since galectin 3 is a known carbohydrate-
binding protein, which facilitates tumour cell interactions with endothelial cell and the cell-




Figure 1.10: The Thomsen-Friedenreich (T) antigen. Schematic representation of the the 
Thomsen-Friedenreich (T) antigen. Tumour-specific modifications are highlighted (grey 
perforated box). Abbreviations: serine (Ser), and threonine (Thr) (Author diagram). 
 
 
Increased expression of the Golgi b1,6 N-acetylglucosaminyltransferase V (MGAT5) has been 
shown to result in increased b1,6 GlcNAc-branching of N-linked integrins, metastasis and 
poor prognosis in breast cancer (Dennis et. al. 1999).  Granovsky and colleagues genetically 
engineered MGAT5 deficient mice to probe a functional link between MGAT5 expression, 
abnormal b1,6 GlcNAc-branching, and breast cancer progression in vivo. The absence of b1,6 
GlcNAc-branching within MGAT5 deficient tissue lysates was confirmed by lectin blotting, 
with minimal Phytohaemagglutinin binding (Granovsky et. al. 2000). Both wild type and 
MGAT5 deficient mice formed microscopic tumour foci within the mammary fat pads by 14 
weeks, indicating that MGAT5 was not important for cancer initiation (Granovsky et. al. 
2000). However, by 20 weeks, the wild type mice were devoid of any normal ductal 
epithelium (0% tumour-free), while the MGAT5 deficient mice exhibited a close to 500% 
decrease in tumour burden, with only a 5% incidence of lung metastases and a lesser 
proportion of proliferating cells within their tumours. Tumour cells extracted from MGAT5 
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deficient mice also exhibited less membrane ruffling and formation of focal adhesion points. 
This phenotype was attributed to the absence of b1,6 GlcNAc-branching within MGAT5 
deficient tissue, which usually triggers phosphoinositide 3 (PI3) kinase-mediated membrane 
reorganisation (Granovsky et. al. 2000). Collectively, the data highlighted the importance of 
glycosylation in promoting cancer progression through plasma membrane plasticity.  
 
These are but a few studies where the functional role of aberrant glycosylation in cancer 
progression has been probed, and causally associated with the hallmarks of cancer (Munkley 
and Elliott 2016; Hanahan and Weinberg 2011). It should be noted that since glycosylation is 
not directly gene-encoded, manipulating the activity of glycoenzymes only provides an 
indirect analysis of how changes in glycan expression result in cancer-associated phenotypes 
(Cheng et. al. 2016). Furthermore, differential glycosylation may not always be driven by 
tumour pathology as the upregulation of glycosylation is important for normal cellular 
processes. For example, endothelial cells express the SLeX antigen (Figure 1.8a) in response 
to chronic inflammation to facilitate leukocyte infiltration (Renkonen et. al. 2002; Peracaula 
et. al. 2008). 
 
 
1.2.6 The discovery of tumour-specific markers 
 
In the 1840s, Bence-Jones and colleagues discovered fragments of immunoglobulin light 
chains, now known as Bence-Jones Proteins, in the acidified urine of patients with multiple 
myeloma (Beetham 2000). Their data underpinned the idea that detecting a cancer-specific 
protein in a readily available clinical sample such as blood or urine, could be used to confirm 
a cancer diagnosis, indicate recurrence, monitor treatment response or treatment failure 
(Virji et. al. 1988; Hounsell 1997). Based on the role of glycosylation in cancer progression, 
several studies have gone on to characterise glycome differentiation between healthy 
individuals and cancer patients, and identify a repertoire of tumour-specific glycoconjugates.  
 
Abelev and colleagues observed a globulin-like protein present in mouse embryos, whose 
expression disappeared in adult mice, but reappeared when mice were transplanted with 
mouse hepatocellular carcinoma cells (Abelev et. al. 1963) (Figure 1.11). This protein was 
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later identified to be alpha fetoprotein (AFP), a glycosylated oncofoetal antigen normally 
produced in the yolk sac and liver during foetal development, but which is re-expressed by 
hepatocellular carcinoma cells and secreted into the blood (Pinho and Reis 2015). Elevated 
levels of AFP detected in serum using an immunological assay is a marker for hepatocellular 




Figure 1.11: Detection of an a-globulin like protein in the sera of mice during development 
and disease. Age-dependent decreases in the concentration of an a-globulin like protein 
were observed during mouse development. Detection of the antigen disappeared from sera 
in adult mice but reaccumulated when mice were implanted with mouse hepatocellular 
carcinoma cells (Figure taken from Abelev et. al. 1963). 
 
 
The first breast tumour-associated antigen, the T antigen (Figure 1.10), was later observed 
by Springer and colleagues, exclusively in membrane extracts and blood samples obtained 
from patients with malignant infiltrative breast adenocarcinoma (Springer et. al. 1975). The 
detection of anti-T antigen autoantibodies in the sera of patients post-mastectomy was 
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increased by over 20% when patients were injected with T-antigen intradermally (Springer 
et. al. 1975). Their data suggested that the T-antigen was capable of triggering the hosts' 
immune response against the tumour (Springer et. al. 1975). 
 
Chan and colleagues used a xenograft mouse model of lymphosarcoma, and Wheat germ 
agglutinin (WGA) lectin, which binds preferentially to N-acetylglucosamine residues 
(Cummings and Etzler 2009), to compare the composition of glycoproteins extracted from 
primary tumours and liver metastases. Extracts obtained from liver metastases exhibited less 
WGA binding than lymphosarcoma tissue extracts, showing an association between 
decreases in glycosylation and increases in tumour aggressiveness (Chan et. al. 1984). When 
lymphosarcoma cells, exhibiting the highest level of WGA binding, were re-implanted into 
regions of the liver, which previously harboured a metastasis deposit, the resulting tumour 
exhibited less WGA binding (Chan et. al. 1984). Their data suggested that a tumours 
immediate environment contributed towards driving differential glycosylation during the 
development of a metastatic phenotype. The cross-talk between the tumour 
microenvironment and glycosylation has been confirmed in subsequent studies (Peixoto et. 
al. 2019). For example, Higai and colleagues treated hepatocellular carcinoma cells with 
interleukin-1b in vitro, to mimic the secretion of proinflammatory cytokines from cells within 
a tumour’s growth environment (Higai et. al. 2006). This induced the expression of 
sialyltransferase ST3Gal IV and the fucosyltransferase FUT VI, resulting in the expression of 
SleX antigens (Figure 1.8a) at the cell surface (Higai et. al. 2006). 
 
Turner and colleagues measured the concentration of serum fucose in a cohort of patients 
with early disease (primary cervical cancer only), clinical disease (various tumour sites) and 
advanced disease (various tumour sites) (Turner et. al. 1985). Raised concentrations of 
fucose, detected by the fucose dehydrogenase method, correlated with an increase in 
advanced disease, which they hypothesised was being spontaneously released into the 
circulation as the tumour grew or by cell death resulting from the hosts' immune response 
(Turner et. al. 1985). 
 
Ng and colleges used WGA lectin autoradiography to show differential glycan content within 
whole-cell extracts obtained from breast biopsies from healthy breast tissue and patients 
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with invasive breast carcinoma. Tumour extracts exhibited less WGA binding, with lectin 
western blot, than extracts from healthy breast tissue (Ng et. al. 1987). This inverse 
correlation between WGA binding and disease aggressiveness was also seen in models of 
lymphosarcoma discussed previously (Chan et. al. 1984) and years later, during the 
progression of pre-invasive Barrett’s oesophagus to adenocarcinoma (Bird-Lieberman et. al. 
2012).  
 
Collectively, these early studies supported the notion that differential glycosylation, and the 




1.2.7 Glycans in the clinic 
 
Targeting glycosylation to improve cancer diagnosis is now embedded in clinical practice and 
involves detecting aberrantly glycosylated glycoproteins or oligosaccharide signatures in 
tissue or serum (Nimse et. al. 2016). These tumour markers, also known as biomarkers, are 
defined as “a measurable phenotypic parameter that characterises an organism’s state of 
health or disease, or a response to a particular therapeutic intervention” (Negm et. al. 2002). 
Biomarkers are generally classed as genomic markers (RNA or DNA), protein markers or 
molecular imaging markers (Peracaula et. al. 2008). 
 
Several of the clinical biomarkers used routinely for cancer diagnosis, therapeutic 
monitoring, detecting disease recurrence and examining tumour burden, are in fact 
glycoproteins or oligosaccharides (Peracaula et. al. 2003) (Figure 1.12). Current biomarkers 
approved by the FDA include AFP in hepatocellular carcinoma, prostate-specific antigen 
(PSA) in prostate cancer, and carcinoembryonic antigen (CEA) in colorectal, pancreatic, 
gastric and breast carcinomas (Pinho and Reis 2015). Biomarkers can be detected with 
monoclonal antibodies in liquified clinical samples using enzyme-linked immunosorbent 
assays (ELISA) or in tissue biopsies using immunohistochemistry (IHC) (Sharma 2009). For 
example, the CA19-9 assay detects the SLea tetrasaccharide (Figure 1.8a) and is used to 
monitor treatment response in biliary, colorectal, gastric and pancreatic cancers (Pinho and 
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Reis 2015). The measurement of these markers is non-invasive and does not interfere with 





Figure 1.12: Serological glycobiomarkers approved by the U.S. Food and Drug 
Administration for use in the clinic. Abbreviations: alpha-fetoprotein (AFP), Sialyl Lewis A 
(SLea), sialylated Thomsen-nouveau (STn), mucin 1, cell surface associated (MUC1), mucin 16, 
cell surface associated (MUC16), carcinoembryonic antigen (CEA), prostate specific antigen 
(PSA), and human chorionic gonadotropin (hCG) (Figure taken from Pinho and Reis 2015).  
 
 
Targeting glycosylation has also been achieved through the development of 
glycotherapeutics. Early forms of glycotherapeutics involved treating Carbohydrate Deficient 
Glycoprotein Syndromes (Varki et. al. 2017) and Congenital Disorders of Glycosylation with 
mannose replacement therapy (Rush et. al. 2000), or Leukocyte Adhesion Deficiency Type II 
with oral fucose (Marquardt et. al. 1999). Now, glycotherapeutics has been used to treat 
cancer (Hudak and Bertozzi 2014) by inhibiting glycosyltransferases (Granovsky et. al. 2000), 
blocking oligosaccharide-mediated cell-cell interactions with inhibitors (Nangia-Makker et. 
al. 2002), or triggering an anti-tumour immune response using carbohydrate-based vaccines 
(Krasnova and Wong 2016).  
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Heparin is an anticoagulant used clinically, which inhibits binding of SleX (Figure 1.8a) to the 
selectins known to promote invasion (Fuster and Esko 2005; Magnani 2004). Other 
therapeutics in clinical trials aim to block the interactions between glycans and glycan-
binding proteins such as the galectin-3 inhibitor, GSC-100, for pancreatic cancer and 
conjugated ganglioside GM2 vaccine for melanoma (Fuster and Esko 2005). Glycoprotein 
targeting immunotherapies used in standard clinical practice include the anti-CD20 
monoclonal antibody, rituximab, for non-Hodgkin lymphoma, the anti-tyrosine kinase 
monoclonal antibody, imatinib, for leukaemia, anti-HER2 antibody, trastuzumab, for breast 
cancer, and the anti-EGFR antibody, cetuximab, for colorectal cancer (Weiner et. al. 2012; 
Madden 2018). 
 
The Fc region and antigen-binding fragment (Fab) of immunoglobulins contain several N- and 
O-glycosylation sites, which facilitate their binding to Fc receptors, and complement during 
the adaptive immune response (Seeling et. al. 2017; Arnold et. al. 2007) (Figure 1.13). Fc-
glyco-engineering involves site-directed mutagenesis of the Fc regions within existing 
immunotherapies, to generate glycosylated or deglycosylated variants, which improves their 
effector functions, specificities and clinical utility (Reusch and Tejeda 2015; Yu et. al. 2017). 
Fc-glyco-engineering was used to generate mogamulizumab, an afucosylated anti-CC-
chemokine receptor 4 antibody approved to treat T-cell lymphomas in Japan, and 
obinutuzumab, a low fucose anti-CD20 antibody approved to treat follicular lymphoma (Yu 





Figure 1.13: The effect of glycosylation on immunoglobulin function. Glycosylation of an 
immunoglobulins (Ig) fragment Fc region or antigen-binding fragment (Fab), can inhibit or 




The presence of circulating immune biomarkers is based on the knowledge that 
autoantibodies are released in response to contact with tumour-associated antigens, which 
act as a “fingerprint” indicating the presence of a tumour (Chapoval et. al. 2015). Immune 
biomarkers that recognise tumour antigens have been identified by culturing antibody-
secreting cells such as B cells, extracted from the lymph nodes of patients with cancer 
(Meeusen et. al. 2017). Immunodiagnostic assays to measure antibodies against glycan-
based tumour antigens are currently in development (Bogen and Sompuram 2004). 
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Understanding the role of glycosylation in cancer has immense clinical value and may 




1.3 Exploiting the cancer glycome in biomarker discovery 
 
1.3.1 The challenges associated with using glycans as cancer biomarkers 
 
The link between aberrant glycosylation and cancer progression has formed the basis for 
using glycans and glycoproteins in the clinical management of cancer (Munkley and Elliott 
2016; Oliveira-Ferrer et. al. 2017). However, the utility of biomarkers has been challenged in 
recent years due to low cancer specificity and high false-positive rates (Mayeux 2004).  
 
An ideal biomarker should correctly diagnose people with cancer (be sensitive), identify 
healthy people without cancer (be specific), correlate with tumour size, and be capable of 
monitoring disease recurrence or treatment response (Sharma 2009). Unfortunately, current 
clinical biomarkers fail to meet the ideal characteristics of a tumour biomarker. Although 
increased levels of AFP are associated with an increase in tumour size, elevated AFP is also 
observed in chronic hepatitis and cirrhosis, making it difficult to distinguish hepatocellular 
carcinoma from benign liver diseases (Adamczyk et. al. 2012). PSA is a serine protease whose 
serum levels, alongside Gleason scoring and clinical staging, is used to monitor tumour 
progression in prostate cancer (Meany and Chan 2011). Serum levels of PSA are elevated in 
prostate cancer but also in other benign conditions such as benign prostatic hyperplasia, 
prostatitis, prostatic intraepithelial neoplasia, and obesity (Adamczyk et. al. 2012). 
Therefore, levels of PSA alone are insufficient in distinguishing prostate cancer from other 
benign prostate diseases (Meany and Chan 2011). Multiple biomarkers measured 
simultaneously within the same patient can often show conflicting results. For example, 
Ishikawa and colleagues describe a breast cancer case report where levels of cancer antigen 
15-3 (CA15-3) dropped significantly in response to a weekly dose of paclitaxel indicating 
successful response to therapy, whilst in contrast, carcinoembryonic antigen (CEA) levels 
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continued to rise indicating disease progression within the same time window (Ishikawa et. 




Figure 1.14: Changes in the concentration of CA15-3, CEA and liver function markers during 
the disease course of a 35-year-old female patient with breast cancer. CA15-3 is used to 
measure treatment response in breast cancer. Elevated CA15-3 was reduced in response to 
PTX treatment, but masked disease progression occurring between 0-5 months. CEA is used 
to monitor metastatic breast cancer and recurrence. Elevated levels of CEA were indicative of 
disease progression, which later correlated with elevated liver function markers, ALT and 
AST. Abbreviations: cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), paclitaxel 
(PTX), epirubicin (EC) cyclophosphamide (VINO), vinorelbine (XC) and disseminated 
intravascular coagulation (DIC), alanine aminotransferase (ALT) and aspartate 




Screening biomarkers in asymptomatic populations has reduced the incidence of several 
cancers (Shieh et. al. 2016) (Figure 1.3). Unfortunately, this has come at the cost of 
overdiagnosis and overtreatment (Shieh et. al. 2016; Bhatt and Klotz 2016). Overdiagnosis 
can result in multiple unnecessary biopsies being taken from patients with benign conditions 
and has been implicated in breast (Wallis 2018) and thyroid (Pandeya et. al. 2016) cancers. 
 
In the European Randomized Study of Screening for Prostate Cancer in men aged 50-74, 
82,000 men were randomly enrolled for prostate cancer screening once every 4 years, and 
99,000 men were assigned to the no-screening control group (Schröder et. al. 2009). 
Elevated PSA was detected in 16.2% of all screening tests taken, and resulted in a reduction 
of 0.7 prostate-cancer deaths per 1000 men. However, 75.9% of the tests positive for 
elevated PSA, were confirmed to be false positives following biopsy (Schröder et. al. 2009). 
Furthermore, the UK’s biggest trial for prostate cancer screening, the Prostate Testing for 
Cancer and Treatment (ProtecT) trial, showed no significant improvement in preventing 
prostate cancer mortality using PSA monitoring (Hamdy et. al. 2016). Therefore, the 




1.3.2 Overcoming the challenges associated with using glycans as cancer biomarkers 
 
Personalised risk-based screening models analyse biomarker levels in the context of other 
clinical variables to improve the clinical utility of biomarkers. The Stockholm-3 (STHLM-3) 
model analyses a set of predefined parameters such as plasma proteins (including free and 
bound PSA), genetic polymorphisms, previous prostate biopsies, age, and family history 
(Grönberg et. al. 2015). The detection of high-grade prostate cancers with a Gleason score of 
³7, in a population cohort of 47,000 asymptomatic men aged 50-69 years, was significantly 
improved using the STHLM-3 model, in comparison to PSA screening alone (Grönberg et. al. 
2015). Of the 603 high-risk prostate cancers detected by the STHLM-3 model, only 124 of 
those patients had elevated PSA levels ³3 ng/ml usually needed to warrant biopsy referral 
(Grönberg et. al. 2015). A two-step prostate cancer screening protocol has now been 
proposed in Europe, which involves a PSA elevation screen to identify high-risk patients, 
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immediately followed by personalised prediction of cancer risk using the Stockholm model. 
This structured screening programme has been shown to reduce unnecessary multiple 
biopsies in patients with elevated PSA levels induced by benign conditions (Ström et. al. 
2018). However, the STHLM-3 prediction risk-based screening programming has yet to be 
integrated into routine clinical practice across Europe.  
 
New tissue and body fluid-based biomarkers are notoriously difficult to get into the clinic 
due to the need for large scale studies to test the sensitivity of the proposed biomarkers to 
individual variation, as well as the development of robust assays for their detection that are 
clinically feasible to conduct without the need for specialist interpretation (Adamczyk et. al., 
2012; Bird-Lieberman et. al. 2012).  Molecular imaging, defined as the “visualisation, 
characterisation, and measurement of biological processes at the molecular and cellular 
levels in humans [using] radiotracer imaging, magnetic resonance imaging (MRI) and optical 
imaging” (Mankoff 2007), provides an alternative approach to tumour characterisation that 
is independent of traditional tissue or serum-based biomarkers (Peracaula et. al. 2008). For 
example, treatment response has been assessed using positron-emission tomography (PET) 
by monitoring the uptake of zirconium-89 radiolabelled anti-HER2 trastuzumab (89Zr-
trastuzumab) within breast cancer metastases (Dijkers et. al. 2010) (Figure 1.15a). Uptake of 
indium-111 radiolabelled trastuzumab (111In-trastuzumab) has also been used to detect new 
HER2 positive metastatic breast cancer lesions in the liver using fused CT and single-photon 
emission (SPECT) imaging (Perik et. al. 2006) (Figure 1.15b). These are examples where 
molecular imaging is enabling a personalised approach to monitoring treatment response 













Figure 1.15: Molecular imaging of breast cancer metastases using radiolabeled 
trastuzumab. (a) Positron-emission tomography (PET) imaging showed increased uptake of 
radiotracer within a single brain metastasis (black arrow), 1 (i), 2 (ii) and 5 (iii) days post 
injection with 89Zr-trastuzumab. The study proposed 4-5 days post administration as the best 
time to assess tumour immunotherapy uptake (Modified from Dijkers et. al. 2010). (b) Fused 
a.
 











                             
b. 
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single-photon emission-computed tomography (SPECT-CT) shows uptake of radiotracer 
within liver metastases (white arrow) 96 hours post-injection with 111In-trastuzumab 
(Modified from Perik et. al. 2006). 
 
 
Molecular imaging is low-throughput in comparison to tissue-based methods, where 
multiple biomarkers can be assessed in a single clinical sample (Mankoff et. al. 2017), and 
also requires specialist interpretation. Therefore, clinical translation of molecular imaging 
may still require traditional tissue or serum-based biomarkers to determine the ideal timing 
of imaging or treatment administration, monitor potential toxicity and side effects to novel 
targeted therapies, and stratify patients into high-risk groups (Fuster and Esko 2005).  
 
 
1.3.3 Detecting glycosylation using lectins 
 
Several methods have been adopted to study the distribution, composition, and function of 
glycans in cancer to search for new and improved cancer biomarkers (Springer and Gagneux 
2016). These techniques include mass spectrometry, generation of carbohydrate-specific 
monoclonal antibodies, editing of glycoenzymes, and lectin affinity assays, to name but a 
few (Adamczyk et. al. 2012; Biskup et. al. 2013; Block et. al. 2005; Saldova et. al. 2011; Hizal 
et. al. 2014; Tao et. al. 2008). Affinity reagents such as lectins and antibodies are the most 
extensively used because their specificities enable them to discriminate among a variety of 
glycan structures, with high-affinity binding due to their bivalency (Cummings and Etzler 
2009). These affinity reagents can be used in combination with basic carbohydrate stains 
such as Periodic acid–Schiff for visualising glycoproteins and glycolipids, alcian blue for 
mucins and hyaluronic acid, which allows visualisation of the glucosaminoglycan hyaluronan 
within cartilage, and ruthenium red for the glycocalyx (Corfield 2017). 
 
Lectins are naturally occurring carbohydrate-binding proteins conserved in plants, viruses, 
bacteria, protozoa, fungi, and animals (Sharon and Lis 1989). Generally, they facilitate 
adhesion by promoting intercellular bridging between soluble glycoconjugates on the 
surface of apposing cells, and within the extracellular matrix (Sharon and Lis 1989). Most 
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commercially available lectins are purified from plants or animals. Their binding specificities 
are well characterised, they are abundant in nature, inexpensive to synthesise, stable under 
a range of experimental conditions, and bind a variety of human tissues (van Kooyk 2008; 
Bird-Lieberman et. al. 2012). Examples include Wheat germ agglutinin (WGA) from Triticum 
vulgaris, which binds N-acetyl-D-glucosamine and sialic acid, and Helix pomatia agglutinin 
(HPA) from the edible snail, which binds to α-N-acetylgalactosamine (Cummings and Etzler 
2009).  
 
Combining lectin affinity assays with glycoproteomic approaches have allowed deeper 
analysis of glycoforms to improve specificity and early diagnosis. For example, in 2006, the 
FDA approved the use of AFP-L3 for detecting hepatocellular carcinoma. AFP-L3 is an 
aberrantly fucosylated version of AFP, generated due to the overexpression of 
fucosyltransferase FUT 8 (Meany and Chan 2011). AFP-L3 levels are significantly elevated in 
hepatocellular carcinoma patients in comparison to benign liver diseases such as cirrhosis, 
providing a marker for the onset of hepatocellular carcinoma (Block et. al. 2005; Meany and 
Chan 2011; Adamczyk et. al. 2012; Pinho and Reis 2015). The AFP-LC3 capture assay 
developed by FUJIFILM Wako Diagnostics U.S.A uses the Lens culinaris agglutinin (LCA) lectin 
to capture aberrantly fucosylated AFP (Figure 1.16). Patients with chronic liver disease and 
elevated AFP-L3 were observed to have a 10.6-fold increased risk of developing 
hepatocellular carcinoma within 21 months 
(http://www.wakodiagnostics.com/afpl3test.html, 2019). AFP-L3 is an example of how the 
identification of aberrantly glycosylated isoforms of an existing biomarker has improved the 
early diagnosis of cancer and enabled identification of high-risk groups (Meany and Chan 






Figure 1.16: The Fuji AFP-L3 diagnostic assay. Lens culinaris agglutinin (LCA) captures 
aberrantly fucosylated AFP. The ratio of AFP-L3 (abnormal) over AFP-L1 (unmodified) is 




Radiolabelled lectins have been used to successfully image glycans in tumour-bearing mice 
using radionuclide imaging (Kojima and Jay 1986). However, lectins can exhibit low tissue 
penetration and can cause concentration-dependent toxicity (Laughlina et. al. 2009). 
Furthermore, lectins have multiple carbohydrate-binding sites, leading to the formation of 
oligomeric structures. These can be difficult to clear and can reduce contrast in vivo (Berg et. 
al. 2002). 
 
Despite the disadvantages associated with lectin imaging, their low tissue penetration can be 
beneficial for superficial imaging of tissue sections such as at the gastrointestinal surface. 
Various glycan targets can be observed at the mucosal surface, providing qualitative 
evidence for the different binding specificities of lectins (Kuo et. al. 2016) (Figure 1.17a). A 
decrease in the binding of a variety of fluorescently labelled lectins to the colorectal luminal 
surface epithelium have been observed during progression from normal epithelium to low-
grade dysplasia, high-grade dysplasia and carcinoma (Kuo et. al. 2016) (Figure 1.17b). The 
progression of oesophageal cancer has also been detected using clinical fluorescence 
endoscopy simply by topical application of fluorescein-labelled WGA (Bird-Lieberman et. al. 
2012). Decreased binding of WGA was seen during the progression of pre-invasive Barrett’s 





Figure 1.17: Differential lectin staining of mucosal surfaces. (a) Differential lectin staining of 
deep luminal mucus deposits within carcinoma tissue (Figure taken from Kuo et. al. 2016). (b) 
Quantification of fluorescence imaging showed decreased binding of WGA, and HPA, 
associated with progression from normal tissue to adenoma in the colon of Apcmin mice 
a.
 























(Figure taken from Kuo et. al. 2016). (b) Esophageal lumen tissue was resected from two 
patients (OES1 and OES2) and labelled with WGA lectin and Alexa Fluor 488 ex vivo. 
Decreased binding of WGA was associated with progression from squamous esophageal to 
esophageal adenocarcinoma. (Figure taken from Bird-Lieberman et. al. 2012). Abbreviations: 
Alcian Blue (AB), periodic acid Schiff (PAS), hematoxylin and eosin (H&E), Helix pomatia 
agglutinin (HPA), jackfruit lectin (JFL), peanut agglutinin (PNA), soybean agglutinin (SBA), 
and wheat germ agglutinin (WGA). Scale bar represents 500 μm. 
 
Issues of sensitivity are being addressed through enhanced multivalency, which has been 
generated using “glycan-decorated biomaterials” such as glyconanoparticles, and 
glycoarrays (Bojarová et. al. 2016; Wang et. al., 2016). Furthermore, the affinity of avidin for 
lectins expressed endogenously by cancer cells has been harnessed to specifically deliver 
avidin–fluorophore conjugates to tumours for optical imaging of tumour-bearing mice 
(Hama et. al. 2006; Hama et. al. 2006). This technique has been used to improve contrast 
during fluorescence endoscopy and surgical procedures required for the detection of 
peritoneal metastases (Hama et. al. 2006). 
 
 
1.3.4 Detecting glycosylation using antibodies  
 
The use of antibodies in the context of glycosylation usually involves detecting glycoproteins 
through epitopes within their polypeptide backbone. Common glycoprotein targeting 
immunotherapies used in standard clinical practice include the anti-CD20 monoclonal 
antibody, rituximab, for non-Hodgkin lymphoma, the anti-tyrosine kinase monoclonal 
antibody, imatinib, for leukaemia, the anti-HER2 monoclonal antibody, trastuzumab, for 
breast cancer, and the anti-EGFR monoclonal antibody, cetuximab, for colorectal cancer 
(Weiner et. al. 2012; Madden 2018). However, there are antibodies which recognise tumour 
cell-associated carbohydrate epitopes (Haji-Ghassemi et. al. 2015; Soliman et. al. 2017). For 
example, dinutuxmab, a glycolipid inhibitor, which targets the overexpressed ganglioside 
GD2, has been approved for the treatment of high-risk cases of neuroblastoma and is the 
first carbohydrate targeting antibody to be approved for use in clinical practice (Dhillon 
2015). Antibodies against the Tn antigen (Figure 1.9) are also being developed to detect Tn 
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antigen on circulating glycoproteins to improve the early detection of cancer (Kveton et. al. 
2017; Ju et. al. 2011). 
 
Hybridoma screening is a technique used to purify monoclonal antibodies against tumour 
antigens from mice immunised with cancer cells or glycoconjugates (Cummings and Etzler 
2009). Antibodies targeting carbohydrates have varying specificities and cross-react with 
multiple epitopes non-specifically, due to the ubiquitous nature of glycosylation. Monoclonal 
antibodies against the N-acetylgalactosamine (GalNac) component of the Tn antigen (Figure 
1.9) have been shown to cross-react with GalNac residues within the blood group A antigen 
(Ju et. al. 2011). Monoclonal antibodies against MUC1, a mucin glycoprotein overexpressed 
in several cancers, has also been shown to lack carbohydrate specificity due to their affinity 




Figure 1.18: The low specificity of anti-MUC1 antibodies. MUC1 antibodies display varying 
specificities. Antibody KL6 (blue) recognises multiple oligosaccharide structures (Figure taken 




Other commercially available antibodies against common tumour antigens such as heparan 
and SLex (Figure 1.8a) have been conjugated to radionuclides and used for tumour detection 
using PET and SPECT imaging, as well as MRI, optical, and ultrasound imaging (Barbet et. al. 
2012; Warram et. al. 2014). The disadvantage of using antibody-based imaging is their 
immunogenicity at high concentrations, slow clearance from the blood, which reduces 
contrast, and accumulation in organs responsible for clearance, such as the liver (Kojima and 
Jay 1986). However, tumour background contrast can be improved by using antibody 
fragments, which clear more rapidly from the circulation, or by increasing the time between 
administration and imaging (Warram et. al. 2014). 
 
 
1.3.5 Detecting glycosylation using bioorthogonal chemical reporters  
 
Another strategy for detecting glycosylation involves the use of chemical reporters. Here, 
cells are treated with a monosaccharide analogue containing a functional group or “chemical 
reporter” not normally present in the cell, such as an azide- or alkyne- group (Laughlin et. al. 
2009). For example, precursors of sialic acid and N-acetylgalactosamine have been labelled 
with an azide group (N-azidoacetylmannosamine (Ac4ManNAz) and N-





Figure 1.19: Bioorthogonal chemical reporters. Chemical structures of synthetic precursors 
of sialic acid and N-acetylgalactosamine labelled with an azide group (red) (N-
azidoacetylmannosamine (Ac4ManNAz) and N-azidoacetylgalactosamine (Ac4GalNAz)). 
Multiple acetylation helps the azidosugar to cross the cell membrane but these groups are 
later lost (Author diagram).  
 
 
The azidosugars are incorporated metabolically into cellular glycan structures (Figure 1.20a).  
These modified glycans can then be detected by covalent ligation of imaging probes or 
affinity reagents that rapidly react with the azide or alkyne group, by Staudinger ligation 
(Saxon and Bertozzi 2000; Saxon et. al. 2002), or cycloaddition (Laughlin et. al. 2006) (Figure 
1.20b). Hence, this technique is termed “bioorthogonal” and applies to dynamic imaging in 








Figure 1.20: Metabolic labelling of glycan’s using bioorthogonal chemistry. (a) The 
azidosugars N-azidoacetylmannosamine (Ac4ManNAz) and N-azidoacetylgalactosamine 
(Ac4GalNAz)) are incorporated biosynthetically into cell surface glycans through the sialic 
acid biosynthesis pathway and N-acetylgalactosamine salvage pathway, respectively. (b) 
Bifunctional probes are composed of one group (*), which covalently reacts with the azido 
(N3, red) sugar incorporated into cell surface glycans. The second group (**) can be detected 
by high affinity binding imaging probes (Neutravidin 650), covalent ligation to fluorescence 
molecules (Tz-Dylight), or direct imaging (TMDIBO-Gd). Imaging probes can be fluorescent, 
conjugated to a radionuclide or conjugated to a contrast agent, which determines the 
imaging modality used to detect azidosugar labelling. Abbreviations: 
tetramethoxydibenzocyclooctyne (TMDIBO), trans-cyclooctene (TCO), phosphine (PHOS), 
lysine (Lys), tetrazine (Tz), and gadolinium (Gd). (Author diagram; TMDIBO-TCO and PHOS-
TCO chemical structures from Neves et. al. 2013. TMDIBO-Lys-Gd chemical structure taken 
from Neves et. al. 2015).  
 
 
Detecting metabolically labelled glycans using chemical reporters has been used to study 
glycosylation during the development of Zebrafish embryos (Laughlin et. al. 2008), image 
glycoprotein sialyation in live Zebrafish (Agarwal et. al. 2015), locate sialylated proteins 
b. 
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within the membrane of Trypanosoma cruzi, investigate the role of lipooligosaccharide 
sialyation in Haemophilus ducreyi virulence, and visualise glycosylation in Caenorhabditis 
elegans (Goon et. al. 2003; Laughlin et. al. 2009). 
 
Bioorthogonal chemistry has also been applied in human cells (Saxon and Bertozzi 2000; 
Dube and Bertozzi 2003). For example, Chang and colleagues used chemical reporters to 
simultaneously quantify cell surface sialyation, and N-acetylgalactosamine glycosylation, 
within the same human cells, using flow cytometry, and fluorescent microscopy. Jurkat cells 
were subjected to dual treatments with peracetylated N-levulinoylmannosamine, a ketone-
linked precursor of sialic acid, and Ac4GalNAz, an azide-linked analogue of N-
acetylgalactosamine (Chang et. al. 2007). Peracetylated N-levulinoylmannosamine was 
detected with hydrazide-biotin, which reacted covalently with the precursors ketone group, 
followed by biotin visualisation using FITC-avidin. Ac4GalNAz was detected with a 
fluorescein-phosphine probe, which reacted covalently with the analogue’s azide group. The 
chemoselectivity of covalent reactions between complementary chemical groups, such as 
between ketones and hydrazides, or azides and phosphines, enables highly specific detection 
by this bioorthogonal metabolic labelling.  
 
The most extensively used chemical reporters in cancer research are variations of sialic acid, 
N-acetylgalactosamine or fucose, due to their associations with cancer progression (Fuster 
and Esko 2005; Laughlin et. al. 2009; Cheng et. al. 2016). Confocal microscopy (Figure 1.21a), 
and flow cytometry (Figure 1.21b) have been used to visualise and quantify azidosugar 
labelling in cancer cell lines (Stöckmann et. al. 2011; Kuo 2015, PhD thesis, unpublished). 
Azidosugar labelling has also been visualised in tumour-bearing mice using whole animal 
fluorescence (Figure 1.21c and d), MRI (Figure 1.21e) and PET imaging (Neves et. al. 2011; 
Neves et. al. 2013; Neves et. al. 2015). Peracetylated alkynyl N-acetylmannosamine, a 





Figure 1.21: Molecular imaging of cell surface glycosylation of cancer cells in vitro and in 
vivo. (a) Lewis lung carcinoma cells labelled with combinations of Ac4GalNAz, TMDIBO-AF647 
(red) and DAPI (blue) visualised using fluorescence microscopy. (b) Flow cytometric analysis 
of human breast cancer cells (MDA MB 231) labelled with combinations of Ac4ManNAz (blue) 
or Ac4GalNAz (yellow), TMDIBO-Biotin, and NeutrAvidin labelled with a fluorescent dye 
(NA650). (c) Fluorescence images of Lewis lung carcinoma (LL2) tumour-bearing BALB/c male 
mice treated with combinations of Ac4ManNAz, biotin-phosphine probe (bPhp) and 
NeutrAvidin 649 (NA649) at 24 h after injection with NA649. (d) Fluorescence images of 
murine Lewis lung carcinoma (LL2) tumour-bearing BALB/c female mice treated with 
combinations of Ac4GalNAz, TMDIBO-TCO and Tz-DyLight at 6 h after injection with Tz-
DyLight. The tumour (black arrow) and kidneys (white arrows) are highlighted. (e) Non-
invasive MRI detection of Ac4GalNAz-dependent metabolic labelling of tumours in vivo (white 
arrow head). BALB/c male mice were treated with combinations of Ac4GalNAz and TMDIBO-
Lys-Gd at 0 and 24 h after injection of TMDIBO-Lys-Gd. Abbreviations: peracetylated N- 
azidoacetylmannosamine (Ac4ManNAz), peracetylated N- azidoacetylgalactosamine 
(Ac4GalNAz), NeutAvidinTM DylightTM650/649 (NA650/649), tetrazine (Tz), 
a.                  b. 
c.    d.     e. 
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tetramethoxydibenzocyclooctyne (TMDIBO), trans-cyclooctene (TCO), phosphine (PHOS), and 
lysine (Lys) (Author diagram created from figures adapted from Stöckmann et. al., 2011; Kuo 
2015, PhD thesis, unpublished; Neves et. al., 2011; Neves et. al., 2013; Neves et. al., 2015).  
 
 
The use of chemical reporters exhibits further superiority over affinity-based reagents such 
as lectins and antibodies due to the use of small molecules requiring much smaller amounts 
of material. However, the ubiquitous nature of glycosylation can generate non-tumour 
labelling, for example, in the organs responsible for clearance and excretion of the probes 
(Neves et. al., 2013) (Figure 1.21d, white arrows). Efforts to improve contrast and the 
specificity of glycan imaging have involved packaging of azidosugars into functionalised 
liposomes to encourage tumour-specific uptake of the labelling reagents (Xie et. al. 2012; Xie 
et. al. 2014). 
 
 
1.3.6 Additional metabolic labelling strategies  
 
Molecular imaging can be conducted by combining affinity reagents and chemical tools. 
Imaging glycosylation using both lectins and bioorthogonal chemical reporters has been used 
to image cell surface fucosylation (Figure 1.22a) and sialylation (Figure 1.22b) in the human 





Figure 1.22: Dual confocal imaging of glycosylation in a hepatocellular carcinoma cell line 
using lectins and bioorthogonal chemical reporters. (a) Human hepatocellular carcinoma 
cells (Hep3B) were grown in the presence of synthetic azido-fucose, a synthetic analogue of 
fucose, which labels cell surface glycans. After 3 days, azido bearing glycans were covalently 
reacted with a fluorescein-conjugated alkyne probe (blue), and subsequently stained with 
Alexa Fluor 594-conjugated wheat germ agglutinin (WGA) lectin (red) (Figure adapted from 
Sawa et. al. 2006). (b) Hep3B cells were grown in the presence of exogenous natural N-
acetylmannosamine (control ManNAc) or synthetic N-4-pentynoylmannosamine (Alkynyl 
ManNAc), which both label cell surface glycans. After 3 days, alkyne-bearing glycans were 
covalently reacted with a biotinylated azido probe (biotin coupled to 1-azido-3-
aminopropane), and the cells stained subsequently with fluorescein-conjugated streptavidin 
(green), Alexa Fluor 594 conjugated WGA lectin (red), and Hoechst (blue). Scale bars 
















A recently developed technique for the metabolic labelling of glycans uses monosaccharide-
imprinted fluorescent nanoparticles, which are more stable than lectins and antibodies 
(Wang et. al. 2016; Shinde et. al. 2015). Here, monosaccharide polymers are synthesised in 
the presence of a target monosaccharide, such as sialic acid, which is subsequently removed. 
The biopolymers are left with sialic acid-deficient cavities, also known as a molecularly 
imprinted polymer (MIP) or nanoparticle. These particles exhibit a pre-engineered specificity 
and affinity for sialic acid when added to cells, which can be detected by conjugating the MIP 
to a fluorophore. This represents a novel technique, which uses chemical engineering to 
enhance the specificity of fluorescence-based glycan imaging.  
 
 
1.4 Project aims, objectives and experimental approaches 
 
1.4.1 Project aims and objectives 
 
Glycan's play an important role in cancer (Figure 1.7 and 1.8), and several studies have 
demonstrated the utility of targeting glycosylation for precision oncology through biomarker 
discovery (Figure 1.16), or the molecular imaging of glycans in vivo using lectins (Figure 1.17) 
and bioorthogonal azidosugars (Figure 1.21c-e). However, the clinical relevance of imaging 
glycosylation is not simply in the identification of tumours, for which many techniques 
already exist, but in the ability to visualise changes in glycosylation that we know occur 
during disease progression (Stowell et. al. 2015; Pinho and Reis 2015; Fuster and Esko 2005; 
Ju et. al. 2011; Vajaria and Patel 2017).  
 
Lectin-based fluorescence imaging has revealed a link between glycosylation and cancer 
progression within mucosal surfaces, as discussed previously (Bird-Lieberman et. al. 2012; 
Kuo et. al. 2016) (Figure 1.17). The association between glycosylation and cancer progression 
has also been observed using lectins and chemical reporters (Figure 1.19) using panels of 
human cell lines constructed to represent the different stages of cancer progression (Figure 
1.23). For example, an increase in Maackia amurensis lectin binding, which binds sialic acid, 
was observed in a panel of breast cancer cell lines (Kuo 2015, Ph.D. thesis, unpublished) 
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(Figure 1.23a). An increase in Ac4ManNAz labelling, a precursor of sialic acid, has also been 
associated with an increase in the metastatic potential of panels of breast (Figure 1.23b), 
prostate (Figure 1.23c) and melanoma (Figure 1.23d) cell lines (Kuo 2015, Ph.D. thesis, 
unpublished; Whittaker, 2015, Part III Dissertation, unpublished). These data confirm that as 
the cancer progresses, glycan expression is altered. Therefore, the correlation between 
increases in glycosylation and metastatic potential suggest that detecting changes in 
glycosylation could be useful for monitoring the propensity of a tumour to metastasise in 
vivo i.e. for assessing the aggressiveness of the disease. The ability to visualise non-invasively 
tumour glycosylation in vivo, using bioorthogonal glycan labelling, would provide qualitative 
insights into glycan dynamics and turnover (Colley et. al. 2017) in real-time. Furthermore, 
the benefits of basic cancer imaging are also realised, such as measuring tumour responses 
to therapy earlier and reducing health care costs by reducing overdiagnosis (Neves et. al. 
2014). Glycan imaging may also be beneficial in clinical trials, where visualising tumour 
regression or stabilisation at a molecular level could reveal the effectiveness of drugs earlier 




Figure 1.23: Detection of lectin binding and azidosugar incorporation in panels of human 
cell lines with increasing metastatic potential. Human breast, prostate and melanoma 
a. 
     
b. 
     
c. 
     
d. 
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human cell lines were selected from the literature, and ordered based on their increasing 
tumourigenicity and metastatic potential following orthotopic implantation into nude mice. 
(a) An increase in Maackia amurensis lectin binding, which preferentially binds sialic acid, 
was observed in a panel of breast cell lines. (b) An increase in Ac4ManNAz labelling (dark 
blue), a precursor of sialic acid, was observed a panel of breast cell lines. (c) An increase in 
Ac4ManNAz labelling (light blue), a precursor of sialic acid, was observed in a panel of 
prostate cell lines. (d) An increase in Ac4ManNAz labelling (dark blue), a precursor of sialic 
acid, was observed in a limited panel of melanoma cell lines. The darker shades in the 
arrows’ greyscales represent an increase in metastatic potential. (a, b and d taken from Kuo 




What is yet to be answered is whether bioorthogonal metabolic labelling (Figure 1.21 and 
1.23b-d) detects global increases in sialyation or increased turnover (Colley et. al. 2017) of 
cell surface glycan's. It is unknown whether azidosugars are preferentially incorporated into 
glycan structures via specific glycosidic linkages, and if this occurs at multiple epitopes within 
a glycoconjugate in a site-specific or tissue-specific manner. This would be influenced by 
changes in the expression or activity of sialyltransferases in the more metastatic cell lines, 
which also has not been investigated. It is possible that the glycans being differentially 
detected during progression using fluorescence-lectin imaging (Figure 1.17 and 1.23a) or 
azidosugar metabolic labelling (Figure 1.23b-d), may be part of a larger array of ‘metastatic 
codes’ associated with a tumour’s glycan profile at any given time point (Fuster and Esko 
2005). In other words, differential azidosugar labelling implies the presence of differentially 
labelled glycoconjugates, which if identified using mass spectrometry, may be predictive 
biomarkers of cancer progression. 
 
The goal of this study was to use bioorthogonal chemistry, to monitor dynamic changes in 
cell surface glycosylation in models of cancer progression, to identify novel biomarkers, and 
to investigate if changes in tumour glycosylation could be imaged using metabolic labelling in 
vivo in advanced models of cancer progression. 
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1.4.2 Experimental approach 
 
The efficiency of glycan labelling using the affinity reagents (e.g. lectins, antibodies) or the 
bioorthogonal chemical reporters (e.g. azido-sugars) can differ between cancer types, often 
requiring extensive optimisation of appropriate reagent concentrations and incubation 
times, which can be time-consuming. Therefore, cell lines were used to optimise protocols 
and preliminarily investigate the utility of targeting glycosylation for biomarker discovery 
and glycan imaging.  
 
Panels of human cell lines representing the progression of cancer have been selected 
previously from the literature, based on their increasing tumourigenicity and metastatic 
potential following orthotopic implantation into nude mice (Kuo 2015, Ph.D. thesis, 
unpublished, and Whittaker, 2015, Part III Dissertation, unpublished). To validate these 
panels as suitable models of cancer progression, the migration and invasion characteristics 
of each cell line were investigated using in vitro assays and immunohistochemistry to 
compare the relative expression of known invasion biomarkers. 
 
Flow cytometry and gel electrophoresis were used to visualise how Ac4ManNAz and 
Ac4GalNAz (Figure 1.24) differentially label glycoconjugates across panels of cell lines, 
representing the stages of cancer progression in vitro. The most widely available 
electrophoresis techniques focus on resolving proteins. Therefore, this projected focused on 
glycoprotein dynamics, despite metabolic labelling also being affected by glycolipid turnover 
(Hakomori 1985; Colley et. al. 2017). Differentially labelled glycoconjugates were identified 
using proteomics. Cell lines were treated with an azidosugar, metabolically labelled 
glycoproteins extracted and covalently tagged with a bifunctional-biotin probe such as 
alkyne-biotin, and the resulting biotin-tagged azidosugar-labelled proteins enriched using 
streptavidin-coupled beads (Figure 1.24). Liquid chromatography-tandem mass 
spectrometry was used to identify proteins differentially azidosugar labelled across the in 
vitro models of cancer progression, which it was anticipated might lead to the discovery of 




Figure 1.24: Summary of bioorthogonal chemical tools used in this project. Human breast 
and prostate cell lines have been selected from the literature previously and ordered based 
on their increasing tumourigenicity and metastatic potential following orthotopic 
implantation into nude mice. To validate these panels as suitable models of cancer 
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using in vitro assays. (a) Synthetic precursors of sialic acid and N-acetylgalactosamine 
labelled with an azide group (N-azidoacetylmannosamine (Ac4ManNAz) and N-
azidoacetylgalactosamine (Ac4GalNAz), were used to study sialyation and N-
acetylgalactosamine glycosylation respectively. (b) For 1D gel electrophoresis analysis, 
azidosugar-labelled glycoproteins were covalently reacted with Alkyne-Alexa Fluor 488 and 
detected in-gel using Alexa-488 fluorescence. For 2D electrophoresis analysis, azidosugar-
labelled glycoproteins were covalently reacted with Alkyne-biotin, resolved by 2D western 
blot and detected by fluorescence imaging using Streptavidin conjugated to Alexa Fluor 800. 
For mass spectrometry analysis, azidosugar-labelled glycoproteins were covalently ligated to 
alkyne-biotin, enriched using streptavidin-coupled beads, and identified by mass 
spectrometry (Author diagram). 
 
 
The use of panels of cell lines is limited due to the loss of cell-cell interactions that exist in 
tissues, and within the tumour microenvironment (Burdall et. al. 2003). Therefore, the 
question exists whether the correlation between azidosugar labelling and progression in 
vitro (Figure 1.23) can be validated in advanced mouse models. The evolution of pancreatic 
ductal adenocarcinoma (PDAC) from intraepithelial neoplasia (PanIN) precursor lesions to 
tumours, has been replicated in p48Cre; LSL-KrasG12D (KC) mice (Hingorani et. al. 2003; 
Westphalen and Olive 2012) (Figure 1.25a and b). Samples from human and mouse 
pancreases have been successfully extracted and grown in matrigel, whilst still maintaining 
the ability to recapitulate the morphology and disease characteristics observed in humans in 
vivo (Boj et. al. 2015; Baker et. al. 2016) (Figure 1.25c). Therefore, azidosugar labelling 
protocols were initially optimised in 3D organoid models of PDAC. Metabolic labelling of 
pancreatic organoids generated from KC mice ex vivo provided preliminary evidence for 
whether increases in Ac4ManNAz between normal tissue, PanIN lesions, and tumours, would 
be observed in vivo. Metabolic labelling studies in KC mice in vivo were then conducted, 
which could support the future use of glycan imaging for monitoring tumour progression 







Figure 1.25: Advanced mouse model of pancreatic ductal adenocarcinoma resulting from 
expression of mutant Kras. (a) Histological progression of intraepithelial neoplasia precursor 
lesions in p48Cre; LSL-KrasG12D (KC) mice over 9 months (Figure taken from Serrao et. al. 
2015). (b) Confirmation of the spectrum of lesions observed in KC mice by H&E staining of 
normal pancreatic tissue (L), splenic lymphoid tissue (M), granuloma tissue (O), pancreatic 
ductal adenocarcinoma (P) and mouse pancreatic intraepithelial neoplasia (Q) (Figure taken 
from Serrao et. al. 2015). (c) Organoid models of ductal pancreatic cancer from human 
tissues. Image shows organoid cultures generated from human tissue extracted from normal 
pancreas, resected primary tumours, resected metastatic lung lesion. Pancreatic organoids 
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can be passaged, cryopreserved and orthotopically implanted into mice. Scale bars: 500 μm 
(Brightfield image), 250 μm (H&E image) (Figure taken from Boj et. al. 2015).  
 
 
The link between aberrant glycosylation and cancer progression has formed the basis for 
using glycoproteins and specific polysaccharide structures in the diagnosis, monitoring, and 
treatment of cancer (Pinho and Reis 2015). However, the utility of cancer biomarkers has 
been challenged in recent years due to low cancer specificity and high false-positive rates 
(Mayeux 2004). Lectins, antibodies, and bioorthogonal monosaccharides have facilitated 
visualisation of glycan distribution, and composition in the context of cancer (Figure 1.17, 
1.21, and 1.22), and are useful tools for discovering novel or improved protein or imaging 
biomarkers (Springer and Gagneux 2016).  Overall, targeting glycosylation to advance 
precision oncology and improve cancer outcomes will likely need a combination of detecting 
an aberrantly glycosylated biomarker in tissue and serum, and then monitoring of tumour 























2.1.1 The burden of cancer 
 
Trends in cancer-related morbidity (Fitzmaurice et. al. 2015) and mortality worldwide, 
highlight cancer as a threat to public health. A surge in the incidence of age-related cancers, 
such as prostate and breast cancers, is also anticipated due to increasing life expectancy, an 
aging population, and the association between cancer risk and age (Cook et. al 1969). The 
global incidence of prostate cancer increased by 217% between 1990-2013 (Fitzmaurice et. 
al. 2015; Drudge-Coates et. al. 2017), which has been attributed to increases in early 
detection through PSA screening, digital rectal examinations and biopsies (Smith-Palmer et. 
al. 2019). Furthermore, in 2006, prostate cancer treatment costs totaled an estimated $9 
billion in the US alone, highlighting the economic burden of prostate cancer (Roehrborn and 
Black 2011). Although breast cancer mortality has declined in Europe (Carioli et. al. 2017), 
the Americas and Australasia (Carioli et. al. 2018), incidence continues to rise, and in the UK 
alone accounts for the greatest proportion of cancer cases in females (Smittenaar et. al. 
2016) (Chapter 1: Figure 1.1). Pre-clinical models are vital to aid our understanding of the 




2.1.2 Histological and molecular progression of cancer 
 
Prostate cancer tumourigenesis starts with the development of proliferative inflammatory 
atrophy (PIA) thought to be initiated by inflammation-induced dysplasia as a result of 
exposure to carcinogens, infectious agents (Taichman et. al. 2007), and unhealthy dietary 
lifestyle patterns (Grönberg 2003), or a familial predisposition due to the inheritance of 
germline mutations (Eeles et. al. 2014). PIA can develop into pre-cancerous prostatic 
 56 
intraepithelial neoplasia (PIN), which can progress to prostate cancer (Taichman et. al. 2007). 
The histological progression of prostate cancer is dependent on androgen, a hormone vital 
for proliferation and inhibition of apoptosis in prostate cancer cells (Debes and Tindall 2002), 
and is often accompanied by genetic alterations (Yokota 2000). Molecular classification 
markers of prostate cancer progression (Logothetis et. al. 2013) include phosphatase and 
tensin homolog (PTEN) loss, TP53 inactivation, E-cadherin loss, B-cell lymphoma 2 (BCL-2) 
overexpression and androgen receptor amplification (Quigley et. al. 2018; Dong 2006).  
 
Metastatic prostate cancer, commonly to the bone (Jin et. al. 2011), remains a public health 
burden (Kelly et.al. 2018) and has been observed in 90% of autopsies in men who died from 
prostate cancer (Bubendorf et. al. 2000). In advanced stages of prostate cancer, cells can 
become androgen-independent, which is accompanied by resistance to castration and 
androgen deprivation therapies (Taichman et. al. 2007), leading to the development of 
androgen-independent prostate cancer (Dutt and Gao 2009). 
 
Breast cancers originate from different mammary cell types, and follow a traditional multi-
step tumourigenesis model, from flat epithelial atypia, to atypical ductal hyperplasia, to 
ductal carcinoma in situ (DCIS), to breast cancer (Bombonati and Sgroi 2011), which is 
divided into luminal, receptor tyrosine kinase erbB-2 (HER2) positive, triple-negative or 
basal-like, claudin-low, ERBB2-positive, and normal-like molecular subtypes (Dai et. al. 2015). 
Up to 40% of pre-malignant DCIS lesions progress to metastatic disease (Cowell et. al. 2013), 
a process influenced by the interaction of breast cancer cells with immune cells, endothelial 
cells and stroma within the breast tumour microenvironment (Soysal et. al. 2015). However, 
a “parallel progression model” (Klein 2009) has also been proposed for breast cancer where 
metastases are believed to develop early in tumourigenesis, with disseminating tumour cells 
being released from small-sized primary tumours before they are detectable with standard 
mammographic techniques (Autier 2018). 
 
10-15% of breast cancer patients present with metastatic disease, with invasive ductal 
carcinoma making up 50-80% of histological metastatic breast cancer subtypes (Weigelt et. 
al. 2005). The principal sites of metastases can depend on the breast cancer subtype. For 
example, luminal (A and B) breast cancers have a high propensity to metastasise to the 
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brain, which occurs less frequently in triple-negative breast cancers, whilst HER2+ breast 
cancers have been shown to have a high propensity to metastasise to the lungs in 
comparison to other breast cancer subtypes (Kimbung et. al. 2015). Therefore, primary 
breast cancers and metastases are very heterogeneous and present different histological, 




2.1.3 Pre-clinical models of cancer progression 
 
Pre-clinical models of prostate (Arriaga and Abate-Shen 2019; Cunningham and You 2015; 
Ittmann et. al. 2013; Parisotto and Metzger 2013; Wu et. al. 2013) and breast (Whittle et. al. 
2015; Fantozzi and Christofori 2006; Park et. al. 2018; Sakamoto et. al. 2015; Holen et. al. 
2017) cancer progression exist in the form of cell lines, spontaneous mouse models and 
xenograft models, which replicate the spectrum of cancer progression states. The PTEN 
knockout transgenic mouse model exhibits a spectrum of pre-cancerous PIN and 
adenocarcinoma lesions and is a suitable model of early prostate cancer progression. The 
transgenic adenocarcinoma of the mouse prostate (TRAMP)-derived orthotopic prostate 
syngeneic (TOPS) model, exhibits primary tumours, as well as lung and lymph node 
metastases, and is a suitable model of advanced metastatic disease (Lardizabal et. al. 2018). 
Transgenic models maintain the immune system and stroma, generating a tumour growth 
environment more representative of that in humans. 3D organoid cultures, which grow 
faster than transgenic models, have been established from transgenic mice, human tissues, 
and circulating tumour cells (Huang et. al. 2016; Drost et. al. 2016; Liu et. al. 2012). However, 
3D organoid models generally exhibit low proliferation and viability rates, due to the 
absence of nutrient supply from the vasculature, which is often counteracted with the use of 
growth factor-rich media preparations (Lancaster and Knoblich 2014). 
 
Transgenic mouse models of breast cancer have been developed based on genetic 
engineering or induced models using a virus or ionising radiation (Sakamoto et. al. 2015; 
Fantozzi and Christofori 2006). However, the most extensively used pre-clinical models of 
breast cancer are xenograft models (Whittle et. al. 2015). Primary human tumour cells or 
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tissue are implanted into mice, leading to the development of tumours, which maintain the 
histological, growth and metastatic features of the original tumour or tissue (Park et. al. 
2018). However, xenograft models require access to fresh patient samples, exhibit low 
engraftment rates in less aggressive breast cancer subtypes, and are often developed in 
immunocompromised mice, omitting the immune system's role in tumorigenesis and making 
them unsuitable for testing immunotherapies (Holen et. al. 2017). Patient-derived xenograft 
models have also failed to recapitulate the 3D architecture observed in de novo prostate 
tumours (Huang et. al. 2016).   
 
Overall, there remains a lack of available mouse models, which accurately recapitulate the 
progression of cancer from early disease to late-stage aggressive disease, that maintain 
tumour-host interactions and that are accessible to multiple research institutes (Pienta et. al. 
2008; Holen et. al. 2017). 
 
 
2.1.4 in vitro models of cancer progression 
 
To date, there exists no single murine, or xenograft model, which replicates the progression 
of prostate or breast cancer from normal epithelium, to pre-cancerous lesions, to primary 
cancer, to advanced metastatic or drug-resistant cancer. However, there exists an extensive 
array of human prostate (Russell and Kingsley 2003) and breast (Dai et. al. 2017; Holliday 
and Speirs 2011) cancer cell lines, which are accessible, easy to grow, and enable high 
throughput studies. We constructed a panel of prostate cancer cell lines, which represented 
a progression model from normal prostate epithelium to metastatic prostate cancer, and a 
panel of breast cancer cell lines, which represented the complexity and heterogeneity of 
breast cancer molecular classifications and advanced metastatic disease states. Panels of cell 
lines, which collectively represent the general epithelial-mesenchymal transition (Chen et. al. 
2017) of apical-basal polarised, tightly adhered, epithelial cells, to highly migratory and 
invasive cancer cells (Northcott et. al. 2018; Lamouille et. al. 2014), were assembled to 
provide a flexible in vitro system to study the role of glycosylation in the progression (Arvelo 





Six human prostate cancer cell lines (Table 2.1a) and four human breast cancer cell lines 
(Table 2.1b) were selected from the literature, based on their increasing tumourigenicity and 
metastatic potential following orthotopic implantation into nude mice.  
 
To validate these progression models, the characteristics of each cell line were investigated 
in vitro using scratch wound assays to compare migration, Boyden chambers to compare 
invasion and immunohistochemistry to compare the relative expression of known invasion 
biomarkers (Pijuan et. al. 2019; Justus et. al. 2014). 
 
 
2.2.1 Validation of in vitro panels of prostate cancer progression 
 
The growth properties of each prostate cancer cell line were characterised. An inverse 
relationship between the cell line growth rates and metastatic potential was observed 
(Figure 2.1). The most metastatic cell line, PC3, grew the slowest over a 72-hour period, as 
measured by the Incucyte’s “Confluence (%)” analysis metric (Figure 2.1a). The LNCAP cell 
line, the least metastatic and non-tumourigenic cell line, had the highest confluence (83%) at 
72 hours and therefore grew the fastest (Figure 2.1b). The doubling times calculated for each 
cell line were generally consistent with reports in the literature (Table 2.1a). As expected, 
the non-malignant PNT1A cell line, representing normal prostate epithelium, exhibited the 
slowest doubling rate, with cell numbers doubling, on average, every 45 hours (Figure 2.1c). 
Doubling time and confluence were strongly correlated (r2 = 0.8087) (Figure 2.1d). 









































































































































































































































































































































































































































































































































































































































































   















































































































































































































































































































































































































































Table 2.1: in vitro models of prostate and breast cancer progression. (a) Summary of the 
characteristics of the prostate cancer cell lines used in this study (Ford et. al. 1985; van 
Steenbruggen et. al. 1989; Thalmann et. al. 1994; Russell et. al. 2003; Mitchell et. al. 2000; 
Avancès et. al. 2001; Burton et. al. 2018). (b) Summary of the characteristics of the breast 
cancer cell lines used in this study (Brinkley et. al. 1980; Cailleau et. al. 1974, Soule et. al. 
1973, Rhodes et. al. 2002; Longueville et. al. 2005; Neve et. al. 2006; Grigoriadis et. al. 2012). 
Abbreviations: androgen receptor (AR), progesterone receptor (PR), prostate-specific antigen 
(PSA), prostate-specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), 
androgen sensitive (AS), androgen insensitive (AI), estrogen receptor (ER), receptor tyrosine-
protein kinase erbB-2 (HER 2), epidermal growth factor (EGFR). (Author diagram). 
 
A scratch wound assay was conducted to assess the migratory properties of each prostate 
cancer cell line (Figure 2.2). Given the strong correlation between doubling time and 
confluence (Figure 2.1d), we anticipated that the slowest growing cell lines, PNT1A and PC3 
(Figure 2.1a) would exhibit the lowest rates of wound closure. Interestingly, the slowest 
growing cell line, PC3, exhibited one of the fastest rates of wound closure over a 72-hour 
period (Figure 2.2a). Therefore, as expected, the most metastatic cell line, PC3, was the most 
migratory. Unexpectedly, the least metastatic cell lines in the panel, PNT1A and LNCAP, 
predicted to be the least motile, showed close to 100% wound closure at 72-hours (Figure 
2.2b). Since there was no correlation between doubling time (Figure 2.2c) and relative 
wound density (r2 = 0.2380) (Figure 2.2d), the rapid wound closure seen with these cell lines 
was not caused by proliferation. This was especially true for the PNT1A cell line, which was 
the slowest growing cell line in the panel (Figure 2.1a, and c). The data suggested that the 
"normal" PNT1A cell line, was, in fact, highly migratory and thus exhibited a metastatic 
characteristic. The LNCAP cell line was the fastest growing cell line in the prostate cancer 
panel. Given the strong correlation between doubling time and confluence (r2 = 0.8087) 
(Figure 2.1d), its high relative wound density at 72 hours (Figure 2.2b) may have been 
influenced by proliferation. Generally, the data validated the panel of cell lines as a suitable 
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Figure 2.1: Growth analysis of a panel of prostate cancer cell lines with increasing 
metastatic potential. (a) Cells were imaged using the Incucyte, every 3 hours, over a 72-hour 
period. At each time point, the percentage of the area that was occupied by cells was 
calculated using the Incucyte’s inbuilt “Confluence (%)” metric. (b) Confluence (%) at 72 hours 
for each prostate cancer cell line. (c) Whole cell counts were obtained every 24 hours, over a 
72-hour period using the LUNA™ Automated Cell Counter, and used to plot a growth curve. 
The gradient of the natural log of the regression line of each curve was used to calculate the 
doubling time (hours) for each prostate cancer cell line. (d) Linear regression of confluence 
(%) at 72 hours as a function of doubling time. All data represent the average ± S.D. of three 
independent experiments, each with 3 replicates. p values represent significance by one-way 
ANOVA. The darker shades in the arrow’s greyscale (b and c) represent an increase in the 
metastatic potential of the panel of prostate cancer cell lines. 
 
 
The scratch wound assay does not sufficiently reflect the migration of cell lines through 3D 
tissue. Therefore, the invasive properties of each prostate cancer cell line were investigated 
using the Boyden chamber assay (Figure 2.3). Fluorescence imaging of the Boyden chambers, 
after a 24-hour incubation period, showed a correlation between the presence of invading 
cells and the metastatic potential of the cell lines (Figure 2.3a). An increase in Relative 
Fluorescence Units, which is directly proportional to cell numbers, correlated with an 
increase in the metastatic potential of the cell lines (Figure 2.3b). The high rate of invasion 
through the basement membrane, seen with the PNT1A cell line, confirmed the highly 
migratory phenotype shown in the scratch wound assay (Figure 2.2). Furthermore, high 
expression of vimentin, a marker of epithelial-mesenchymal transition (EMT) (Chen et. al. 
2017), was observed in the highly metastatic PC3 cell line, as expected, but also in the PNT1A 
cell line (Figure 2.3c). Again, the data suggested that the PNT1A cell line exhibited metastatic 






Figure 2.2: Migration analysis of a panel of prostate cancer cell lines with increasing 
metastatic potential. (a) Cells were grown to 95% confluence and a scratch introduced using 
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the 96-pin IncuCyte® WoundMaker (Essen Bioscience). The scratch area was imaged using 
the Incucyte, every 3 hours, over a 72-hour period. At each time point, the percentage cell 
density in the wound area relative to the cell density outside of the wound area was 
calculated using Incucyte’s inbuilt “Relative Wound Density (%)” metric. (b) Relative Wound 
Density (%) at 72 hours for each prostate cancer cell line. (c) Whole cell counts were obtained 
every 24 hours, over a 72-hour period using the LUNA™ Automated Cell Counter, and used to 
plot a growth curve. The gradient of the natural log regression line for each curve was used 
to calculate the doubling time (hours) for each prostate cancer cell line. (d) Linear regression 
of Relative Wound Density (%) at 72 hours as a function of doubling time. All data represent 
the average ± S.D. of three independent experiments, each with 3 replicates. p values 
represent significance by one-way ANOVA. The darker shades in the arrow’s greyscale (b and 
c) represent an increase in the metastatic potential of the panel of prostate cancer cell lines. 
 
 
The prostate cancer cell lines, which exhibited a significant (p < 0.05, 0.05 or 0.001) 
difference in invasion (Figure 2.3b), were analysed by immunohistochemistry to compare the 
relative expression of known invasion biomarkers and validate the PC3 cell line as a suitable 
model for metastatic prostate cancer (Figure 2.3d). The PC3 cell line stained negative for PSA 
(column 2) and PSMA (column 3), as documented in the literature (Table 2.1a). PSMA exists 
in a soluble form within normal prostate epithelial cells but during the progression of cancer, 
switches to an insoluble membrane-bound form (Laidler et. al. 2005), which is overexpressed 
in high-grade prostate cancers in comparison to benign tissues (Chang et. al. 2004). It is also 
negatively regulated by androgen and subsequently overexpressed in androgen-insensitive 
prostate cancers (Denmeade et al. 2003). Therefore, the expression of PSMA has been 
associated with invasive disease, despite the lack of evidence supporting a functional role in 
promoting prostate cancer progression. In contrast, the anti-invasive role of PSMA has been 
investigated. For example, PSMA-expressing cell lines (LNCAP and CWR22Rv1), had reduced 
invasive capacity through Matrigel, in comparison to cell lines which did not express PSMA 
(DU145 and PC3) (Ghosh et. al. 2005). This is consistent with the minor reductions in PSMA 
expression, which correlated with increases in the metastatic potential of the prostate 
cancer cell lines used in this study (Figure 2.3c, column 3). Furthermore, loss of PSMA 
expression has been observed during the switch from androgen-sensitive to androgen-
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insensitive in highly metastatic PC3 and Du 145 cell lines (Laidler et. al. 2005), consistent 
with our IHC data (Figure 2.3 c, column 3). The metastatic PC3 cell line exhibited the highest 
expression of vimentin (column 4), whose overexpression has been implicated in prostate 
cancer progression and metastasis (Satelli and Li 2011; Wei et. al. 2008). A reduction in the 
expression of E-cadherin was observed in the PC3 cell line compared to the LNCAP cell lines 
(column 6), consistent with E-cadherin loss associated with EMT in tumour cells (Petrova et. 
al. 2016). Therefore, the IHC data validated the PC3 cell line as a suitable representative of 
the advanced stages of prostate cancer.    
 
 
Collectively, the migratory (Figure 2.2), and invasive (Figure 2.3) phenotypes of the prostate 






































Figure 2.3: Invasion analysis of a panel of prostate cancer cell lines with increasing 
metastatic potential. (a) Cells were subjected to Boyden chamber analysis to measure 
migration across the basement membrane. Representative images of invading cells at the 
bottom of the polycarbonate membrane insert, 24 hours after seeding in the upper chamber, 
are shown. (b) Invading cells were detached from the bottom of the polycarbonate 
membrane insert, lysed and stained with CyQuant® GR dye. Fluorometric quantification of 
invading cells is represented for each prostate cancer cell line. (c) Representative western 
blots showing the relative abundance of vimentin in 30 µg of extract from the prostate 
cancer cell lines. (d) Immunohistochemistry staining (in brown), was used to measure relative 
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protein expression of known invasion markers: prostate-specific antigen (PSA; column 2), 
prostate-specific membrane antigen (PSMA; column 3), vimentin (column 4), phosphatase 
and tensin homolog (PTEN; column 5), E-cadherin (column 6), β-catenin (column 7), and 
mucin 1 cell surface associated (MUC1; column 8). Sections were also stained with 
haematoxylin and eosin (H&E, column 1). All data represent the average ± S.D. of two 
independent experiments, each with 3 replicates. p values represent significance by one-way 
ANOVA. Scale bars in histology represent 50μM, magnification 20x. The darker shades in the 
arrow’s greyscale represent an increase in the metastatic potential of the panel of prostate 
cancer cell lines. 
 
2.2.2 Validation of in vitro panels of breast cancer progression 
 
The growth properties of each breast cancer cell line were characterised. All growth rates 
were similar over a 72-hour period (Figure 2.4a). Only the least metastatic cell line, MDA MB 
453, and most metastatic cell line, MDA MB 231, showed significant differences (p < 0.05) in 
their degree of confluence at 72 hours (Figure 2.4b). All doubling times were similar (Figure 
2.4c), and did not correlate with degree of confluence (r2 = 0.01787) (Figure 2.4d). Therefore, 
migration of the breast cancer cell lines, assessed by scratch wound assays, should not be 
influenced by cell proliferation, allowing assessment of real migratory phenotypes. 
 
As expected, the least metastatic cell line, MDA MB 453, exhibited the slowest wound 
closure over a 72-hour period (Figure 2.5a). The most metastatic cell lines in the panel, MDA 
MB 468 and MDA MB 231, showed the highest relative wound density at 72 hours (Figure 
2.5b). As there was no correlation between doubling time (Figure 2.5c) and relative wound 
density (r2 = 0.01199) (Figure 2.5d), the general increase in relative wound density at 72 
hours (Figure 2.5b) was caused by an increase in the motility of the cell lines. This correlated 




Figure 2.4: Growth analysis of a panel of breast cancer cell lines with increasing metastatic 
potential. (a) Cells were imaged using Incucyte, every 3 hours, over a 72-hour period. At each 
time point, the percentage of the image area occupied by cells was calculated using the 
Incucyte’s inbuilt “Confluence (%)” metric. (b) Confluence (%) at 72 hours for breast cancer 
cell line. (c) Whole cell counts were obtained every 24 hours, over a 72-hour period, using the 
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LUNA™ Automated Cell Counter, and used to plot a growth curve. The gradient of the natural 
log regression line of each curve was used to calculate the doubling time (hours) for each 
breast cancer cell line. (d) Linear regression of the degree of confluence (%) at 72 hours as a 
function of doubling time. All data represent the average ± S.D. of three independent 
experiments, each with 3 replicates. p values represent significance by one-way ANOVA. The 
darker shades in the arrow’s greyscale (b and c) represent an increase in the metastatic 
potential of the panel of breast cancer cell lines. 
 
The invasive properties of each breast cancer cell line were investigated using the Boyden 
chamber assay (Figure 2.6). There was a correlation between the presence of invading breast 
cancer cells and the metastatic potential of the cell lines (Figure 2.6a). An increase in 
Relative Fluorescence Units, also correlated with an increase in the metastatic potential of 
the cell lines (Figure 2.6b). The breast cancer cell lines were analysed by 
immunohistochemistry to compare the relative expression of known invasion biomarkers 
(Figure 2.6c). The MCF 7 cell line was the only cell line to stain positive (in brown) for 
estrogen receptor (ER; column 2) and progesterone receptor (PR; column 3), consistent with 
the immunoprofile documented in the literature (Table 2.1b). A decrease in the expression 
of PTEN (column 5) correlated with an increase in the metastatic potential of the cell lines. 
However, the literature provides conflicting information about the inactivation, reduced 
expression and loss of PTEN during the progression of breast cancer, with reduced PTEN 
expression being observed in anywhere between 4 to 63% of breast cancers (Li et. al. 2017; 
Álvarez-Garcia et. al. 2019). A clear increase in expression of E-cadherin (column 6) 
correlated with an increase in the metastatic potential of the cell lines, contrary to E-






Figure 2.5: Migration analysis of a panel of breast cancer cell lines with increasing 
metastatic potential. (a) Cells were grown to 95% confluence and a scratch introduced using 
the 96-pin IncuCyte® WoundMaker (Essen Bioscience). The scratch area was imaged using 
Incucyte, every 3 hours, over a 72-hour period. At each time point, the percentage cell density 
in the wound area relative to the cell density outside of the wound area was calculated using 
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Incucyte’s inbuilt “Relative Wound Density (%)” metric. (b) Relative Wound Density (%) at 72 
hours for each breast cancer cell line. (c) Whole cell counts were obtained every 24 hours, 
over a 72-hour period, using the LUNA™ Automated Cell Counter, and used to plot a growth 
curve. The gradient of the natural log regression line of each curve was used to calculate the 
doubling time (hours) for each breast cancer cell line. (d) Linear regression of Relative Wound 
Density (%) at 72 hours as a function of doubling time. All data represent the average ± S.D. 
of three independent experiments, each with 3 replicates. p values represent significance by 
one-way ANOVA. The darker shades in the arrow’s greyscale (b and c) represent an increase 
in the metastatic potential of the panel of breast cancer cell lines. 
 
 
Collectively, the migratory (Figure 2.5), and invasive (Figure 2.6) phenotypes of the breast 



































      
 74 
 
Figure 2.6: Invasion analysis of a panel of breast cancer cell lines with increasing 
metastatic potential. (a) Cells were subjected to Boyden chamber analysis to measure 
migration across the basement membrane. Representative images of invading cells at the 
bottom of the polycarbonate membrane insert, 24 hours after seeding in the upper chamber, 
are shown. (b) Invading cells were detached from the bottom of the polycarbonate 
membrane insert, lysed and stained with CyQuant® GR dye. Fluorometric quantification of 
invading cells is shown for each breast cancer cell line. (c) Immunohistochemistry staining 
(brown), was used to measure relative protein expression of known invasion markers: 
estrogen receptor (ER; column 2), progesterone receptor (PR; column 3), vimentin (column 4), 
phosphatase and tensin homolog (PTEN; column 5), E-cadherin (column 6), β-catenin (column 
7), and mucin 1 cell surface associated (MUC-1; column 8). Sections were also stained with 
haematoxylin and eosin (H&E; column 1). All data represent the average ± S.D. of three 
independent experiments, each with 3 replicates. p values represent significance by one-way 
ANOVA. Scale bars in histology represent 50 μM, magnification 20x. The darker shades in the 
arrow’s greyscale (b and c) represent an increase in the metastatic potential of the panel of 







































There remains a lack of available preclinical models, which accurately recapitulate the 
progression of cancer from early disease to the late-stage aggressive disease observed in 
patients (Pienta et. al. 2008; Holen et. al. 2017). However, there exists an extensive array of 
human prostate (Russell and Kingsley 2003) and breast (Dai et. al. 2017; Holliday and Speirs 
2011) cancer cell lines, derived from different disease states, which are easy to culture for 
high throughput studies. In this study, we constructed a panel of prostate (Table 2.1a) and 
breast cancer cell lines (Table 2.1b), which represented a progression model from normal 
epithelium to metastatic cancer, based on their cellular origin’s and their characteristics 
when orthotopically implanted into mice in vivo. 
 
During the metastatic process, tumour cells with enhanced plasticity migrate from the 
primary tumour, and express de novo glycans such as Sialyl LewisX and Sialyl LewisA on 
mucins and glycosphingolipids.  These interact with glycan-binding selectins present on 
endothelial cells, activated platelets and leukocytes, and secreted extracellular matrix 
proteins, facilitating adherence and transversion through the vasculature, and promoting 
tumour dissemination via the bloodstream, and formation of emboli at distant endothelial 
sites (Bogenrieder and Herly 2003; Fuster and Esko 2005). Therefore, we expected cell lines 
derived from metastases to be highly migratory, complemented by reduced expression of 
cell-adhesion promoting proteins such as E-cadherin (Petrova et. al. 2016), and highly 
invasive, confirmed by high expression of proteins associated with EMT, such as vimentin 
(Chen et. al. 2017). The tumourigenic PC3 prostate cancer cell line, derived from a lumbar 
metastasis, exhibited one of the fastest rates of wound closure over a 72-hour period (Figure 
2.2a and b), the highest number of invasive cells traversing the basement membrane (Figure 
2.3a and b), the highest expression of vimentin (Figure 2.3d, column 4), and the lowest 
expression of E-cadherin (Figure 2.3d, column 6), consistent with molecular characteristics 
commonly observed during the metastatic process. The non-tumourigenic LNCAP cell line 
was the least invasive cell line in the prostate cancer panel (Figure 2.3a and b). Therefore, 




A unique characteristic of prostate cancer progression observed in humans is the switch 
from androgen dependence to androgen independence (Dutt and Gao 2009), which has 
detrimental effects on treatment interventions due to the accompanied resistance to 
castration and androgen deprivation therapies (Taichman et. al. 2007). Our panel of prostate 
cancer cell lines collectively represent a progression from androgen sensitivity in the AR 
expressing LNCAP cell line, to androgen insensitivity in the LNCAP C4, LNCAP C4-2 and LNCAP 
C4-2B cell lines, to an eventual loss of AR expression and androgen insensitivity in the PC3 
cell lines (Table 2.1a). However, the highly migratory and invasive PC3 cell line, although of 
metastatic origin, is negative for PSA (Table 2.1a; Figure 2.3, column 2), and is not 
representative of the high expression of PSA observed in patients with aggressive prostate 
cancer. Several studies have reported loss of AR expression between the LNCAP and PC3 cell 
lines, and the absence of PSA expression in a PC3 cell line (Mitchell et. al. 2000; Tai et. al. 
2011), which are consistent with our IHC data, and the immunoprofiles reported in the 
literature (Table 2.1a). Therefore, the PC3 cell line is limited in its ability to model the key 
clinical characteristics of prostate cancer progression observed in patients. This is the benefit 
of conducting studies in panels of multiple cell lines, rather than in a single cell line.  
 
The MDA MB 453, MCF 7, MDA MB 468 and MDA MB 231 breast cancer cell lines, selected 
from the literature based on their increasing tumourigenicity, exhibited an increase in 
relative wound density at 72 hours (Figure 2.5b), which correlated with an increase in the 
metastatic potential of these breast cancer cell lines, which was illustrated by the increasing 
presence of invasive cells traversing the basement membrane during Boyden chamber 
analysis (Figure 2.6a). PTEN, a tumour suppressor protein, is frequently lost in cancers, 
causing unregulated activation of the phosphatidylinositol 3 kinase (PI3K)/protein kinase B 
(AKT) pathway and its downstream effector functions such as cell cycle progression and 
stimulation of angiogenesis (Milella et. al. 2015). Consistent with these reports, a decrease in 
the expression of PTEN correlated with an increase in the metastatic potential of the breast 
cancer cell lines used in this study (Figure 2.6c, column 5). However, the literature provides 
conflicting information about the inactivation, reduced expression and loss of PTEN during 
the progression of breast cancer, with reduced PTEN expression being observed in anywhere 
between 4 to 63% of breast cancers (Li et. al. 2017; Álvarez-Garcia et. al. 2019).  A clear 
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increase in the expression of E-cadherin (Figure 2.6c, column 6) correlated with an increase 
in the metastatic potential of the breast cancer cell lines and was contrary to loss of E-
cadherin frequently associated with EMT in tumour cells and aggressive disease (Petrova et. 
al. 2016). E-cadherin loss has been strongly correlated with invasive lobular breast 
carcinoma (Horne et. al. 2018; Singhai et. al. 2011), and proposed as a prognostic marker for 
this breast cancer subtype. However, few studies have correlated E-cadherin expression in 
other breast cancer histological subtypes. Furthermore, re-expression of E-cadherin has 
been reported in breast cancer metastases and overexpression plays an oncogenic role in 
the MDA MB 468 cell line (Hugo et. al. 2017), consistent with increases in E-cadherin 
expression observed across our panel of breast cancer cell lines.  
 
The panel of breast cancer cell lines used in this study collectively represent the 
heterogeneous nature of breast cancer molecular subtypes (Dai et. al. 2015) such as luminal 
A (MCF 7), luminal B (MDA MB 453), receptor tyrosine kinase erbB-2 (HER2) positive (MDA 
MB 453), and triple-negative or basal-like (MDA MB 468 and MDA MB 231) (Dai et. al. 2015) 
(Table 2.1b). However, their varied cellular origins do not accurately represent the clonal 
evolution of cancer, which begins in a single cell type (Greaves et. al. 2012). In this respect, 
the metastatic end of the breast cancer panel could be improved based on lentivirus 
barcoding techniques used by Wagenblast and colleagues to analyse drivers of breast cancer 
metastasis (Wagenblast et. al. 2015). In this study, 4T1 cell lines were infected with lentivirus 
barcode libraries. Individual clones were isolated using FACS, and implanted into mammary 
fat pads, followed by the formation of tumours and metastases. Samples from the tumours 
and metastases to the brain, lung, lymph nodes, liver, and blood were extracted and 
sequenced. Clones of 4T1 cells responsible for metastases to specific regions of the body 
could then be traced back to the original cell lines cultured in vitro based on their unique 
lentivirus barcodes. These cell lines may be available at the CRUK CI (Hannon group) and 
would provide a panel of metastatic breast cancer cell lines derived from the same primary 
tumour. 
 
Collectively, the migratory and invasive phenotypes of the cell lines, were consistent with 
molecular characteristics commonly observed during the metastatic process, validating the 
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panels as suitable in vitro models of prostate (Table 2.1a) and breast (Table 2.1b) cancer 
progression.  
 
The panels of cell lines used in this study were limited by the availability of cell lines 
representing normal prostate or breast tissue epithelium. The PNT1A cell line is the most 
extensively used model of normal prostate cells. However, despite being the slowest 
growing cell line in the panel (Figure 2.1a, and c), the PNT1A cell line was highly motile in 
scratch wound closure analysis (Figure 2.2) and invasive in Boyden chamber analysis (Figure 
2.3a-c), and subsequently deemed an unsuitable model for normal prostate epithelium.  
 
The Hb4a cell line (Stamps et. al. 1994), derived from normal breast tissue, exhibits highly 
rearranged chromosomes, which limited its use as a model for normal breast epithelial cells 
(Davidson et. al. 2000). The MCF10A cell line, derived from non-malignant breast tissue 
(Chavez et. al. 2010), has been shown not to stain for markers usually expressed in normal 
breast tissue, such as β-casein and α-lactalbumin, and also expresses stem-like, luminal and 
basal cell markers when cultured in 2D or 3D culture (Qu et. al. 2015). Due to its instability 
under different culturing conditions, its utility as a model of normal breast epithelium 
remains unclear. Abnormal changes in morphology have been observed when adapting 
normal primary Human Mammary Epithelial Cells (HMECs) to HuMEC (InvitrogenTM) or 
MEGM (LONZA) media (Kuo 2015, PhD thesis, unpublished). There remains a need to find a 
common media preparation that will allow the growth of “normal” breast cell lines. 
 
In this study, we validate a flexible in vitro system to study the role of glycosylation in 








2.4 Materials and Methods 
 
2.4.1 Cell lines 
 
The PNT1A, LNCAP, and LNCAP C4-2B human prostate cell lines were obtained from the 
Cancer Research UK Cambridge Institute Biorepository, based on stocks made available by 
Joe Kuo. The LNCAP C4, LNCAP C4-2, and PC3 human prostate cancer cell lines were 
purchased from ATCC. All prostate cell lines were cultured in RPMI with L-glutamine (Gibco®, 
InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories).  
 
The MDA MB 453, MCF 7, MDA-MB-468, and MDA MB 231 human breast cancer cell lines 
were obtained from the Cancer Research UK Cambridge Institute Biorepository, based on 
stocks made available by Joe Kuo. All breast cell lines were cultured in DMEM with L-
glutamine (Gibco®, InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories). 
 
Cell lines were genotyped and authenticated by Short Tandem Repeat (STR) DNA profiling 
and comparison with available databases from ATCC or DSMZ. All cell lines tested negative 
for Mycoplasma using the MycoProbe™ Kit (R&D Systems). 
 
 
2.4.2 Tissue culture 
 
Cell lines were maintained in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) at 5% CO2, 
in 37 °C humidified incubators, and cultured to 80% confluence. Briefly, cells were washed 
once with warm Phosphate Buffered Saline (PBS; 20 ml/flask; 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4 per litre, pH 7.4), and trypsinised. Prostate cancer cell lines were 
trypsinised for 4 minutes at 37oC, apart from the PC3 cell line, which was trypsinised for 7 
minutes. Breast cancer cell lines were trypsinsed for 7 minutes at 37oC. Trypsinised cells 
were added to equal volumes of media, centrifuged at 700 x g for 4 minutes (4oC), and 
resuspended in fresh media. Viable cell counts were obtained by Trypan blue dye exclusion 
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2.4.3 Growth assays  
 
Cell lines were seeded at 3 x 104 cells/cm2 in NuncTM 24 well plates (Thermo ScientificTM) 
with 0.5 ml media and placed in a 20x FLR Incucyte (Essen Bioscience) for 72 hours. Each well 
was imaged in 9 positions, every 3 hours for 72 hours. At each time point, the percentage of 
the area that was occupied by cells was calculated using the Incucyte’s inbuilt “Confluence 
(%)” metric. The average confluency from the 9 images, across the 3 wells was calculated 
and used to plot a growth curve.  
 
In parallel, cell lines were seeded at 3 x 104 cells/cm2 in NuncTM 24 well plates (Thermo 
Fisher ScientificTM) with 0.5 ml media. Whole-cell counts (including dead cells) were obtained 
every 24 hours, over 72 hours using the LUNA™ Automated Cell Counter (Logos Biosystems) 
and used to plot a growth curve. The gradient of the natural log of the regression line of 
each curve was used to calculate the doubling time (hours) for each cell line. 
 
 
2.4.4 Scratch wound assays 
 
Cells were seeded at 3 x 104 cells/cm2 in 96 well Imagelock (Essen Bioscience) plates with 
100 μl media. At 90% confluence, wells were scratched manually using the 96-pin IncuCyte® 
WoundMaker (Essen Bioscience), the debris washed from the wounds with 100 μl warm PBS, 
and each well topped up with 100 μl fresh media. Plates were immediately placed in a 20x 
FLR Incucyte (Essen Bioscience), and each scratch imaged at 1 central position every 3 hours, 
over 72 hours. At each time point, the percentage cell density in the wound area relative to 
the cell density outside of the wound area was calculated using Incucyte’s inbuilt “Relative 




2.4.5 Invasion assays 
 
The invasive properties of the cell lines were assayed using the CytoSelectTM Cell Invasion 
Assay Kit (Cell Biolabs), according to the manufacturer’s protocol (Figure 2.7).  
 
 
Figure 2.7: Schematic representation of the Cytoselect® Boyden Chamber assay. (Figure 
taken from Cambridge Bioscience, https://www.bioscience.co.uk/cpl/132954/, 2019).  
 
 
Briefly, 100 μl of serum-free media was added to the upper chambers to rehydrate the 
basement membrane lining the polycarbonate insert. After a 1-hour incubation at room 
temperature, the rehydration medium was removed. 150 μl of phenol red-free media (10% 
FBS) was added to the feeder tray beneath the polycarbonate insert. The upper chamber 
was seeded with 100 μl of cell suspension containing 2 x 106 cells/ml in phenol red-free 
media (10% FBS). After a 48-hour incubation at 5% CO2, in 37 °C incubators, invaded cells 
were dislodged from the underside of the polycarbonate insert using 150 μl Cell Detachment 
Solution, dyed with CyQuant® GR Dye (diluted 1:75 in the kits 4x lysis buffer), and 
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transferred into a fresh clear bottom, black sided, 96-well microtiter plate (Costar).  Cy2 
fluorescence (489 nm maximum excitation wavelength, 506 nm maximum emission 
wavelength) was imaged using a Typhoon scanner (GE Healthcare) to obtain a plate image, 
and subsequently quantified with a PHERAstar FS plate reader (BMG Labtech) at 480 nm/520 





5.5 x 107 - 1 x 108 cells were washed with 1.5 ml PBS and pelleted at 12, 000 x g for 1 minute. 
The supernatant was removed, and the cell pellets fixed in 1 ml 10% neutral buffered 
formalin at room temperature for 24-hours. Fixed pellets were harvested by centrifugation 
(12, 000 x g for 1 minute), resuspended in 0.5 ml of 70% ethanol solution, and incubated for 
30 minutes at room temperature. Cells were pelleted at 12,000 x g for 1 minute, the 
supernatant removed, and air-dried to remove residual ethanol. Dried cell pellets were 
resuspended in 0.5 ml of 2% agar (20 mg/ml in Milli-Q 18.2 Ω water) and left to solidify at 
room temperature for approximately 1 hour.  
 
Cells embedded in agar were submitted to the Histopathology core at the Cancer Research 
UK Cambridge Institute, where they were sliced into 3 μm sections and stained using the 
BondTM Polymer Refine Detection protocol on the Bond-III Automated Platform (Leica 
Biosystems Ltd). Briefly, sections were de-waxed and de-hydrated using the automated Leica 
ST5020 (Leica Biosystems Ltd), and incubated in hydrogen peroxide (HRP; 3-4% v/v) to 
quench endogenous peroxidase activity. Sections obtained from the prostate cancer cell 
pellets were stained with the following primary antibodies: rabbit anti-PSA (1:2500; Dako), 
rabbit anti-PSMA (1:50; Novocastra), mouse anti-vimentin (1:400; Novocastra), mouse anti-
PTEN (1:200; Dako), mouse anti-E-cadherin (1:25; Dako), mouse anti-β-catenin (1:5000; BD 
Biosciences), and mouse anti-MUC1 (1:2500; Abcam). Sections obtained from the breast 
cancer cell pellets were stained with the following primary antibodies: mouse anti-ER (1.071 
μl/ml Novocastra), mouse anti-PR (1:50; Dako), mouse anti-vimentin (1:400; Novocastra), 
mouse anti-PTEN (1:200; Dako), mouse anti-E-cadherin (1:25; Dako), mouse anti-β-catenin 
(1:5000; BD Biosciences), and mouse anti-MUC1 (1:2500; Abcam). Mouse or rabbit primaries 
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were localised using a Post-Primary IgG linker reagent or Poly-HRP IgG, respectively, and the 
complexes visualised by addition of chromogen 3,3’-Diaminobenzidine tetrahydrochloride 
hydrate (DAB). DAB Enhancer was used for all antibodies (Leica, AR9432), except for the 
anti-ER and anti-PR assays. Slides were counterstained using the Automated Schedule for 
Haematoxylin and Eosin Stain on a Leica ST5020 (Leica Biosystems). Slides were mounted 
and scanned on a Leica AT2 at 20x magnification at a resolution of 0.5 μm per pixel.  
 
 
2.4.7 Preparation of whole-cell lysates 
 
Prostate cancer cell lines were cultured and counted as described previously, seeded at 3 x 
104 cells/cm2 in 100 mm cell culture dishes (15 ml media/dish) (Corning), and incubated in 5 
% CO2, at 37 °C for 24 hours. After 24 hours, dishes were washed twice with warmed PBS 
and replaced with fresh media (15 ml media /dish). After 24 hours, cells were harvested by 
trypsinisation and centrifugation, as described previously. Cell viability was measured by 
Trypan blue dye exclusion using a LUNA™ Automated Cell Counter (Logos Biosystems). Cells 
were incubated with 1 ml RIPA buffer (Thermo Fisher ScientificTM) supplemented with 1x 
HaltTM Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher ScientificTM) and 1x 0.5 M 
EDTA solution (Thermo Fisher ScientificTM), for 30 minutes at 4oC on an end-over-end shaker 
(30 rpm). Lysates were centrifuged at maximum speed (21, 000 x g) for 20 minutes at 4oC 
and the supernatant transferred into a fresh Nostick® hydrophobic microcentrifuge tubes 
(Scientific Specialties, Inc.).  
 
The total protein concentrations were determined using the DC™ Protein Assay (BIO-RAD), 




2.4.8 Western blot  
 
Whole-cell lysates from each prostate cancer cell line were resolved on precast 4-12% 1mm 
Bis-Tris gels (Thermo Fisher ScientificTM) in 1x NuPAGE MOPS buffer (Invitrogen) (30 μg/lane, 
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30 min 60 V, 120 min 120 V), and 1D gels transferred onto nitrocellulose membranes using 
an iBlot 2 (Life). Blots were incubated in 1x Odyssey® PBS block buffer (LI-COR) for 1 hour, 
followed by an overnight incubation at 4oC with the following primary antibodies in PBS 
blocking buffer (0.1% tween, 0.1% SDS): rabbit monoclonal anti-vimentin (1:1000; Cell 
Signalling Technologies), and rabbit monoclonal anti-b-actin (1:1000; Cell Signalling 
Technologies). After overnight incubation, primary antibodies were removed, and the blots 
washed 3 times (PBS + Tween (0.1%), 5 minutes). Blots were incubated for 1 hour at room 
temperature with a goat anti-rabbit IRDye 680 RD secondary antibody (1:15, 000; LI-COR) in 
PBS blocking buffer (0.1% tween, 0.1% SDS). Blots were washed 3 times in PBS (0.1% Tween) 
for 5 minutes, once in PBS for 5 minutes, and imaged on an Odyssey CLx Infrared Imaging 
System (LI-COR Biosciences). 
 
 
2.4.9 Statistical analysis  
 


















Chapter 3: Detection of differential glycosylation using 
bioorthogonal chemistry in in vitro models of cancer 






3.1.1 Aberrant sialyation and N-acetylgalactosamine glycosylation in cancer 
 
Glycans are the complex carbohydrate structures formed when monosaccharides, namely 
glucose (Glc), N-acetyl-glucosamine (GlcNAc), Galactose (Gal), N-acetyl-galactosamine 
(GalNAc), Mannose (Man), Xylose (Xyl), Glucuronic acid (GlcA), Fucose (Fuc) and N-
acetylneuraminic acid (NeuAc), also known as sialic acid, link together via glycosidic bonds 
(Prestegard and Widmalm, 2017). Glycans act as cellular decorations with roles in 
intracellular signalling, hormone regulation, cell migration, plasma membrane structuring, 
immunity, host-pathogen recognition, and drug sensitivity (Pinho and Reis 2015; Varki 2017). 
Their synthesis is dependent on the dynamic interactions between glycoenzymes within a 
specific cell type. These dynamic interactions are sensitive to physiological and pathological 
changes (Reily et.al. 2019; Krasnova and Wong 2016; Mariño et. al. 2010). In cancer, 
alterations in the expression of glycoenzymes and their location within the Golgi 
compartments, alterations to the tertiary conformation of peptide backbones and nascent 
glycan chains, as well as fluctuations in the abundance of acceptor substrates, sugar 
nucleotide donors and cofactors (Pinho and Reis 2015; Adamczyk et. al. 2012), change the 
repertoire of cell surface glycan structures. The overall consequence is the generation of 
tumour-associated glycan patterns such as hypersialylation, aberrant fucosylation, glycan 
truncation, hyperbranching, and overexpression of glycosphingolipids (Pinho and Reis 2015) 
(Chapter 1: Figure 1.7). 
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Increases in sialyation (Büll et. al. 2014) of cell surface glycoproteins (Schultz et. al. 2012) 
and glycolipids (Daniotti et al. 2013) has been observed in prostate (Munkley et. al. 2016), 
breast (Kölbl et. al. 2016), and pancreatic cancers (Munkley 2019), and is associated with 
increased disease progression and metastasis (Stowell et. al. 2015). This has been attributed 
to overexpression of sialyltransferases (Bhide and Colley 2017), secretion of active 
sialyltransferases into the circulation (Zhang et. al. 2018) and downregulation of sialic acid 
cleaving sialidases (Uemura et. al. 2009), all of which contribute towards the generation of 
tumour-associated antigens such as the Sialyl Lewis antigens (Natoni et. al. 2016; Pinho and 
Reis 2015) (Chapter 1: Figure 1.8a). 
 
Increases in cell surface N-acetylgalactosamine during cancer progression has also been 
observed, for example, elevated levels of unmodified or sialylated Thomsen-nouveau (Ju et. 
al. 2011) (Chapter 1: Figure 1.9) and Thomsen-Friedenreich (Springer et. al. 1975) (Chapter 1: 
Figure 1.10) antigens, which are composed of an N-acetylgalactosamine residue connected 
to serine or threonine residues by an a-glycosidic bond. As disease progresses, glycosylation 
is altered.  
 
 
3.1.2 Imaging aberrant tumour glycosylation using bioorthogonal chemistry  
 
Traditionally, global increases in cell surface glycosylation associated with cancer progression 
have been quantified using glycan-binding lectins with various monosaccharide specificities 
(van Kooyk 2008; Kuo et. al. 2016) (Chapter 1: Figure 1.17a). For example, decreased binding 
of topically applied fluorescein-labelled wheat germ agglutinin lectin was detected during 
the progression of pre-invasive Barrett’s oesophagus to adenocarcinoma (Bird-Lieberman et. 
al. 2012) (Chapter 1: Figure 1.17c). This correlation between increases in glycosylation and 
metastatic potential suggest that detecting changes in glycosylation could be useful for 
monitoring the propensity of a tumour to metastasise in vivo i.e. for assessing the 
aggressiveness of the disease. 
 
Novel ways of detecting aberrant glycosylation include the use of bioorthogonal 
monosaccharide analogues containing a functional azide group or “chemical reporter” not 
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normally present in the cell (Laughlin et. al. 2009), which are incorporated metabolically into 
cellular glycan structures, and subsequently detected by covalent ligation of imaging probes 
or affinity reagents that react rapidly with the azide group (Saxon and Bertozzi 2000; Saxon 
et. al. 2002) (Chapter 1: Figure 1.20). Bioorthogonal azide-based chemical reporters, 
generally called azidosugars, have been used to study glycosylation in zebrafish, 
Trypanosoma cruzi, Haemophilus ducreyi, Caenorhabditis elegans and human cell lines 
(Laughlin et. al. 2008; Lantos et. al. 2016; Agarwal et. al. 2015; Goon et. al. 2003; Laughlin et. 
al. 2009; Saxon and Bertozzi 2000; Dube and Bertozzi 2003). The most extensively used 
chemical reporters in cancer research are variants of sialic acid, N-acetylgalactosamine and 
fucose, due to their association with cancer progression (Fuster and Esko 2005; Laughlin et. 
al. 2009; Cheng et. al. 2016), such as precursors of sialic acid and N-acetylgalactosamine, 
which have been labelled with an azide group (N-azidoacetylmannosamine (Ac4ManNAz) and 
N-azidoacetylgalactosamine (Ac4GalNAz)). We previously validated a panel of prostate 
(Chapter 2: Table 2.1a) and breast (Chapter 2: Table 2.1b) cancer cell lines as suitable in vitro 
models of cancer progression using scratch wound assays to compare migration, Boyden 
chambers to compare invasion and immunohistochemistry to compare the relative 
expression of known invasion biomarkers (Pijuan et. al. 2019; Justus et. al. 2014). Here, we 
applied bioorthogonal labelling techniques, which have been used previously to visualise cell 
surface glycosylation in cancer cell lines in vitro (Stöckmann et. al., 2011; Kuo 2015, PhD 
thesis, unpublished) (Chapter 1: Figure 1.21a and b) and in tumour bearing mice in vivo 
(Neves et. al. 2011; Neves et. al. 2013; Neves et. al. 2016) (Chapter 1:21c-e).  These 
bioorthogonal labelling techniques were used in our in vitro model of breast cancer 
progression (Chapter 2: Table 2.1b), and the p48Cre; LSL-KrasG12D (KC) mouse model 
(Hingorani et. al. 2003; Westphalen and Olive 2012) of pancreatic ductal carcinoma (Chapter 
1: Figure 1.25).  
 
The clinical relevance of imaging glycosylation in models of cancer progression is not simply 
in the identification of tumours, for which many techniques already exist, but in the ability to 
visualise changes in glycosylation that we know occur during disease progression (Stowell et. 
al. 2015; Pinho and Reis 2015; Fuster and Esko 2005; Ju et. al. 2011; Vajaria and Patel 2017). 
The ability to visualise non-invasively tumour glycosylation in vivo, using bioorthogonal 
precursors of sialic acid (Ac4ManNAz) and N-acetylgalactosamine (Ac4GalNAz), and clinically 
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relevant imaging modalities, would provide qualitative insights into glycan dynamics and 
turnover (Colley et. al. 2017) in real-time. Glycan imaging may also support cancer grading in 
order to distinguish between benign lesions and those with the potential to become 






Human breast cancer cell lines were selected from the literature, based on their increasing 
tumourigenicity and metastatic potential following orthotopic implantation in the mammary 
fat pads of nude mice (Chapter 2: Table 2.1b). Previous work in the lab showed a correlation 
between increases in N-azidoacetylmannosamine labelling, a precursor of sialic acid, and 
increases in the metastatic potential of these breast cancer cell lines (Kuo 2015, Ph.D. thesis, 
unpublished) (Chapter 1: Figure 1.23a, b, and d). In this study, the migratory (Chapter 2: 
Figure 2.5), and invasive (Chapter 2: Figure 2.6) phenotypes of these breast cancer cell lines 
were used to validate the panel as a suitable in vitro model of breast cancer progression. 
The, dynamic increases in sialylation in these cell lines, observed using bioorthogonal 
chemistry, suggested that glycosylation was altered during cancer progression and that 
changes in tumour glycosylation could be imaged using metabolic labelling in vivo in 
advanced models of cancer progression. 
 
Metabolic labelling of the breast cancer cell lines was conducted in Quantum 286 media 
(PAA Laboratories), which was eventually discontinued. Therefore, the cell lines were 
adapted to new DMEM media preparations and the metabolic labelling protocol optimised 







3.2.1 Flow cytometric analysis of metabolically labelled breast cancer cell lines 
 
Breast cancer cells were incubated with precursors of sialic acid and N-acetylgalactosamine 
that had been labelled with an azide group (N-azidoacetylmannosamine (Ac4ManNAz) and N-
azidoacetylgalactosamine (Ac4GalNAz) respectively), and which are incorporated 
biosynthetically into cell surface glycans. Cell line viability was similar when treated with 
vehicle (0.1% DMSO), Ac4ManNAz (50 μM) or Ac4GalNAz (50 μM). Therefore, azidosugar-
induced cytotoxicity was undetectable during the incubation period required for metabolic 
labelling (24 hours). The incorporated azide groups were reacted sequentially with TMDIBO-
(PEG)3-biotin and NeutrAvidinTM DyLightTM 650 (NA650), followed by fluorescence detection 
using flow cytometry (Figure 3.1). 
 
Debris (Figure 3.1a, i), cell aggregates (Figure 3.1a, ii) and dying cells (Figure 3.1a, iii) were 
excluded from the analysis. NA650 fluorescence on viable cells was quantified (Figure 3.1a, 
iv). The Mean Fluorescence Intensity ratio (MFI ratio) for a single cell line was calculated 
(Figure 3.1b) by normalising the average fluorescence intensity from Ac4ManNAz-labelled (in 
red) or Ac4GalNAz-labelled (in green) cells, against background fluorescence. Minimal 
background was observed in the absence of the azido-sugars, in cells treated with TMDIBO-
(PEG)3-biotin/NA650/Sytox® Green (in brown), NA650/Sytox® Green (in black), Sytox® Green 




Figure 3.1: Flow cytometric analysis of metabolically labelled MDA MB 231 breast cancer 
cells. (a) Gating parameters, based on forward scatter cell area analysis plots, were 
implemented to exclude debris (i), and aggregated cells (ii). Non-viable cells were excluded 
based on high Sytox® Green fluorescence and a low intracellular NADH concentration 
determined by measuring UV fluorescence. (iii) NA650 fluorescence was quantified on viable 
cells only (iv). (b) Representative histograms showing NA650 fluorescence from MDA MB 231 
breast cancer cells metabolically labelled with N-azidoacetylmannosamine (Ac4ManNAz, red) 
or N- azidoacetylgalactosamine (Ac4GalNAz, green). Background controls were included to 
detect non-specific fluorescence (brown, black, dark grey, and light grey). 
 
 
The mean fluorescence intensity (MFI) ratios from each of the metabolically labelled breast 
cancer cell lines were compared (Figure 3.2). An increase in Ac4ManNAz and Ac4GalNAz 
labelling correlated with an increase in the metastatic potential of the cell lines (Figure 3.2a). 
The most metastatic cell line, MDA MB 231, showed the highest labelling with Ac4ManAz and 
Ac4GalAz. In each cell line, there was at least a 2-fold increase in labelling with Ac4ManNAz 
when compared with Ac4GalNAz (Figure 3.2b). 
 






























     


































Figure 3.2: Metabolic labelling of a panel of breast cancer cell lines with increasing 
metastatic potential. Breast cancer cells were labelled sequentially with N-
azidoacetylmannosamine (Ac4ManNAz) or N- azidoacetylgalactosamine (Ac4GalNAz), and 
then TMDIBO-(PEG)3-biotin and NeutrAvidinTM DyLightTM 650 (NA650). Fluorescence 
detection of NA650 using flow cytometric analysis followed. The Mean Fluorescence Intensity 
ratio (MFI ratio) for each cell line was calculated by normalising the average fluorescence 
intensity from azidosugar-labelled cells against background fluorescence. (a) MFI ratios in 
breast cancer cell lines metabolically labelled with Ac4ManNAz (black) or Ac4GalNAz (grey). 
(b) The fold difference in Ac4ManNAz labelling versus Ac4GalNAz labelling for each cell line. 
All data represent the average ± S.D. of three independent experiments, each with 3 
replicates. p values represent significance assessed by one-way ANOVA. The darker shades in 
the arrow’s greyscale (a, b) represent an increase in the metastatic potential of the panel of 
breast cancer cell lines. 
 
 
There was no correlation between doubling time (Figure 3.3a) and Ac4ManAz (Figure 3.3b) 
or Ac4GalNAz (Figure 3.3c) incorporation into cell surface glycans. 




































































































































Figure 3.3: Investigating the effect of doubling time on metabolic labelling using linear 
regression correlation analysis. Breast cancer cells were labelled sequentially with N-
azidoacetylmannosamine (Ac4ManNAz) or N- azidoacetylgalactosamine (Ac4GalNAz), and 
then TMDIBO-(PEG)3-biotin and NeutrAvidinTM DyLightTM 650 (NA650). Fluorescence 
detection of NA650 using flow cytometric analysis followed. The Mean Fluorescence Intensity 
ratio (MFI ratio) for each cell line was calculated by normalising the average fluorescence 
intensity from azidosugar-labelled cells against background fluorescence. (a) Whole cell 
counts were obtained every 24 hours, over a 72-hour period using the LUNA™ Automated Cell 
Counter, and used to plot a growth curve. The gradient of the natural log regression line of 
each curve was used to calculate the doubling time (hours) for each cell line. (b) MFI ratios 
for each cell line treated with Ac4ManNAz (i) plotted as a function of doubling time (ii). (c) 
MFI ratios for each cell line treated with Ac4GalNAz (i) plotted as a function of doubling time 
(ii). All data represent the average ± S.D. of three independent experiments, each with 3 
replicates. p values represent significance by one-way ANOVA. The darker shades in the 
arrow’s greyscale represent an increase in the metastatic potential of the panel of breast 
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Previous work in the lab (Whittaker 2015, Part III dissertation, unpublished data) showed an 
increase in Ac4ManNAz labelling in a panel of prostate cancer cell lines, which this study has 
validated to be a suitable in vitro model of prostate cancer progression (Chapter 2: Figure 2.2 
and Figure 2.3). Collectively, these data have demonstrated the use of bioorthogonal 
chemistry for detecting differential Ac4ManAz-specific sialyation and Ac4GalNAz-specific N-
acetylgalactosamine glycosylation of plasma membrane glycoconjugates in human tumour 
cell line models of breast and prostate cancer progression. Differential glycosylation may be 
a sensitive and specific marker for monitoring cancer progression. 
 
 
3.2.2 Metabolic labelling of the p48Cre; LSL-KrasG12D (KC) mouse model of pancreatic 
cancer progression 
 
The correlation between increases in glycosylation and metastatic potential (Chapter 1: 
Figure 1.23; Figure 3.2) could be useful for monitoring tumour glycosylation in vivo. Towards 
imaging of differential glycosylation, and in the absence of available in vivo models of breast 
cancer progression (Holen et. al. 2017), biorthogonal labelling techniques were tested in 
advanced mouse models of pancreatic cancer progression that have been studied previously 
in our lab (Chapter 1: Figure 1.25). 
 
3D pancreatic tumour organoids were generated from p48Cre; LSL-KrasG12D (KC) mice 
(Hingorani et. al. 2003; Westphalen and Olive 2012) and labelled with Ac4ManNAz or 
Ac4GalNAz, TMDIBO-(PEG)3-biotin, and NeutrAvidinTM DyLightTM 650 (NA650). Metabolically 
labelled organoids were fixed in formalin, and NA650 fluorescence visualised using a Leica 
Tandem confocal microscope (Figure 3.4). A slice through the z-stack generated from a 
region of interest (Figure 3.4a and b, black boxes) showed a hollow center devoid of cells, 
typical of organoids of ductal origin, and concentration of NA650 fluorescence at the cell 
surface. These data, demonstrated, what we believe to be the first instance of bioorthogonal 






Figure 3.4: Fluorescence confocal microscopy of metabolically labelled 3D pancreatic 
tumour organoids. Azidosugar-specific-NA650 fluorescence (red) detected in organoids 
labelled with Ac4ManNAz (a) or Ac4GalNAz (b). A slice through the z-stack generated from a 
region of interest (black boxes in a and b). DAPI (blue), Bright field (grey). Scale bars 
represent 100 μm. 
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Following successful azidosugar labelling of pancreatic tumour organoids (Figure 3.4), 
metabolic labelling was tested in vivo, using a mouse model of pancreatic cancer 
progression. Generally, control mice (with a normal pancreas), and KC mice (with a diseased 
pancreas), aged 3, 6 and 12 months, were treated with vehicle or varying dosing regimens of 
N-azidoacetylmannosamine (Ac4ManAz) via oral gavage or i.p. injection. Pancreatic tissue 
was collected and the membrane proteome isolated by mechanical homogenisation and 
detergent-based fractionation. The incorporated azide groups were covalently ligated to 
alkyne-Alexa Fluor 488, ex vivo, using copper-catalysed chemistry. Labelled extracts were 
resolved by gel electrophoresis, and subjected to western blot analysis or in-gel fluorescence 
imaging. 
 
Enrichment of the membrane proteome was confirmed by western blot analysis (Figure 3.5). 
Abundant proteins from the plasma membrane (E-cadherin) and the mitochondria 
(mitochondrial import inner membrane translocase subunit Tim23), were detected (Figure 
3.5a). As expected, detection of proteins abundant in the cytosol (β-actin) was minimal 
(Figure 3.5a). 
 
Next, metabolic labelling was compared between 3 month and 12-month-old KC mice 
treated with three doses of Ac4ManNAz by oral gavage. Minimal protein was detected by 
Coomassie stain in extracts obtained from the 3-month-old KC mouse (Figure 3.5b). To 
confirm if this was due to poor protein extraction from the tissue, pancreatic tissue from the 
3-month-old KC mice was subjected to mechanical homogenisation and detergent-based 
fractionation three times. For comparison, this was also conducted in pancreatic tissue from 
a 12-month-old KC mouse. The protein concentration of the cytosolic and membrane 
fractions was measured using the Biorad assay after each round of extraction and showed 
that the majority of protein was extracted from the tissues in the first round of processing 
(Figure 3.5c). Although Ac4ManNAz-specific glycosylation was detected in the extracts from 
the 3-month-old KC mouse using Alexa-488 fluorescence, degradation of protein in the 
sample was inferred by band smearing on the silver stained gel (Figure 3.5d). All buffers used 
in the fractionation process contained protease inhibitors. Therefore, protein degradation 
may have been caused by delays in the time between tissue extraction and freezing the 




Figure 3.5: Enrichment of the membrane proteome from mouse pancreatic tissue 
metabolically labelled in vivo. Alkyne-Alexa Fluor 488-labelled membrane extracts were 
obtained from control mice and KC mice, aged 3 and 12 months, that were treated with 
vehicle or varying dosing regimens of N-azidoacetylmannosamine (Ac4ManAz) by oral gavage 
or i.p. injection. 10 μg of the extracts were resolved by gel electrophoresis and subjected to 
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western blot analysis or in-gel fluorescence imaging. (a) Representative western blots 
showing the relative abundance of fraction controls in 10 μg of extract from pancreatic tissue 
treated with vehicle: E-Cadherin (plasma membrane protein, 97 kDa), β-actin (cytoskeletal 
protein, 42 kDa), mitochondrial import inner membrane translocase subunit Tim23 (TIMM 
23, mitochondrial membrane protein, 22 kDa). (b) Coomassie stains of cytosolic and 
membrane protein extracts from 3 month and 12-month-old mice treated with three doses of 
Ac4ManNAz by oral gavage. (c) Pancreatic tissue extracted from 3 month and 12-month-old 
KC mice was subjected to mechanical homogenisation and detergent-based fractionation 
three times. Protein concentrations of the cytosolic and membrane fractions are shown. (d) 
In-gel Alexa-488 fluorescence detection of azidosugars incorporated into the membrane 
proteome of pancreatic tissue extracted from a 3-month-old KC mouse, treated with three 
doses of Ac4ManAz by oral gavage. Total protein was visualised using Coomassie and silver 
staining. Background controls were included to detect non-specific fluorescence. 10 μg was 
loaded per lane. 
 
 
Metabolic labelling, using Alexa-488 fluorescence, was compared between 6 month and 12-
month-old KC mice treated with vehicle or varying dosing regimens of Ac4ManAz by oral 
gavage or i.p. injection (Figure 3.6). Stronger metabolic labelling was detected in the 6-
month-old mice treated with three doses of Ac4ManAz by oral gavage, in comparison to 
treatment using i.p. injection (Figure 3.6a). Administering the azidosugar via i.p. injection 
may have caused its dilution in the circulation, resulting in a lower concentration reaching 
the pancreas, and reducing glycosylation-specific Alexa-488 fluorescence. 
 
Coomassie stains of samples extracted from the 12-month-old control mice showed 
consistent extraction of tissue from similar regions of the pancreas (Figure 3.6b). We 
expected the pancreas of the control mice, irrespective of age, to be homogeneous. 
However, different banding patterns were observed in samples extracted from the KC mice. 
This was likely due to heterogeneity in disease burden, and thus cell types present in the 
pancreas of KC mice. 
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The extent of metabolic labelling was compared between 6 month and 12-month-old mice, 
based on the reasoning that older KC mice, exhibiting greater tumour burden, would show 
higher azidosugar labelling (Figure 3.6c). We could not confidently investigate age-
dependent metabolic labelling due to high levels of background fluorescence, which was 
generally higher in the older, 12-month-old KC mouse (Figure 3.6b). This is likely to reduce 
image contrast and hinder our ability to detect tumour glycosylation in vivo during the late, 
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Figure 3.6: Age-dependent metabolic labelling of KC mice in vivo. Alkyne-Alexa 488 labelled 
membrane extracts were obtained from control mice and KC mice, aged 6 and 12 months, 
that were treated with vehicle or varying dosing regimens of N-azidoacetylmannosamine 
(Ac4ManAz) via oral gavage or i.p. injection. 10 μg of the extracts were resolved by gel 
electrophoresis and subjected to in-gel fluorescence imaging. Total protein per lane was 
visualised using Coomassie staining. (a) In-gel Alexa-488 fluorescence detection of 
azidosugars incorporated into the membrane proteome of pancreatic tissue extracted from a 
6-month-old KC mouse, treated with three doses of Ac4ManAz by oral gavage or i.p. injection. 
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Less than 10 μg of protein was loaded for samples +Ac4ManAz/3x i.p. and +Ac4ManAz/3x 
i.p./+Alexa-488, due to negligible protein extraction from the pancreatic tissue. The total 
protein amount in the same gel was visualised using Coomassie staining. (b) In-gel Alexa-488 
fluorescence detection of azidosugars incorporated into the membrane proteome of 
pancreatic tissue extracted from a 12-month-old KC mouse, treated with three doses of 
Ac4ManAz by oral gavage or i.p. injection. Degradation of protein in the sample 
+Ac4ManAz/3x i.p./+Alexa-488 was inferred by band smearing on the Coomassie stained gel. 
(c) Comparison of Alexa-488 fluorescence in Ac4ManAz labelled 6 month and 12-month-old 
KC mice. Background controls were included to detect non-specific fluorescence. 
 
 
Twelve-month-old control and KC mice were metabolically labelled with Ac4ManAz using 
varying dosage regimens: one, two, or three doses of Ac4ManAz by oral gavage or three 
doses of Ac4ManAz by i.p. injection (Figure 3.7). The effect of dosing regimen on metabolic 
labelling was compared. No significance difference in Alexa-488 fluorescence was observed 




Figure 3.7: Dose regimen-dependent metabolic labelling of 12-month-old KC mice in vivo.  
Alkyne-Alexa 488 labelled membrane extracts were obtained from 12-month-old control mice 
and KC mice, that had been treated with vehicle or varying dosing regimens of N-
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azidoacetylmannosamine (Ac4ManAz). Regimens were one, two, or three doses of Ac4ManAz 
by oral gavage or three doses of Ac4ManAz by i.p. injection. 10 μg of the extracts were 
resolved by gel electrophoresis and subjected to in-gel fluorescence imaging. Total protein 
per lane was visualised using Coomassie staining. Degradation of protein in the sample 
+Ac4ManAz/3x i.p./+Alexa-488 was inferred by band smearing on the Coomassie stained gel. 
Background controls were included to detect non-specific fluorescence. 
 
 
Overall, the data suggested that monitoring differential tumour glycosylation using in vivo 
models of pancreatic cancer progression may pose challenges such as reduced contrast 
caused by non-specific background. Maintaining tissue integrity after extraction may need to 





Bioorthogonal azide-based chemical reporters (Laughlin et. al. 2009), generally called 
azidosugars, have been used to visualise glycosylation in tumour-bearing mice using whole 
animal fluorescence (Figure 1.21c and d), MRI (Figure 1.21e) and PET imaging (Neves et. al. 
2011; Neves et. al. 2013; Neves et. al. 2015). However, these protocols have yet to be 
translated into preclinical models of cancer progression. In this study, we quantified 
azidosugar labelling in a previously validated in vitro model of breast cancer progression 
(Chapter 2) and an advanced mouse model of pancreatic cancer, with the ultimate aim of 
imaging tumour glycosylation in vivo. Imaging tumour glycosylation using a clinically relevant 
imaging modality to measure the propensity of a tumour to metastasise, and may enable us 
to distinguish lowly glycosylated benign lesions from highly glycosylated aggressive lesions to 
reduce unnecessary biopsies, and misdiagnosis. 
 
An increase in Ac4ManNAz and Ac4GalNAz labelling correlated with an increase in the 
metastatic potential of the breast cancer cell lines (Figure 3.2a). Zhou and colleagues used 
lectin arrays to study differential glycosylation in the metastatic MDA MB 231 cell lines, and 
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5 additional cell lines with increasing metastatic potential, derived from the tumourigenic 
MDA MB 231 cell line. An increase in Ricinus communis agglutinin binding, which recognises 
lactose and galactose, an increase in Sambucus nigra lectin binding (also called elderberry 
bark lectin), which recognises sialic acid (Zhou et. al. 2015), and a decrease in wheat germ 
agglutinin lectin binding, which recognises N-acetylglucosamine, was correlated with an 
increase in the metastatic potential of the MDA MB 231 derived cell lines. This is consistent 
with the increases in cell surface Ac4ManNAz observed here (Figure 3.3b), and increases in 
sialylation associated with an increase in the metastatic potential of several cancers (Natoni 
et. al. 2016).  Levels of Helix pomatia agglutinin (HPA) binding, which recognises N-
acetylgalactosamine, has been previously quantified using flow cytometry in breast cancer 
cell lines. Increased HPA binding was detected in the HMT 3522 cell line, representing 
normal breast epithelium (Briand et. al. 1987), and tumourigenic MDA MB 453, MCF 7 and 
MDA MB 468 cell lines (Chapter 2: Table 2.1b), illustrating a general increase in N-
acetylgalactosamine incorporation into cell surface glycoconjugates (Brooks et. al. 2001). 
Increased levels of HPA binding in primary breast cancer paraffin-embedded tissue sections 
have also been correlated with tumour size and the presence of axillary lymph node 
metastases (Brooks and Leathem 1991). Furthermore, glycoproteomic analysis of N-glycan's 
released from human breast tissue extracts and serum proteins, using high-performance 
liquid chromatography, revealed significant increases in the levels of N-acetylgalactosamine-
containing Sialyl Lewis X in breast cancer patients, relative to healthy individuals, and even 
higher levels in breast cancer patients with circulating tumour cells (Saldova et. al. 2011). 
These studies are consistent with an increase in Ac4GalNAz labelling, which correlated with 
an increase in the metastatic potential of the breast cancer cell lines observed in this study 
(Figure 3.3c).  
 
Chan and colleagues used a xenograft mouse model of lymphosarcoma, and WGA, to 
compare the composition of glycoproteins extracted from primary tumours and liver 
metastases. When lymphosarcoma cells, exhibiting the highest level of WGA binding, were 
re-implanted into regions of the liver, which previously harboured a metastatic deposit, the 
resulting tumour exhibited less WGA binding (Chan et. al. 1984). Their data suggested that a 
tumours immediate environment contributed towards driving differential glycosylation 
during the development of a metastatic phenotype, a now well-reported concept (Peixoto 
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et. al. 2019). Therefore, we investigated if the differential glycosylation observed in cell lines 
with increasing metastatic potential could be replicated in advanced mouse models, which 
were more representative of a tumours 3D architecture, and the host-tumour 
microenvironment. In the absence of available in vivo models of breast cancer progression 
(Holen et. al. 2017), biorthogonal labelling techniques were tested in the p48Cre; LSL-
KrasG12D (KC) mouse model (Hingorani et. al. 2003; Westphalen and Olive 2012), where the 
evolution of pancreatic ductal adenocarcinoma (PDAC) from intraepithelial neoplasia (PanIN) 
precursor lesions to tumours, has been replicated (Hingorani et. al. 2003; Westphalen and 
Olive 2012) (Chapter 1: Figure 1.25a and b).  
 
We demonstrated, what we believe to be the first instance of bioorthogonal metabolic 
labelling and visualisation of cell surface glycans in 3D pancreatic tumour organoids (Figure 
3.4). Ac4ManNAz and Ac4GalNAz labelling were localised to the plasma membrane, as 
observed previously by confocal microscopy in metabolically labelled Lewis lung carcinoma 
(Stöckmann et. al. 2011), and MDA MB 231 breast cancer (Kuo 2015, PhD thesis, 
unpublished) cell lines.  
 
We cultured and cryopreserved pancreatic organoids obtained from normal pancreatic 
tissue, and PanIN precursor lesions, to quantify azidosugar labelling in this 3D organoid 
model of pancreatic cancer progression. Organoids derived from less aggressive phenotypes 
required complicated and expensive growth factor-rich media preparations. Furthermore, 
organoids exhibited low proliferation rates, which hindered the high throughput culturing 
needed to obtain enough cell numbers for quantitative flow cytometry. Studies using the 
pancreatic organoids was consequently abandoned. 
 
Next, we adopted an alternative approach by conducting metabolic labelling of KC mice in 
vivo, following by quantification of azidosugar labelling ex vivo. Control mice (with a normal 
pancreas), and KC mice (with a diseased pancreas), aged 3, 6 and 12 months, were treated 
with vehicle or varying dosing regimens of Ac4ManAz via oral gavage or i.p. injection. 
Pancreatic tissue was collected and the membrane proteome isolated based on the 
observation of extensive azidosugar labelling within the plasma membrane of KC pancreatic 
tumour organoids (Figure 3.4). The incorporated azide groups were covalently ligated to 
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alkyne-Alexa Fluor 488, ex vivo, using copper-catalysed chemistry. Labelled extracts were 
resolved by gel electrophoresis, and subjected to western blot analysis and in-gel 
fluorescence imaging. 
 
Increases in sialyation (Büll et. al. 2014) of cell surface glycoproteins (Schultz et. al. 2012) has 
been observed in pancreatic cancers (Munkley 2019) and associated with increased disease 
progression and metastasis (Stowell et. al. 2015). Therefore, the extent of Ac4ManNAz-
sialylation was compared between 6 month and 12-month-old mice, based on the reasoning 
that older KC mice, exhibiting greater tumour burden, would show higher levels of 
azidosugar labelling. We could not confidently investigate age-dependent metabolic labelling 
due to high levels of background fluorescence, which was generally higher in the older, 12-
month-old KC mouse (Figure 3.6b). Improving delivery of the azidosugars to pancreatic 
tumours may reduce background labelling, and could be achieved using liposomes, nasal 
administration or osmotic pumps (Xie et. al., 2012; Xie et. al., 2014). This would be beneficial 
for fluorescence imaging, which despite being highly sensitive and high throughput, is 
limited by light absorption and scattering, which prevents deep imaging in opaque organisms 
such as mice (Ntziachristos 2006). Overall, the correlation between mouse age and non-
specific background suggest that imaging of tumour glycosylation in vivo may be more 
suitable in monitoring the early stages of the disease. 
 
Our data have yet to support the notion that bioorthogonal glycan imaging could be useful 
for monitoring the propensity of a tumour to metastasise in vivo i.e. for assessing the 
aggressiveness of the disease. Translating this concept would require biorthogonal labelling 
of live tissue by administering azidosugars directly to patients in vivo. A more realistic 
scenario would be to conduct metabolic labelling of patient tissue biopsies to quantify 
azidosugar labelling ex vivo. Spiciarich and colleagues successfully metabolically labelled 
prostate tissue slices derived from radical prostatectomy specimens and observed 
Ac4ManNAz specific labelling of cell surface glycoconjugates using confocal microscopy 
(Spiciarich et. al. 2017). However, this ex vivo bioorthogonal metabolic labelling technique 
has not been translated into clinical practice. Our flow cytometry data, although limited, 
suggest that the glycoprotein fraction may be principally responsible for generating the 
increases in sialyation and N-acetylgalactosamine glycosylation observed with an increase in 
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the metastatic potential of the breast cancer cell lines (Figure 3.3). Assessing the dynamics of 
azidosugar incorporation into cell surface glycoproteins using gel electrophoresis may 
confirm the presence of differentially glycosylated glycoproteins, which if identified using 
mass spectrometry, may be predictive biomarkers of cancer progression. 
 
 
3.4 Materials and Methods 
 
3.4.1 Cell lines 
 
The MDA MB 453, MCF 7, MDA-MB-468, and MDA MB 231 human breast cancer cell lines 
were obtained from the Cancer Research UK Cambridge Institute Biorepository, based on 
stocks made available by Joe Kuo. All breast cell lines were cultured in DMEM with L-
glutamine (Gibco®, InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories). 
 
Cell lines were genotyped and authenticated by Short Tandem Repeat (STR) DNA profiling 
and comparison with available databases from ATCC or DSMZ. All cell lines tested negative 
for Mycoplasma using the MycoProbe™ Kit (R&D Systems). 
 
 
3.4.2 Tissue culture 
 
Cell lines were maintained in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) at 5% CO2, 
in 37 °C humidified incubators, and cultured to 80% confluence. Briefly, cells were washed 
once with warm Phosphate Buffered Saline (20 ml/flask; 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 
0.24 g KH2PO4 per litre, pH 7.4), and trypsinised for 7 minutes at 37oC. Trypsinised cells were 
added to equal volumes of media, centrifuged at 700 x g for 4 minutes (4oC), and 
resuspended in fresh media. Viable cell counts were obtained by Trypan blue dye exclusion 




3.4.3 Bioorthogonal metabolic labelling in vitro for flow cytometry 
 
N-azidoacetylmannosamine (Ac4ManNAz), N-azidoacetylgalactosamine (Ac4GalNAz) and 
TMDIBO-PEG3-biotin were synthesised by Henning Stöckmann, Department of Chemistry. 
 
Cells were seeded at 1.75 x 104 cells/cm2 in NuncTM 175 cm2 flasks (Thermo Fisher 
ScientificTM) and maintained at 5% CO2, in 37 °C humidified incubators for 3 days before 
metabolic labelling experiments. Flasks were then washed once with 20 ml warm Phosphate 
Buffered Saline (PBS; 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 per litre, pH 7.4), and 
cells trypsinised for 7 minutes at 37oC. Trypsinised cells were added to equal volumes of 
media, centrifuged at 700 x g for 4 minutes (4oC) and resuspended in fresh media. Viable cell 
counts were obtained by Trypan blue dye exclusion using a LUNA™ Automated Cell Counter 
(Logos Biosystems), and cells seeded at 3 x 104 cells/cm2 in NuncTM 6 well plates (Thermo 
Fisher ScientificTM) with 3 ml media/well. Plates were incubated in 5 % CO2, 37 °C for 24 
hours. After 24 hours, the media was replaced with fresh media only (0.1% DMSO, vehicle 
control) or fresh media supplemented with 50 μM Ac4ManNAz or Ac4GalNAz. Cells were 
incubated in 5 % CO2 at 37 °C for 24 hours. After 24 hours, cells were harvested by 
trypsinisation and counted as described previously. 
 
4 x 105 cells from each treatment group were transferred into separate Nostick® 
hydrophobic microcentrifuge tubes (Scientific Specialties, Inc.), pelleted by centrifugation 
(700 x g for 4 minutes at 4oC), and washed with 1 ml ice-cold Flow Cytometry Staining (FACS) 
buffer (PBS with 1% FBS). From here onwards, all samples and dyes were kept on ice. The 
washed pellets were resuspended in 100 μl FACS buffer or 100 μl FACS buffer supplemented 
with 20 μM TMDIBO-PEG3-biotin, and incubated in a heating block for 25 minutes at 37oC 
with agitation (400 rpm). Reactions were quenched with 700 μl FACS buffer, cells harvested, 
and the pellets washed 3 times with FACS buffer as before. After washing, cells were 
resuspended in 100 μl FACS buffer, or 100 μl FACS buffer supplemented with 0.835 μM 
NeutAvidinTM DylightTM 650 (Thermo Fisher ScientificTM) and 50 nM Sytox® Green cell death 
marker (InvitrogenTM), or 100 μl FACS buffer supplemented with 50 nM Sytox® Green cell 
death marker (InvitrogenTM) only. Cells were incubated in a heating block for 15 minutes at 
37oC with agitation (400 rpm). Reactions were quenched with 700 μl FACS buffer, cells 
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harvested, and the pellets washed twice with FACS buffer as before. Washed cells were 
filtered into 35 μm pore cell strainer capped cytometry tubes (Falcon®, BD Life Sciences), 
and analysed using an LSR II flow cytometer (BD Life Sciences). 
10,000 events were recorded per analysis from viable cells only, characterised by their high 
ultraviolet autofluorescence (high cellular NADH content) and low Sytox® Green 
fluorescence (intact membrane, dye exclusion). The Mean Fluorescence Intensity ratio (MFI 
ratio) was obtained by normalising the average fluorescence intensity from azidosugar 
labelling against background fluorescence. 
 
 
3.4.4 Pancreatic tumour organoid cultures 
 
Mouse pancreatic tumours were isolated from p48Cre; LSL-KrasG12D (KC) mice (Hingorani 
et. al. 2003; Westphalen and Olive 2012) by Dr Aarthi Gopinathan (Jodrell Laboratory, CRUK 
CI) following a protocol from the Tuveson Lab (Available at: 
http://tuvesonlab.labsites.cshl.edu/protocolsreagents/, 2019). Briefly, this involved 
dissecting the tumour from the pancreas, disruption of the tumour by mincing, enzymatic 
digestion, and treatment with DNAase and trypsin. Following centrifugation and 
resuspension of the cell pellet in Matrigel (BD Biosciences) 25 μl Matrigel (BD Biosciences) 
domes were spotted into a pre-warmed 48-well plate on top of a pre-warmed water bottle 
(NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) filled with Milli-Q 18.2 Ω water), and 
brought to the Brindle lab for culturing. Organoids were cultured following a protocol from 
the Tuveson Lab (Available at: http://tuvesonlab.labsites.cshl.edu/protocolsreagents/, 






Figure 3.8: Pancreatic organoid cultures. Diagrams show a cross-section of pancreatic 
organoid culturing methods reported by the Cleavers and Tuveson labs (a) and the 
Muthuswamy lab (b). Matrigel is depicted in blue, organoids in yellow, and culture medium in 
brown. (Figure extracted from Baker et. al. 2016). 
 
 
Generally, 25 μl domes of Matrigel (BD Biosciences) were melted by resuspension in 500 μl 
ice-cold DMEM with glucose, L-glutamine (Gibco®, InvitrogenTM) and 5 % FBS (FBS Gold, PAA 
Laboratories). The suspension was placed in a 15 ml Falcon tube containing 8 ml ice-cold 
media. Wells were washed with 500 μl ice-cold DMEM to dissolve any residual matrigel and 
added to the 15 ml Falcon tube. Organoids were pelleted by centrifugation at 700 x g for 6 
minutes and an appropriate amount of the supernatant removed (2 ml media remaining). 
Pellets were resuspended, and media topped up to a total of 10 ml. Disrupted organoids 
were pelleted at 700 x g for 6 minutes, the supernatant removed and pellets resuspended in 
fresh Matrigel (25 μl per dome) (BD Biosciences). 25 μl of the matrigel suspension was 
“spotted” into the centre of each well of a 48 well plate (Corning), and incubated at 37oC for 
15 minutes on a pre-warmed water bottle to allow the matrigel to set. Wells were topped up 
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3.4.5 Bioorthogonal metabolic labelling of pancreatic tumour organoids for confocal 
microscopy 
 
Metabolic labelling of pancreatic tumour organoids was conducted based on a modified “5% 
media overlay” culturing method reported in the literature (Baker et. al. 2016) (Figure 3.8b). 
 
Each chamber of a 6-chambered glass coverslip (Ibidi®) was evenly coated with 100 μl fresh 
Matrigel (BD Biosciences). Coated slides were incubated at 37oC for 30 minutes on a pre-
warmed water bottle to allow the matrigel to set. Organoids were split, as described 
previously. After removing all the supernatant, the organoid pellet was resuspended in 1 ml 
pre-warmed TrypLETM (Thermo Fisher ScientificTM), which is a gentler and more stable 
alternative to trypsin. Cells were incubated in a 37oC incubator for 10 minutes and gently 
shaken 3 times during the incubation period. TrypLETM was neutralised by adding 10 ml ice-
cold media, and the solution resuspended to break up the “white spaghetti” 
characteristically generated after trypsinising organoids. The single-cell suspension was 
centrifuged at 700 x g for 6 minutes (4oC) and the supernatant completely aspirated. The 
pellet was resuspended in a 3.5 ml solution of warm media containing 5% Matrigel, and 400 
μl of the suspension pipetted over each chamber in a drop-wise manner. The remaining 
suspension was used to obtain a cell count and measure of viability using the Vi-CELL XR cell 
viability analyser (Beckman Coulter). After 24 hours, chamber contents were replaced with 
300 μl fresh media only or fresh media supplemented with 50 μM Ac4ManNAz or Ac4GalNAz, 
and incubated at 5% CO2, in 37 °C humidified incubators for 24 hours.  
 
After 24 hours, media was removed and chambers washed twice in 200 μl pre-warmed Flow 
Cytometry Staining (FACS) buffer (PBS with 1% FBS). A single wash involved pipetting FACS 
buffer over the wells twice before placing in a 37oC incubator for 10 minutes. The wash was 
removed completely and chambers overlaid with 100 μl FACS buffer or FACS buffer 
supplemented with 20 μM DIBO-PEG3-biotin, and incubated at 37oC for 30 minutes. After 30 
minutes, the TMDIBO-biotin was removed completely and the wells washed 4 times with 
200 μl FACS buffer. The final wash with FACS buffer was removed completely and chambers 
overlaid with 100 μl FACS buffer, or FACS buffer supplemented with 0.835 μM NeutAvidinTM 
DylightTM 650 (NA650) (Thermo Fisher ScientificTM), and incubated at 37oC for 20 minutes. 
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After 20 minutes, NA650 was removed, and the wells washed twice with 200 μl warm FACS 
buffer. Organoids were fixed in 200 μl 10% neutral buffered formalin for 10 minutes at room 
temperature. After 10 minutes, the formalin was removed completely, and the chambers 
washed 4 times with FACS buffer. Organoids were counterstained with DAPI (300 nM) and 




3.4.6 Bioorthogonal metabolic labelling of p48Cre; LSL-KrasG12D (KC) mice in vivo and 
chemoselective ligation of the metabolically labelled membrane proteins ex vivo  
 
p48Cre; LSL-KrasG12D (KC) mice (Hingorani et. al. 2003; Westphalen and Olive 2012) aged 3, 
6 and 12 months, and C57BL/6 control wild-type mice (Serrao et. al. 2015) (age matched to 
KC mice) were bred in-house at the Cancer Research UK Cambridge Institute, and 
metabolically labelled with Ac4ManNAz in vivo by Dr André Neves (Brindle Laboratory, CRUK 
CI).  
 
Mice were dosed daily, either orally by gavage, or intraperitoneally, for up to 3 days, with a 
solution of Ac4ManNAz (150 mg/kg) in DMSO:PEG400:PBS (5:10:85%) or with the solvent 
vehicle alone. 24 hours after the last dose of azido-sugar, mice were sacrificed and the 
pancreas removed and rapidly frozen in isopentane on dry ice. 
 
The membrane protein fraction was isolated from pancreatic tissue using a modified 
protocol of the Qproteome® Cell Compartment kit (Qiagen). Briefly, samples of pancreatic 
tissue were cut into small pieces and transferred to Precellys® 7 ml bead-containing vials. A 
weight-adjusted volume of Extraction Buffer CE1 was added (5 ml/g tissue) and the tissue 
homogenised at 4oC using 3x cycles of 6000 rpm for 30 seconds, using a Precellys Evolution 
homogeniser (Bertin Technologies). Homogenisation was carried out by Ms Sarah McGuire 
(Brindle Laboratory, CRUK CI). Lysates were transferred to fresh Nostick® hydrophobic 
microcentrifuge tubes (Scientific Specialties, Inc.), and centrifuged at 1000 x g for 10 minutes 
at 4oC. The supernatant, primarily containing cytosolic proteins, was transferred into a fresh 
Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, Inc.) and stored at -20oC. 
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The remaining pellet was resuspended in 1 ml Extraction Buffer CE2 and incubated for 30 
minutes at 4oC on an end-over-end shaker (30 rpm). Lysates were centrifuged at 6000 x g for 
10 minutes at 4oC. The supernatant, primarily containing membrane proteins, was 
transferred into fresh Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, 
Inc.). Lysates were stored at -20oC. 
 
Four volumes of ice-cold acetone were added to the membrane protein-enriched fractions 
and incubated for 1 hour on ice. Precipitated proteins were pelleted by centrifugation at 12, 
000 x g for 10 minutes (4oC). The supernatant was discarded and the protein pellets air-dried 
for 15 minutes. Dried protein pellets were resuspended in 100 μl Tris-HCL buffer (50 mM, pH 
8, 0.5% SDS). Residual acetone was removed by the sequential addition of 600 μl methanol, 
150 μl chloroform, and 400 μl Milli-Q 18.2 Ω water, with vortexing. After centrifugation at 
18, 000 x g for 10 minutes (4oC), the upper aqueous phase was removed and the precipitated 
proteins washed twice with 450 μl methanol. The pellets were air-dried for a minimum of 15 
minutes and resuspended in 100 μl Tris-HCL buffer (50 mM, pH 8, 0.5% SDS). The total 
protein concentration was determined using the DC™ Protein Assay (Bio-Rad), using BSA as a 
standard. Lysates were stored at -20oC. 
 
Up to 200 μg of metabolically labelled protein was chemoselectively reacted with alkyne-
Alexa Fluor 488 (Life Technologies), using the Click iT Protein Reaction Kit (Life Technologies), 
according to the manufacturer’s protocol. Residual reactants were removed by 
methanol/chloroform/Milli-Q 18.2 Ω water precipitation, as described previously. Protein 
pellets were dried for a minimum of 15 minutes, resuspended in 200 μl Tris HCL buffer (50 
mM, pH 8, 0.5% SDS), and sonicated for 30 seconds (9 cycles of 10 seconds ON and 5 
seconds OFF) using the Biorupter ® Plus (Diagenode). The total protein concentration was 
determined using the DC™ Protein Assay (BIO-RAD), using BSA as a standard. Samples were 







3.4.7 1D gel electrophoresis and in-gel imaging of azidosugar labelled glycoproteins 
 
Metabolically labelled membrane protein fractions reacted with alkyne-Alexa Fluor 488 in 
Tris-HCL buffer (50 mM, pH 8, 0.5% SDS) were loaded on to precast 4-12% 1mm Bis-Tris gels 
(Thermo Fisher ScientificTM) and resolved in 1x NuPAGE MOPS buffer (Invitrogen) (10 
μg/lane; 30 min at 60 V and 120 min for 120 V). Alexa Fluor 488 fluorescence (Cy2; 489 nm 
maximum excitation wavelength, 506 nm maximum emission wavelength) was imaged in-gel 
with a Typhoon scanner (GE Healthcare). Gels were subsequently stained with Instant Blue™ 
Coomassie (Expedeon) or silver stain (Pierce Kit) and imaged using an Odyssey CLx Infrared 
Imaging System (LI-COR Biosciences) or Image Scanner III (GE Healthcare), respectively. 
 
 
3.4.8 Statistical analysis  
 



















Chapter 4: Investigation of differential glycosylation using 
bioorthogonal chemistry and gel electrophoresis in in vitro 





4.1.1 Cell surface protein glycosylation in cancer 
 
Glycans are the complex carbohydrate structures formed when monosaccharides link 
together via glycosidic bonds. Glycoproteins are defined by the amino acid upon which the 
glycan structures are installed (Chapter 1: Figure 1.4). The synthesis of the N-linked 
glycoproteins involves covalent attachment of N-acetylglucosamine to an asparagine (Asn) 
residue, via its amide side chain, within the target sequence: Asn-X-Serine/Threonine (X = 
any amino acid except proline) (Chapter 1: Figure 1.5). The synthesis of the O-linked 
glycoproteins involves the covalent attachment of carbon 1 in N-acetylgalactosamine to 
serine or threonine residues via their hydroxyl groups (Pinho and Reis 2015). Within a single 
polypeptide, multiple asparagine, serine, and threonine residues are available for glycan 
installation. This can occur at different positions, across different polypeptides, at any given 
time. Monosaccharides can bond at different carbon positions, between carbons with the 
same stereochemistry (α-glycosidic bond), between carbons with different stereochemistries 
(β-glycosidic bond), and in linear or branched forms (Seeberger 2017), and can conjugate to 
acyl (non-sugar) groups within proteins that are embedded in the cell membrane or 
secreted. Therefore, glycoproteins are highly diverse and their synthesis is dependent on the 
dynamic interactions between glycoenzymes within a specific cell type. These dynamic 
interactions are sensitive to physiological and pathological changes (Reily et.al. 2019; 
Krasnova and Wong 2016; Mariño et. al. 2010) such as in cancer, where abnormal changes in 
the expression and degradation of glycoproteins have been implicated (Ohtsubo et. al. 2006; 
Varki et. al. 2017) due to mislocalisation of glycosyltransferases, altered expression of 
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glycoenzymes and chaperones, and mutations in genes encoding glycosyltransferases 
(Stowell et. al. 2015). 
 
Aberrant glycosylation of N-linked (Chapter 1: Figure 1.5) and O-linked glycoproteins can 
affect growth factor signalling, cell proliferation, adhesion, and migration, and promote 
tumour progression through enhanced cell-matrix interactions, invasion, angiogenesis, and 
metastasis (Moremen et. al. 2012) (Chapter 1: Figure 1.8b). For example, the synthesis of 
complex N-glycan's on E-cadherin by MGAT5 upregulation causes E-cadherin internalisation 
and disruption of cell-to-cell adhesion sites.  O-glycosylated CD44 binds endothelial E-
selectin promoting metastasis, and O-glycosylated integrins mediate attachment of tumour 
cells to the extracellular matrix (Oliveira-Ferrer et. al. 2017). Aberrant O-glycosylation of 
glycoproteins with an unmodified or sialylated core 1 O-glycan called the Thomsen-
Friedenreich (T) antigen (Chapter 1: Figure 1.10), has been suggested as the most common 
tumour associated glycan alteration on carrier proteins, overexpression of which has been 
correlated with increases in disease progression, metastasis and poor prognosis in several 
cancers (Stowell et. al. 2015).  
 
Aberrant O-glycosylation of mucins has been observed in over 90% of breast cancers and 
associated with overexpression of N-acetylgalactosaminyltransferases such as GALNACT6, 
and reduced cell adhesion (Burchell et. al. 2018). In prostate cancer, aberrant glycosylation 
of O-linked glycoproteins is thought to be mediated by overexpressed glycosyltransferases, 
such as ST6GALNAC1, which are induced by activated androgen receptors (Munkley 2017) 
and that synthesise tumour associated antigens such as sialylated Tn antigen and Sialyl Lewis 
X (Chapter 1: Figure 1.8). Androgen has also been shown to control aberrant mannose 
trimming of N-glycan's on proteins by inducing the overexpression of mannosidases such as 
EDEM3 (Munkley et. al. 2016). Elevated levels of Sialy Lewis A antigens (Chapter 1: Figure 
1.8) on carrier proteins such as mucin 1 (MUC1) are associated with pancreatic cancer 
progression and are monitored in the clinical CA 19-9 assay (Pinho and Reis, 2015). Increased 
fucosylation of mucins, and N-linked integrins and extracellular matrix adhesion proteins 
have been detected in the tissue or blood of patients with pancreatic intraepithelial 
neoplasia (PanIN) precursor lesions, pancreatic cancer and metastatic disease, when 
compared to healthy individuals (Munkley 2019; Pan et. al. 2016). Therefore, cell surface 
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glycoproteins and their associated glycan structures facilitate interaction of tumour cells 
with the tumour microenvironment and are vital for promoting cancer progression (Peixoto 
et. al. 2019). 
 
 
4.1.2 Detection of aberrantly glycosylated cell surface glycoproteins using bioorthogonal 
chemistry  
 
Traditional methods for studying aberrant glycosylation include the use of affinity reagents 
such as lectin arrays and antibodies, which recognise the carbohydrate moieties (Cummings 
2009). 
 
Lectins such as wheat germ agglutinin (WGA), which binds preferentially to N-
acetylglucosamine residues (Cummings and Etzler 2009), Helix pomatia agglutinin (HPA), 
which can recognise the N-acetylgalactosamine residues of the Thomsen-nouveau (Tn) 
antigen (Chapter 1: Figure 1.9), and peanut agglutinin (PNA), which can recognise T antigen 
(Chapter 1: Figure 1.10), and Core 2 O-glycan’s (Oliveira-Ferrer et. al. 2017) (Chapter 1: 
Figure 1.4, red perforated box), have been used to characterise tumours using 
histochemistry and lectin blotting. For example, extracts obtained from liver metastases 
exhibited less WGA binding than lymphosarcoma tissue extracts (Chan et. al. 1984), breast 
tumour extracts exhibited less WGA binding than extracts from healthy breast tissue (Ng et. 
al. 1987), and increases in HPA binding have been observed in lymph node metastases (Kölbl 
et. al. 2015), and decreases in WGA binding have been seen during the progression of pre-
invasive Barrett’s oesophagus to adenocarcinoma (Bird-Lieberman et. al. 2012) (Chapter 1: 
Figure 1.17c). However, steric hinderances can affect interactions of lectins with aberrantly 
glycosylated glycoproteins (Stowell et. al. 2015). 
 
Anti-carbohydrate antibodies are also in development, which recognise Tn antigen 
presented on circulating glycoproteins (Kveton et. al. 2017). However, defining the exact 
glycan sequences recognised by anti-carbohydrate antibodies has proven more difficult than 
defining the peptide epitopes traditionally targeted by antibodies (Stowell et. al. 2015). Anti-
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Tn antibodies, based on the IgM or IgG immunoglobulin classes, have shown varying 
affinities and specificities for the Tn antigen (Blixt et. al. 2012). 
 
More novel ways of detecting aberrantly glycosylated proteins involve the use of 
bioorthogonal monosaccharide analogues containing a functional azide group or “chemical 
reporter” not normally present in the cell (Laughlin et. al. 2009), which are incorporated 
metabolically into cellular glycan structures, and subsequently detected by covalent ligation 
of imaging probes or affinity reagents that rapidly react with the azide group (Saxon and 
Bertozzi 2000; Saxon et. al. 2002) (Chapter 1: Figure 1.20). We previously demonstrated the 
use of bioorthogonal chemistry for detecting differential N-azidoacetylmannosamine 
(Ac4ManAz)-specific sialyation and N-azidoacetylgalactosamine  (Ac4GalNAz)-specific N-
acetylgalactosamine (Chapter 1: Figure 1.19) glycosylation of plasma membrane 
glycoproteins and glycolipids in human tumour cell line models of breast (Chapter 3: Figure 
3.2) and prostate cancer (Whittaker 2015, Part III dissertation, unpublished data) (Chapter 1: 
Figure 1.23c) progression, using flow cytometry. In this study, we used gel electrophoresis to 
visualise how Ac4ManNAz and Ac4GalNAz (Figure 1.24) differentially label glycoproteins 
across panels of cell lines, some of which had previously been validated as suitable in vitro 
models of cancer progression using scratch wound assays, to compare migration, Boyden 
chambers, to compare invasion, and immunohistochemistry to compare the relative 
expression of known invasion biomarkers (Pijuan et. al. 2019; Justus et. al. 2014) (Chapter 2). 
Additionally, we used deglycosylating enzymes to visualise specific azidosugar labelling of N-
linked glycoproteins.  
 
The correlation between global increases in glycosylation of cell surface glycans and 
metastatic potential suggest that detecting changes in glycosylation could be useful for 
monitoring the propensity of a tumour to metastasise in vivo i.e. for assessing the 
aggressiveness of the disease. The data also suggest that the glycans differentially detected 
using flow cytometry (Chapter 1: Figure 1.23) may be part of a larger array of ‘metastatic 
codes’ associated with a tumour’s glycan profile at any given time point (Fuster and Esko 
2005). In other words, differential azidosugar labelling detected by flow cytometry implies 





In order to understand the biological basis for the increases in metabolic labelling observed 
using flow cytometry (Chapter 3: Figure 3.2), the dynamics of azidosugar incorporation into 
cell surface glycoproteins was assessed using gel electrophoresis. 
 
4.2.1 Enrichment of the membrane proteome 
 
Cell extracts were obtained using detergent-based, non-denaturing fractionation. The 
Qproteome® Cell Compartment kit (Qiagen) was used to remove the cytosolic fraction, 
followed by solubilisation and isolation of the cell membranes. The membrane-enriched 
fraction contained plasma membrane proteins and proteins from membrane-bound 
organelles such as the golgi and mitochondria. Membrane-enriched extracts were desalted 
using acetone precipitation and methanol, chloroform and water extraction, to generate a 
purified membrane enriched extract, suitable for further analysis. 
 
Enrichment of the membrane proteome was confirmed by western blot analysis (Figure 4.1). 
Abundant proteins from the plasma membrane (E-cadherin) and the mitochondria (voltage-
dependent anion channel, and mitochondrial import inner membrane translocase subunit 
Timm 23), were detected (Figure 4.1a). As expected, detection of proteins abundant in the 
cytosol (glyceraldehyde 3-phosphate dehydrogenase) and the nucleus (lamin b) was 
minimal.  
 
The cellular localisation of proteins within the membrane-enriched extracts (Figure 4.1b) was 
also confirmed by mass spectrometry. Spectra representing individual peptides generated 
from in-gel tryptic digestion (Figure 4.1b) were searched against databases of known primary 
peptide sequences using the Mascot software 
(http://www.matrixscience.com/search_intro.html, 2019). Proteins identified with Mascot 
were classified (Table 4.1) by their cellular location using gene ontology analysis 
(www.pantherdb.org) (Table 4.2). The majority of gene hits within the membrane protein 
category were designated as plasma or integral membrane proteins (Table 4.3), confirming 
enrichment of cell surface proteins, the cellular region predominantly labelled using 
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bioorthogonal glycan labelling techniques (Chapter 1: Figure 1.20). Plasma membrane 
proteins consistently accounted for between 37-38% of designated membrane proteins 
within the membrane protein category, across different prostate (LNCAP C4-2 and LNCAP 
C4-2B) and breast (MDA MB 468 and MDA MB 231) cancer cell lines, confirming replication 
and optimisation of our enrichment and purification protocols in different cancer cell types 




Figure 4.1: Enrichment of the membrane proteome confirmed using western blot. 
Membrane-enriched extracts were obtained from two prostate cancer cell lines (LNCAP C4-2 
and LNCAP C4-2B) and two breast cancer cell lines (MDA MB 468 and MDA MB 231) using 
detergent-based fractionation. (a) Representative western blots showing the relative 
abundance of fraction controls in 10 µg of extract from the prostate cancer cell lines: E-
Cadherin (plasma membrane protein, 97 kDa), lamin b (nuclear protein, 66 kDa), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, cytosolic protein, 37 kDa), voltage-
dependent anion channel (VDAC, mitochondrial protein, 31 kDa), mitochondrial import inner 
membrane translocase subunit Tim23 (TIMM 23, mitochondrial membrane protein, 22 kDa). 
(b) Coomassie staining of extracts (10 μg) resolved by gel electrophoresis, and Coomassie 
stained. Lanes were segmented into 24 pieces, and subjected to tryptic digestion, followed by 
protein identification by liquid chromatography-tandem mass spectrometry. 





























      

































Table 4.1: Protein classifications by GO terms. GO term definitions were collated from The 
Jackson Laboratory Gene Ontology browser 





Table 4.2: Proteins identified from the membrane proteome using mass spectrometry 
classified by cellular component. Proteins identified with Mascot from two prostate cancer 
cell lines (LNCAP C4-2 and LNCAP C4-2B), and two breast cancer cell lines (MDA MB 468 and 






Table 4.3: Proteins identified from the membrane proteome using mass spectrometry 
classified by membrane component. Proteins identified with Mascot from two prostate 
cancer cell lines (LNCAP C4-2 and LNCAP C4-2B), and two breast cancer cell lines (MDA MB 




4.2.2 Azidosugar labelling of the membrane proteome of prostate cancer cell lines 
 
Prostate, breast, and pancreatic cancer cell lines, were incubated with precursors of sialic 
acid and N-acetylgalactosamine that had been labelled with an azide group (N-
azidoacetylmannosamine (Ac4ManNAz) and N-azidoacetylgalactosamine (Ac4GalNAz) 
respectively), and which are incorporated biosynthetically into cell surface glycans. The 
membrane proteome was isolated and the incorporated azide groups covalently ligated to 
alkyne-Alexa Fluor 488 using copper-catalysed chemistry. Azidosugar-labelled glycoproteins 
were resolved by gel electrophoresis and detected directly, in-gel, using Alexa-488 
fluorescence (Clark et. al. 2008; Cieniewski-Bernard et. al. 2014).  
 
No background fluorescence was observed in extracts from prostate cancer cells treated 
with vehicle (0.1% DMSO) only, or vehicle and the alkyne-Alexa Fluor 488 probe (Figure 4.2a, 
i). A general increase in the overall Alexa Fluor 488 fluorescence correlated with an increase 
in the metastatic potential of the prostate cancer cell lines (Figure 4.2a, ii). There was no 
correlation between increases in Ac4ManNAz (r2 = 0.02245) (Figure 4.2b, i) or Ac4GalNAz (r2 = 
0.4642) (Figure 4.2c, i) labelling of the glycoproteins and doubling time (Figure 4.2b, ii and 
4.2c, ii). Therefore, the azidosugar labelling of the glycoproteins appeared to be affected by 
increases in the invasive potential of the prostate cancer cell lines (Chapter 2: Figure 2.3), 































































































































































































Figure 4.2: In-gel fluorescence detection of azidosugars incorporated into the membrane 
proteome of prostate cancer cells. (a) Representative in-gel Alexa Fluor 488 fluorescence 
images from a panel of prostate cell lines with increasing metastatic potential (i). Total 
protein per lane was visualised using Coomassie staining. Background controls were included 
to detect non-specific fluorescence. For each lane treated with N- azidoacetylmannosamine 
(Ac4ManNAz) or N- azidoacetylgalactosamine (Ac4GalNAz), total Alexa Fluor 488 
fluorescence was quantified using Fiji Image analysis software, normalised against the 
Coomassie stain fluorescence within the same lane, and presented as a ratio (ii). Whole cell 
counts were obtained every 24 hours, over a 72-hour period using the LUNA™ Automated Cell 
Counter, and used to plot a growth curve. The gradient of the natural log regression line of 
each curve was used to calculate the doubling time (hours) for each prostate cancer cell line. 
(b) Ac4ManNAz-specific fluorescence for each cell line (i) was plotted as a function of 
doubling time (ii). (c) Ac4GalNAz-specific fluorescence for each cell line (i) was plotted as a 
function of doubling time (ii). All data represent the average ± S.D. of three independent 
experiments, each with 3 replicates. p values represent significance assessed by one-way 
ANOVA. The darker shades in the arrow’s greyscale represent an increase in the metastatic 
potential of the panel of prostate cancer cell lines. Abbreviations: M = Ac4ManNAz treated, G 
= Ac4GalNAz treated. 
 
 
4.2.3 Azidosugar labelling of the membrane proteome of breast cancer cell lines 
 
No background fluorescence was observed in extracts from breast cancer cells treated with 
vehicle (0.1% DMSO) only, or vehicle and the alkyne-Alexa Fluor 488 probe (Figure 4.3a, i). A 
general increase in the overall Alexa-488 fluorescence correlated with an increase in the 
metastatic potential of the breast cancer cell lines (Figure 4.3a, ii). There was no correlation 
between increases in Ac4ManNAz (r2 = 0.01493) (Figure 4.3b, i) or Ac4GalNAz (r2 = 0.04585) 
(Figure 4.3c, i) labelling of the glycoproteins and doubling time (Figure 4.3b, ii and 4.3c, ii). 
Therefore, the azidosugar labelling of the glycoproteins was affected by increases in the 
invasive potential of the breast cancer cell lines (Chapter 2: Figure 2.6), but not proliferation. 
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Previously, we used flow cytometric analysis to quantify global azidosugar labelling of the 
glycoproteins and glycolipids in the breast cancer cell lines (Chapter 3). Breast cancer cells 
were incubated with Ac4ManNAz or Ac4GalNAz. The incorporated azide groups were reacted 
sequentially with TMDIBO-(PEG)3-biotin and NeutrAvidinTM DyLightTM 650 (NA650), followed 
by fluorescence detection using flow cytometry. The Mean Fluorescence Intensity ratio (MFI 
ratio) for each cell line was calculated by normalising the average fluorescence intensity 
from azidosugar-labelled cells against background fluorescence (Chapter 3: Figure 3.1).  An 
increase in Ac4ManNAz and Ac4GalNAz labelling correlated with an increase in the metastatic 
potential of the breast cancer cell lines (Chapter 3: Figure 3.2). We observed a strong 
positive correlation (r2 = 0.8217) (Figure 4.3d, i) between increases in Ac4ManNAz-MFI ratios 
of the breast cancer cell lines, representing global sialylation of the glycoconjugates, and 
increases in the Ac4ManNAz-Alexa Fluor 488 fluorescence (Figure 4.3b, i), representing 
specific sialylation of the glycoproteins. Therefore, increases in global cell surface sialylation 
in the breast cancer cell lines detected by flow cytometry (Chapter 3: Figure 3.3) were driven 
by increased sialyation of the glycoproteins.  
 
There was no correlation (r2 = 0.2020) (Figure 4.3d, ii) between increases in Ac4GalNAz-MFI 
ratios of the breast cancer cell lines, representing global N-acetylgalactosamine glycosylation 
of the glycoconjugates, and Ac4GalNAz-Alexa Fluor 488 fluorescence (Figure 4.3c, i), 
representing specific N-acetylgalactosamine glycosylation of the glycoproteins. Whilst the 
increases in global N-acetylgalactosamine glycosylation quantified with flow cytometry were 
statistically significant between the breast cancer cell lines (Chapter 3: Figure 3.3c, i), only a 
significant difference in specific labelling of the glycoproteins was observed between the 
least metastatic (MDA MB 453) and most metastatic (MDA MB 231) cell lines in the breast 
cancer panel. This suggested that the glycoprotein fraction was not principally responsible 
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Figure 4.3: In-gel fluorescence detection of azidosugars incorporated into the membrane 
proteome of breast cancer cells. (a) Representative in-gel Alexa Fluor 488 fluorescence 
images from a panel of breast cancer cell lines with increasing metastatic potential (i). Total 
protein per lane was visualised using Coomassie staining. Background controls were included 
to detect non-specific fluorescence. For each lane treated with N- azidoacetylmannosamine 
(Ac4ManNAz) or N- azidoacetylgalactosamine (Ac4GalNAz), total Alexa Fluor 488 
fluorescence was quantified using Fiji Image analysis software, normalised against the 
Coomassie stain fluorescence within the same lane, and presented as a ratio (ii). Whole cell 
counts were obtained every 24 hours, over a 72-hour period using the LUNA™ Automated Cell 
Counter, and used to plot a growth curve. The gradient of the natural log regression line of 
each curve was used to calculate the doubling time (hours) for each breast cancer cell line. 
(b) Ac4ManNAz-specific fluorescence for each cell line (i) were plotted as a function of 
doubling time (ii). (c) Ac4GalNAz-specific fluorescence for each cell line (i) were plotted as a 
function of doubling time (ii). (d) Breast cancer cells were labelled sequentially with 
Ac4ManNAz or Ac4GalNAz, TMDIBO-(PEG)3-biotin and NeutrAvidinTM DyLightTM 650 (NA650). 
Fluorescence detection of NA650 using flow cytometric analysis followed. The Mean 
Fluorescence Intensity ratio (MFI ratio) for each cell line was calculated by normalising the 
average fluorescence intensity from azidosugar-labelled cells against background 
fluorescence. MFI ratios for each cell line treated with Ac4ManNAz (i) Ac4GalNAz (ii) were 
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independent experiments, each with 3 replicates. p values represent significance by one-way 
ANOVA. The darker shades in the arrow’s greyscale represent an increase in the metastatic 
potential of the panel of prostate cancer cell lines. Abbreviations: M = Ac4ManNAz treated, G 
= Ac4GalNAz treated. 
 
 
4.2.4 Azidosugar labelling of the membrane proteome of pancreatic cancer cell lines 
 
Four human pancreatic cell lines were selected from the literature based on their increasing 
tumourigenicity (Table 4.4). Azidosugar-labelled glycoproteins were extracted from the 
pancreatic cell lines, which had been metabolically labelled with Ac4ManNAz in vitro, 
resolved via gel electrophoresis, and detected using Alexa Fluor 488 fluorescence, as 
described previously. 
 
No background fluorescence was observed in extracts from pancreatic cancer cells treated 
with vehicle (0.1% DMSO) only, or vehicle and the alkyne-Alexa Fluor 488 probe (Figure 
4.4a). The metastasis derived Capan 1 cell line exhibited higher levels of Ac4ManNAz 
labelling than the tumour derived Capan 2 cell line (Figure 4.4b), consistent with increases in 
sialylation associated with an increase in metastatic potential (Natoni et. al. 2016). A high 
degree of Ac4ManNAz metabolic labelling was observed in the human telomerase (hTERT)- 
human pancreatic nestin expressing (HPNE) cell line (H4023) and the hTERT-HPNE derived 
hTERT-HPNE E6/E7 cell line (H4036), which both represent normal pancreatic epithelium 
(Table 4.1). This is contrary to reports correlating an increase in sialyation with an increase in 
cancer aggressiveness (Natoni et. al. 2016). Further independent repeats are needed to 




Table 4.4: in vitro model of pancreatic cancer progression. Summary of the characteristics 
of the pancreatic cancer cell lines used in this study (Lee et. al. 2003; Lee et. al. 2005; 
Campbell et. al. 2007; Kyriazis et. al. 1982; Deer et. al. 2010; Kyriazis et. al. 1986; Dahiya et. 
al. 1993). Abbreviations: hTERT = human telomerase, HPNE = human pancreatic nestin 



































































Figure 4.4: In-gel fluorescence detection of azidosugars incorporated into the membrane 
proteome of pancreatic cancer cells. (a) Representative in-gel Alexa Fluor 488 fluorescence 
images from a panel of pancreatic cell lines with increasing metastatic potential. Total 
protein per lane was visualised using Coomassie staining. Background controls were included 
to detect non-specific fluorescence. (b) For each lane treated with N- 
azidoacetylmannosamine (Ac4ManNAz), total Alexa Fluor 488 fluorescence was quantified 
using Fiji Image analysis software, normalised against the Coomassie stain fluorescence 
within the same lane, and presented as a ratio. All data represent the average ± S.D. of one 
experiment, each with 3 replicates. p values represent significance by one-way ANOVA. The 
darker shades in the arrow’s greyscale represent an increase in the metastatic potential of 
the panel of pancreatic cancer cell lines. Abbreviations: M = Ac4ManNAz treated, G = 
Ac4GalNAz treated, H4023 = human telomerase (hTERT)- Human Pancreatic Nestin 
Expressing (HPNE) cell line and H4036 = hTERT-HPNE E6/E7 (H4036) cell line. 
 
 
Overall, an increase in the overall Alexa Flour 488 fluorescence was seen across the prostate 
(Figure 4.2b, i and c, i), breast (Figure 4.3b, i and c, i) and pancreatic (Figure 4.4b) cancer cell 
lines. Whether treated with Ac4ManNAz or Ac4GalNAz, the overall intensity of Alexa Fluor 
488 fluorescence from the most metastatic cell line in each panel (PC3 prostate cancer cell 
line, MDA MB 231 breast cancer cell line, and Capan 1 pancreatic cancer cell line) was always 
significantly higher than the overall intensity of Alexa Fluor 488 fluorescence from the least 
metastatic cell line in each panel (PNT1A normal prostate cell line, MDA MB 453 breast 
cancer cell line, and H4023 normal pancreatic cell line). Therefore, a general increase in 
azidosugar-specific glycosylation was associated with an increase in metastatic potential. 
 
 
4.2.5 Specific azidosugar labelling of N-linked glycoproteins probed using deglycosylation 
enzymes 
 
Loss of azidosugar-specific fluorescence in metabolically labelled lysates treated with 
bacterial sialidases (neurominidases), which cleave terminal sialic residues in 
glycoconjugates (Lewis and Lewis 2012) (Chapter 1: Figure 1.4), has been used previously to 
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confirm the presence of bioorthogonally labselled sialylglycoproteins by 1D western blot 
(Luchansky et. al. 2004; Belardi et. al. 2013; Kang et. al. 2015; Spiciarich et. al. 2017). 
Therefore, we investigated the azide-specific labelling of N-linked glycoproteins using 
peptide-N4-(N-acetyl-α-glucosaminyl) asparagine amidase (PNGase), an enzyme which 
specifically cleaves N-glycans from the innermost asparagine residues within the N-linked 
glycoproteins (Kuhn et. al. 1994). 
 
Cleavage of N-glycans by PNGase F was optimised using the glycoprotein horseradish 
peroxidase (HRP), and monitored by electrophoretic mobility shifts to a faster migrating 
product with a lower molecular weight, generated from N-glycan specific changes in 
mass:charge ratio (Freeze and Kranz 2010; Hofherr et. al. 2014). Deglycosylation of HRP 
(Figure 4.5a, black arrowhead), was observed as early as 3 hours after treatment with 
PNGase F (Figure 4.5a, white arrowhead). Next, the LNCAP C4-2B prostate cancer and MDA 
MB 468 breast cancer cell lines were metabolically labelled with Ac4ManNAz or Ac4GalNAz. 
Metabolically labelled membrane enriched extracts were labelled with alkyne-Alexa Fluor 
488 and treated with PNGase F from Elizabethkingia miricola prior to in-gel fluorescence 
imaging as described previously. The presence of azidosugar labelled N-glycosylated proteins 
was confirmed by monitoring electrophoretic mobility shifts in bands of Alexa Fluor 488 
fluorescence (Figure 4.5).  After 3 hours of treatment with PNGase F, loss of Alexa Fluor 488 
fluorescence was observed in Ac4ManNAz or Ac4GalNAz labelled glycoproteins extracted 
from the LNCAP C4-2B prostate cancer (Figure 4.5b) and the MDA MB 468 breast cancer 
(Figure 4.5c) cell lines, particularly between a 50 – 150 kDa molecular weight range. 
Remaining bands of Ac4ManNAz or Ac4GalNAz specific Alexa Fluor 488 fluorescence may 
represent azidosugar labelled residues inaccessible to PNGase F (Luchansky et. al. 2004). 
 
The core structure of the O-glycosylated proteins contains an innermost serine or threonine 
residue linked to an N-acetylgalactosamine residue (Chapter 1: Figure 1.4, red perforated 
boxes). Therefore, we expected the majority of glycoproteins labelled with Ac4GalNAz, which 
is a synthetic analogue of N-acetylgalactosamine, to be O-glycans, and consequently not 
cleavable by PNGase F. This was confirmed by observing negligible shifts in Alexa-488 
fluorescence bands in samples treated with Ac4GalNAz and PNGase F, in comparison to cell 
lysates metabolically labelled with Ac4ManNAz. Overall, our data confirmed azide-specific 
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metabolic labelling of N-linked glycoproteins and the potential in using bioorthogonal 


































































Figure 4.5: In-gel fluorescence detection of azidosugar-labelled N-glycans within the 
membrane proteome using PNGase F deglycosylation. Horseradish peroxidase and 
membrane-enriched extracts were treated with PNGase F from Elizabethkingia miricola, for 
0, 3, 24, 72 and 96 hours. Total protein (10 µg per lane) was visualised using Coomassie 
staining. (a) Cleavage of N-glycans and deglycosylation of horseradish peroxidase treated 
with PNGase F (white arrowhead) monitored by mobility shifts (black arrowhead). (b) 
Representative cleavage of azidosugar-labelled N-glycans monitored by mobility shifts in 
Alexa-488 fluorescence bands in the LNCAP C4-2B prostate cancer cell line. (c) Representative 
cleavage of azidosugar-labelled N-glycans monitored by loss of Alexa-488 fluorescence in the 
MDA MB 468 breast cancer cell line. Background controls were included to detect non-
specific fluorescence. Abbreviations: M = Ac4ManNAz treated, G = Ac4GalNAz treated. 
 
 
4.2.6 Azidosugar labelling of the membrane proteome analysed using 2D gel 
electrophoresis 
 
For a more in-depth assessment of the complex changes in glycoprotein populations and 
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and charge using 2D-gel electrophoresis. Two prostate cancer cell lines (LNCAP C4-2 and 
LNCAP C4-2B) with increasing metastatic potential were incubated with Ac4ManNAz and 
Ac4GalNAz. The membrane proteome was isolated by detergent-based fractionation, the 
incorporated azide groups covalently ligated to alkyne-biotin, and lysine residues in the 
labelled proteins tagged with a Cy3 NHS ester. The labelled extracts were resolved by 2D 
western blot and total protein detected by Cy3 fluorescence (Figure 4.6a). Proteins labelled 
with Ac4ManNAz (Figure 4.6b) or Ac4GalNAz (Figure 4.6c) were then detected using 
Streptavidin-800 fluorescence. 
 
Eight spots exhibiting an increase in both Ac4ManNAz and Ac4GalNAz labelling were 
observed (Figure 4.6b and c, white arrowheads). The regions of glycan-specific Streptavidin-
800 fluorescence and total protein Cy3 fluorescence from each of the eight spots were co-
registered and compared between the two prostate cancer cell lines (Figure 4.6d). An 
increase in azidosugar labelling was observed despite the expression of proteins within the 
eight spots, appearing similar. This suggested that differential glycosylation may be a more 
sensitive and specific marker for monitoring cancer progression, than increases in total 
protein expression alone. 
 
We observed regions exhibiting an increase in Ac4GalNAz labelling, that correlated with an 
increase in the metastatic potential of the prostate cancer cell lines (Figure 4.6c, black 
arrowheads). Furthermore, more spots of Streptavidin-800 fluorescence were detected 
when the prostate cancer cell lines were treated with Ac4GalNAz (Figure 4.6c), in comparison 
to Ac4ManNAz (Figure 4.6b). This was expected, as this is due to labelling of the core 
structure (serine/threonine-N-acetylgalactosamine) present in all O-glycosylated proteins 
(Chapter 1: Figure 1.4, red perforated boxes). These data demonstrated the use of 
bioorthogonal chemistry in detecting the differential Ac4ManAz-specific sialyation and 
Ac4GalNAz-specific N-acetylgalactosamine glycosylation of proteins in an in vitro model of 
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Figure 4.6: Fluorescence detection of azidosugars incorporated into the membrane 
proteome of prostate cancer cell lines using 2D-gel electrophoresis. The membrane 
proteome was extracted from two prostate cancer cell lines (LNCAP C4-2 and LNCAP C4-2B) 
labelled with N-azidoacetylmannosamine (Ac4ManNAz) or N- azidoacetylgalactosamine 
(Ac4GalNAz), and alkyne-biotin. 35 μg of the labelled extracts were reacted Cy3 NHS ester, 
resolved by 2D western blot and azidosugar-labelled glycoproteins detected using 
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fluorescence. (b) Detection of Ac4ManNAz-labelled proteins using Streptavidin-800 
fluorescence. (c) Detection of Ac4GalNAz-labelled proteins using Streptavidin-800 
fluorescence. Regions exhibiting an increase in Ac4GalNAz labelling, that correlated with an 
increase in the metastatic potential of the prostate cancer cell lines, are highlighted (black 
arrowheads). (d) Eight spots exhibiting an increase in both Ac4ManNAz and Ac4GalNAz 
labelling are highlighted (white arrowheads in b and c). Streptavidin-800 fluorescence and 
Cy3 fluorescence have been co-registered. The darker shades in the arrow’s greyscale 
represent an increase in the metastatic potential of the prostate cancer cell lines. 
 
 
2D gel electrophoresis analysis of the glycosylated membrane proteome was similarly 
conducted using two breast cancer cell lines (MDA MB 468 and MDA MB 231) with 
increasing metastatic potential (Figure 4.7). Azidosugar-labelled extracts were resolved by 
2D western blot and total protein detected by Cy3 fluorescence (Figure 4.7a). Proteins 
labelled with Ac4ManNAz (Figure 4.7b) or Ac4GalNAz (Figure 4.7c) were then detected using 
Streptavidin-800 fluorescence. 
 
We observed regions exhibiting an increase in Ac4ManNAz labelling, that correlated with an 
increase in the metastatic potential of the breast cancer cell lines (Figure 4.7b, black 
arrowheads). Spots exhibiting a decrease in both Ac4ManNAz and Ac4GalNAz labelling were 
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Figure 4.7: Fluorescence detection of azidosugars incorporated into the membrane 
proteome of breast cancer cell lines using 2D-gel electrophoresis. The membrane proteome 
was extracted from two breast cancer cell lines (MDA MB 468 and MDA MB 231) labelled 
with N-azidoacetylmannosamine (Ac4ManNAz) or N- azidoacetylgalactosamine (Ac4GalNAz), 
and alkyne-biotin. 35 μg of the labelled extracts were minimally reacted with Cy3 NHS ester, 
resolved via 2D western blot and azidosugar labelled glycoproteins detected using 
Streptavidin 800 fluorescence. (a) Representative total protein images using Cy3 
fluorescence. (b) Detection of Ac4ManNAz-labelled proteins using Streptavidin-800 
fluorescence. Regions exhibiting an increase in Ac4ManNAz labelling, that correlated with an 
increase in the metastatic potential of the prostate cancer cell lines, are highlighted (black 
arrowheads). (c) Detection of Ac4GalNAz-labelled proteins using Streptavidin-800 specific 
fluorescence. Regions exhibiting an increase in both Ac4ManNAz and Ac4GalNAz labelling are 
highlighted (white arrowheads in b and c). The darker shades in the arrow’s greyscale 
represent an increase in the metastatic potential of the breast cancer cell lines. 
 
 
Total protein images of membrane-enriched extracts from the prostate (Figure 4.6a) and 
breast (Figure 4.7a) cancer cell lines were remarkably similar. This suggested that although 
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targeted for aberrant glycosylation are influenced by tumour type and the repertoire of 
glycoenzymes expressed. Collectively, the data continued to demonstrate the use of 
bioorthogonal chemistry in specifically detecting the differential sialyation and N-
acetylgalactosamine glycosylation of proteins from human cell lines representing the 





The link between aberrant protein glycosylation and cancer progression has formed the 
basis for using glycoprotein detection in the clinical management of cancer. However, the 
utility of biomarkers has been challenged in recent years due to low cancer specificity and 
high false-positive rates (Mayeux 2004). Improved aberrantly glycosylated variants of 
established biomarker have been discovered that improve the clinical utility of these 
biomarkers, such as AFP-L3, an aberrantly fucosylated version of AFP significantly elevated in 
hepatocellular carcinoma patients, in comparison to benign liver diseases such as cirrhosis, 
providing a marker for the onset of hepatocellular carcinoma (Block et. al. 2005; Meany and 
Chan 2011; Adamczyk et. al. 2012; Pinho and Reis 2015). 
 
Towards the identification of novel aberrantly glycosylated proteins, with the aim of 
discovering prognostic markers of progression, we utilised bioorthogonal chemistry and gel 
electrophoresis to visualise differential N-azidoacetylmannosamine (Ac4ManAz)-specific 
sialyation and N-azidoacetylgalactosamine (Ac4GalNAz)-specific glycosylation of 
glycoproteins across panels of cell lines, some of which had been validated previously as 
suitable in vitro models of cancer progression (Chapter 2). Panels of prostate, breast, and 
pancreatic cancer cell lines, with increasing metastatic potential, were incubated with 
Ac4ManNAz and Ac4GalNAz, which were incorporated biosynthetically into cell-surface 
glycans. The membrane proteome was isolated and the incorporated azide groups covalently 
ligated to alkyne-Alexa Fluor 488 using copper-catalysed chemistry. Azidosugar-labelled 




An increase in the overall Alexa Fluor 488 fluorescence was seen across the prostate (Figure 
4.2b, i and c, i), breast (Figure 4.3b, i and c, i) and pancreatic (Figure 4.4b) cancer cell lines. 
Whether treated with Ac4ManNAz or Ac4GalNAz, the overall intensity of Alexa Fluor 488 
fluorescence from the most metastatic cell line in each panel (PC3 prostate cancer cell line, 
MDA MB 231 breast cancer cell line, and Capan 1 pancreatic cancer cell line) was always 
significantly higher than the overall intensity of Alexa Fluor 488 fluorescence from the least 
metastatic cell line in each panel (PNT1A normal prostate cell line, MDA MB 453 breast 
cancer cell line, and H4023 normal pancreatic cell line). Therefore, a general increase in 
azidosugar-specific glycosylation was associated with an increase in metastatic potential. 
This is consistent with increases in the sialyation (Büll et. al. 2014) of cell surface 
glycoproteins (Schultz et. al. 2012; Stowell et. al. 2015) observed during disease progression 
in prostate (Munkley et. al. 2016), breast (Kölbl et. al. 2016), and pancreatic cancers 
(Munkley 2019), which has been attributed to the generation of tumour-associated antigens 
on carrier proteins such as the Sialyl Lewis antigens, and unmodified or sialylated Thomsen-
nouveau (Ju et. al. 2011) (Chapter 1: Figure 1.9) and Thomsen-Friedenreich (Springer et. al. 
1975) (Chapter 1: Figure 1.10) antigens (Natoni et. al. 2016; Pinho and Reis 2015). 
 
A high degree of Ac4ManNAz metabolic labelling was observed in the human telomerase 
(hTERT)- human pancreatic nestin expressing (HPNE) cell line (H4023) and the hTERT-HPNE 
derived hTERT-HPNE E6/E7 cell line (H4036), which are both considered to represent normal 
pancreatic epithelium (Table 4.4). The parent hTERT-HPN cell line has previously been shown 
with tandem mass spectrometry to have significantly higher levels of a2,3-sialylation and 
sialyl Lewis X antigen (Chapter 1: Figure 1.8) than the tumourigenic pancreatic 
adenocarcinoma (PDAC) PaTu-S, PaTu-T, PDAC 1, and PDAC 2 cell lines (Holst et. al. 2017). 
This is contrary to reports correlating an increase in sialyation with an increase in cancer 
aggressiveness (Natoni et. al. 2016), but consistent with high levels of Ac4ManNAz-specific 
Alexa Fluor 488 fluorescence observed in metabolically labelled lysates prepared from the 
hTERT-HPN cell lines (Figure 4.4). Further independent repeats are needed to confirm if the 
increases in Alexa Fluor 488 fluorescence are statistically significant. Future studies would 
involve validating the characteristics of each pancreatic cell line using scratch wound assays 
to compare migration, Boyden chambers to compare invasion and immunohistochemistry to 
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compare the relative expression of known invasion biomarkers (Pijuan et. al. 2019; Justus et. 
al. 2014).  
 
Previously, we used flow cytometric analysis to quantify global azidosugar labelling of the 
glycoproteins and glycolipids in a panel of breast cancer cell lines (Chapter 3). An increase in 
global Ac4ManNAz and Ac4GalNAz labelling correlated with an increase in the metastatic 
potential of the breast cancer cell lines (Chapter 3: Figure 3.2). We observed a strong 
positive correlation (r2 = 0.8217) (Figure 4.3d, i) between increases in global Ac4ManNAz-
sialylation of the glycoconjugates observed by flow cytometry, and increases in the 
Ac4ManNAz-Alexa Fluor 488 fluorescence (Figure 4.3b, i), representing specific sialylation of 
the glycoproteins. Therefore, the glycoprotein fraction may be principally responsible for the 
increased glycan labelling observed with an increase in the metastatic potential of the breast 
cancer cell lines (Chapter 3: Figure 3.3). 
 
What is yet to be answered is whether increases in bioorthogonal metabolic labelling detects 
global increases in glycoprotein sialyation or increased turnover (Colley et. al. 2017) of cell 
surface N- and O-glycans. It is unknown whether azidosugars are preferentially incorporated 
into glycan structures via specific glycosidic linkages, and if this occurs at multiple epitopes 
within a glycoconjugate in a site-specific or tissue-specific manner. This would be influenced 
by changes in the expression or activity of sialyltransferases in the more metastatic cell lines, 
which also has not been investigated. We confirmed the azide-specific labelling of N-linked 
glycoproteins using PNGase F, an enzyme which specifically cleaves N-glycans from the 
innermost asparagine residues within the N-linked glycoproteins (Kuhn et. al. 1994) (Figure 
4.5). Future studies could involve using bacterial sialidases (neuraminidases), which cleave 
terminal sialic residues in glycoconjugates (Lewis and Lewis 2012) to confirm the presence of 
bioorthogonally labelled sialoglycoproteins (Luchansky et. al. 2004; Belardi et. al. 2013; 
Spiciarich et. al. 2017). Furthermore, quantitative mass spectrometry is required to confirm 
if increases in azidosugar labelling are influenced by the overexpression of glycoproteins 
across the panels of cell lines used in this study. 
 
For a more in-depth assessment of the complex changes in glycoprotein populations and 
azidosugar incorporation, labelled membrane enriched extracts were resolved based on size 
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and charge using 2D-gel electrophoresis. Populations of azidosugar labelled proteins in 
prostate (Chapter 4: Figure 4.6, arrowheads) and breast cancer (Chapter 4: 4.7, arrowheads) 
cell lines, exhibited distinct laddered spot patterns. a1-antitrypsin extracted from the serum 
of patients with congenital disorders of glycosylation type 1 (CGD I), a condition defined by 
underglycosylation of proteins, and resolved by 2D gel electrophoresis, exhibited a distinct 
laddered spot pattern (Mills et. al. 2001; Mills et. al. 2003). Subsequent analysis of a1-
antitrypsin spots using matrix-assisted laser-desorption ionisation–time-of-flight mass 
spectrometry, revealed 3 subforms: unglycosylated, monoglycosylated or diglycosylated a1-
antitrypsin, which differed by one sialic acid residue, observed on 2D gels by an increase in 
isoelectric point (pI) of 0.1 pH unit (Mills et. al. 2001; Mills et. al. 2003). PSA extracted from 
the serum of healthy individuals and prostate cancer patients, resolves on 2D gels into 5 
spots, representing the 5 isoforms of PSA (F1-F5), with pIs of 6.4, 6.6, 6.8 and 7.0, 
respectively (Sarrats et. al. 2010). High-performance liquid chromatography (HPLC) analysis 
showed that the F1-3 subforms where mono and disialylated, the F4 subform was 
monosialyated and the F5 subform was unglycosylated (Sarrats et. al. 2010). Therefore, the 
increase in pIs or reduced acidity of the PSA subforms from F1-F5 was attributed to 
decreases in sialic acid content. Based on these studies, the laddering pattern observed here 
with the azidosugar labelled proteins may be caused by differential glycan content of protein 
glycoforms.  This is supported by the observation of differences in the Streptavidin-800 
fluorescence of protein spots within a single cell type. Additionally, we compared azidosugar 
labelling of glycoproteins between two prostate cancer cell lines with increasing 
tumourigenicity. Eight spots exhibited an increase in both Ac4ManNAz and Ac4GalNAz 
labelling in the LNCAP C4 and LNCAP C4-2B prostate cancer cell lines (Figure 4.6b and c, 
white arrowheads), despite the expression of proteins within the eight spots, appearing 
similar. 
 
Overall, using 1D and 2D gel electrophoresis, we observed differential glycosylation of 
protein populations within a single line, and between cell lines with increasing metastatic 
potential. Our data suggest that differential glycosylation may be a more sensitive and 
specific marker for monitoring cancer progression, than increases in total protein expression 
alone. 
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4.4 Materials and Methods 
 
4.4.1 Cell lines 
 
The PNT1A, LNCAP, and LNCAP C4-2B human prostate cell lines were obtained from the 
Cancer Research UK Cambridge Institute Biorepository, based on stocks made available by 
Joe Kuo. The LNCAP C4, LNCAP C4-2, and PC3 human prostate cancer cell lines were 
purchased from ATCC. All prostate cell lines were cultured in RPMI with L-glutamine (Gibco®, 
InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories).  
 
The MDA MB 453, MCF-7, MDA-MB-468, and MDA MB 231 human breast cancer cell lines 
were obtained from the Cancer Research UK Cambridge Institute Biorepository, based on 
stocks made available by Joe Kuo. All breast cell lines were cultured in DMEM with L-
glutamine (Gibco®, InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories). 
 
The human telomerase (hTERT)- human pancreatic nestin expressing (HPNE) (H4023) and 
hTERT-HPNE E6/E7 (H4036) human pancreatic cell lines were purchased from ATCC and 
cultured in M3: BaseF media (Incell). The Capan 1 and Capan 2 cell lines were obtained from 
the Cancer Research UK Cambridge Institute Biorepository, based on stocks made available 
by the Jodrell group. The Capan 1 and Capan 2 cell lines were cultured initially in IMEM 
(Gibco®, InvitrogenTM) and Mc Coy's (Gibco®, InvitrogenTM) media respectively, and 10% 
Foetal bovine serum (FBS Gold, PAA Laboratories). All pancreatic cell lines were then 
adapted to M3: BaseF media (Incell) in a step-wise manner by Ms Laura Brandt (Part III 
undergraduate student, Brindle Laboratory, CRUK CI). This involved periodically modifying 
the old:new media ratio from 50:50, to 75:25 and finally 0:100. Culturing of the pancreatic 
cell lines following adaptation was carried out by Dr. André Neves (Brindle Laboratory, CRUK 
CI). 
 
Cell lines were genotyped and authenticated by Short Tandem Repeat (STR) DNA profiling 
and comparison with available databases from ATCC or DSMZ. All cell lines tested negative 
for Mycoplasma using the MycoProbe™ Kit (R&D Systems).  
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4.4.2 Tissue culture 
 
Cell lines were maintained in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) in 5% CO2, 
in 37 °C humidified incubators, and cultured to 80% confluence. Briefly, cells were washed 
once with 20 ml warm Phosphate Buffered Saline (PBS; 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 
0.24 g KH2PO4 per litre, pH 7.4), and trypsinised. Prostate cancer cell lines were trypsinised 
for 4 minutes at 37oC, apart from the PC3 cell line, which was trypsinised for 7 minutes. 
Breast cancer cell lines were trypsinised for 7 minutes at 37oC. Pancreatic cell lines were 
trypsinised for 5-10 minutes at 37oC. Trypsinised cells were added to equal volumes of 
media, centrifuged at 700 x g for 4 minutes (4oC), and resuspended in fresh media. Viable 
cell counts were obtained by Trypan blue dye exclusion using a LUNA™ Automated Cell 
Counter (Logos Biosystems), and cells seeded at 3 x 104 cells/cm2.  
 
 
4.4.3 Extraction and purification of the membrane protein fraction 
 
Prostate and breast cell lines were seeded at 3 x 104 cells/cm2 in NuncTM 175 cm2 flasks 
(Thermo Fisher ScientificTM) and maintained at 5% CO2, in 37 °C humidified incubators for 24 
hours. After 24 hours, the media was replaced with 20 ml fresh media and cells incubated in 
5 % CO2 at 37 °C for 24 hours. After 24 hours, cells were harvested by trypsinisation and 
centrifugation and counted using the LUNA™ Automated Cell Counter (Logos Biosystems), as 
described previously. 
 
5 x 106 cells were transferred into Nostick® hydrophobic microcentrifuge tubes (Scientific 
Specialties, Inc.), washed twice in 2 ml ice-cold PBS, and fractionated using a Qproteome® 
Cell Compartment kit (Qiagen), according to the manufacturer’s protocol. Briefly, washed 
cell pellets were incubated in 1 ml Extraction Buffer CE1 for 10 minutes at 4oC on an end-
over-end shaker (30 rpm). Lysates were centrifuged at 1000 x g for 10 minutes at 4oC. The 
supernatant, primarily containing cytosolic proteins, was transferred into a fresh Nostick® 
hydrophobic microcentrifuge tubes (Scientific Specialties, Inc.) and stored at -20oC. The 
remaining pellet was resuspended in 1 ml Extraction Buffer CE2 and incubated for 30 
minutes at 4oC on an end-over-end shaker (30 rpm). Lysates were centrifuged at 6000 x g for 
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10 minutes at 4oC. The supernatant, primarily containing membrane proteins, was 
transferred into fresh Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, 
Inc.).  
 
Four volumes of ice-cold acetone were added to the membrane protein-enriched fractions 
and incubated for 1 hour on ice. Precipitated proteins were pelleted by centrifugation at 12, 
000 x g for 10 minutes (4oC). The supernatant was discarded and the protein pellets air-dried 
for 15 minutes. Dried protein pellets were resuspended in 100 μl Tris-HCL buffer (50 mM, pH 
8, 0.5% SDS). Residual acetone was removed by the sequential addition of 600 μl methanol, 
150 μl chloroform, and 400 μl Milli-Q 18.2 Ω water, with vortexing. After centrifugation at 
18, 000 x g for 10 minutes (4oC), the upper aqueous phase was removed and the precipitated 
proteins washed twice with 450 μl methanol. The pellets were air-dried for a minimum of 15 
minutes, and resuspended in 100 μl Tris-HCL buffer (50 mM, pH 8, 0.5% SDS). The total 
protein concentration was determined using the DC™ Protein Assay (Bio-Rad), using BSA as a 
standard. Lysates were stored at -20oC. 
 
 
4.4.4 Western blot  
 
Membrane enriched lysates were resolved on precast 4-12% 1mm Bis-Tris gels (Thermo 
Fisher ScientificTM) in 1x NuPAGE MOPS buffer (Invitrogen) (10 μg/lane, 30 min 60 V, 120 min 
120 V), and 1D gels transferred onto nitrocellulose membranes using an iBlot 2 (Life). Blots 
were incubated in 1x Odyssey® PBS block buffer (LI-COR) for 1 hour, followed by an 
overnight incubation at 4oC with a 1:1000 dilution of the following primary antibodies in PBS 
blocking buffer (0.1% tween, 0.1% SDS): rabbit monoclonal anti-E-cadherin (Cell Signalling 
Technologies), rabbit monoclonal anti-lamin b (Cell Signalling Technologies), goat polyclonal 
anti-GAPDH (Abcam), rabbit monoclonal anti-VDAC (Cell Signalling Technologies), and rabbit 
polyclonal anti-TIMM 23 (Abcam). After overnight incubation, primary antibodies were 
removed, and the blots washed 3 times (PBS + Tween (0.1%), 5 minutes). Blots were 
incubated for 1 hour at room temperature with a 1:1000 dilution of a goat anti-rabbit IRDye 
800 CW secondary antibody (LI-COR) in PBS blocking buffer (0.1% tween, 0.1% SDS). Blots 
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were washed 3 times in PBS (0.1% Tween) for 5 minutes, once in PBS for 5 minutes, and 





Membrane-enriched lysates were resolved by 1D gel electrophoresis as described above, 
stained with Instant Blue™ Coomassie dye (Expedeon), and submitted to the Proteomics 
Core Facility at the Cancer Research UK Cambridge Institute.  
 
Each gel lane was cut into 24 bands and transferred into a microcentrifuge tube. The bands 
were cut into pieces, destained, reduced (Dithiothreitol in 100 mM Ammonium bicarbonate 
pH 8.5), alkylated (iodoacetamide) and subjected to enzymatic digestion with sequencing 
grade trypsin overnight at 37°C. After digestion, the supernatants were suspended in 10 μl of 
0.1% formic acid for further LC-MS analysis. 
 
For each band, peptides were loaded on to a reverse-phase trap column (2 cm x 100 μm i.d.) 
and separated on an analytical column (25 cm × 75 μm i.d.) with 5–45% acetonitrile gradient 
in 0.1% formic acid and 5% DMSO at 300 nl/min flow rate for 100 minutes. In each data 
collection cycle, one full MS scan (400 - 1,600 m/z) was acquired in the Orbitrap ion mass 
analyser (Thermo Fisher ScientificTM ) (60K resolution, automatic gain control (AGC) setting 
of 3×106 and Maximum Injection Time (MIT) of 50 ms). The most abundant ions were 
selected using the data-dependent acquisition algorithm “Top N”, for fragmentation by 
Higher-energy collisional dissociation (HCD). HCD was performed with a collision energy of 
30%, an AGC setting of 5×104, an isolation window of 2.0 Da, a MIT of 200 ms. Previously 
analysed precursor ions were dynamically excluded for 30 seconds. 
 
 
4.4.6 Database searching 
 
The Proteome Discoverer 1.4. (Thermo Fisher ScientificTM) was used for the processing of 
HCD tandem mass spectra. The SequestHT search engine was used and all the spectra 
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searched against the Uniprot Homo sapiens FASTA database (taxon ID 9606 - Version 
February 2018). All searches were performed using a static modification of 
Carbamidomethylation at Cysteines (+57.021Da). Methionine oxidation (+15.9949Da) and 
Deamidation on Asparagine and Glutamine (+0.984) were included as dynamic 
modifications. Mass spectra were searched using a precursor ion tolerance of 20 ppm and a 
fragment ion tolerance of 0.02 Da. For peptide confidence, 1% FDR was applied and peptides 
uniquely matched to a protein were used for further analysis. 
 
 
4.4.7 Bioorthogonal metabolic labelling of cell lines in vitro for gel electrophoresis  
 
N-azidoacetylmannosamine (Ac4ManNAz), N-azidoacetylgalactosamine (Ac4GalNAz) and 
TMDIBO-PEG3-biotin were synthesised by Henning Stöckmann, Department of Chemistry. 
 
Cells were seeded at 1.75 x 104 cells/cm2 in NuncTM 175 cm2 flasks (Thermo Fisher 
ScientificTM) and maintained in 5% CO2, in 37 °C humidified incubators for 3 days before 
metabolic labelling experiments. Flasks were then washed once with 20 ml warm Phosphate 
Buffered Saline (PBS; 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 per litre, pH 7.4), and 
the cells trypsinised. Prostate cancer cell lines were trypsinised for 4 minutes at 37oC, apart 
from the PC3 cell line which was trypsinised for 7 minutes. Breast cancer cell lines were 
trypsinised for 7 minutes at 37oC. Pancreatic cell lines were trypsinised for 5-10 minutes at 
37oC. Trypsinised cells were added to equal volumes of media, centrifuged at 700 x g for 4 
minutes (4oC) and resuspended in fresh media. Viable cell counts were obtained by Trypan 
blue dye exclusion using a LUNA™ Automated Cell Counter (Logos Biosystems), and cells 
seeded at 3 x 104 cells/cm2 in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM). Plates 
were incubated in 5 % CO2, 37 °C for 24 hours. After 24 hours, the media was replaced with 
fresh media only (0.1% DMSO, vehicle control) or fresh media supplemented with 50 μM 
Ac4ManNAz or Ac4GalNAz, using a surface:area volume ratio equivalent to a 6 well plate 
(52.5 ml media supplemented with DMSO or azidosugars). Cells were incubated in 5 % CO2 
at 37 °C for 24 hours. After 24 hours, cells were harvested by trypsinisation and counted, as 
described previously.  
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5 x 106 cells were transferred into Nostick® hydrophobic microcentrifuge tubes (Scientific 
Specialties, Inc.), washed twice in 2 ml ice-cold PBS, fractionated using a Qproteome® Cell 
Compartment kit (Qiagen), and purified using acetone precipitation and 
methanol/chloroform/Milli-Q 18.2 Ω water precipitation, as described previously. The total 
protein concentration was determined using the DC™ Protein Assay (BIO-RAD), using BSA as 
a standard. 
 
Up to 200 μg of metabolically labelled protein was chemoselectively reacted with either 
alkyne-Alexa Fluor 488 (Life Technologies) for 1D gel electrophoresis or alkyne-biotin (Life 
Technologies) for 2D gel electrophoresis, using the Click iT Protein Reaction Kit (Life 
Technologies), according to the manufacturer’s protocol. Residual reactants were removed 
by methanol/chloroform/Milli-Q 18.2 Ω water precipitation, as described previously. Protein 
pellets were dried for a minimum of 15 minutes, and resuspended in 200 μl Tris HCL buffer 
(50 mM, pH 8, 0.5% SDS) and sonicated for 30 seconds (3 cycles of 10 seconds ON and 5 
seconds OFF) using the Biorupter ® Plus (Diagenode). The total protein concentration was 
determined using the DC™ Protein Assay (BIO-RAD), using BSA as a standard. Samples were 
stored at -20oC.  
 
 
4.4.8 1D gel electrophoresis and in-gel imaging of azidosugar labelled glycoproteins  
 
Metabolically labelled membrane protein fractions reacted with alkyne-Alexa Fluor 488 in 
Tris-HCL buffer (50 mM, pH 8, 0.5% SDS) were loaded on precast 4-12% 1 mm Bis-Tris gels 
(Thermo Fisher ScientificTM) and resolved in 1x NuPAGE MOPS buffer (Invitrogen) (10 
μg/lane; 30 min at 60 V and 120 min for 120 V). Alexa Fluor 488 fluorescence (Cy2; 489 nm 
maximum excitation wavelength, 506 nm maximum emission wavelength) was imaged in-gel 
with a Typhoon scanner (GE Healthcare). Gels were stained subsequently with Instant Blue™ 
Coomassie (Expedeon) or silver stain (Pierce Kit) and imaged using an Odyssey CLx Infrared 
Imaging System (LI-COR Biosciences) or Image Scanner III (GE Healthcare), respectively. 
 
For each lane treated with Ac4ManNAz or Ac4GalNAz, total Alexa Fluor 488 fluorescence was 
quantified using the “Gel analysis” pre-installed plug-in on the Fiji image analysis. Generally, 
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the Fiji “Rectangular select” tool was used to outline each lane, the relative density within 
each lane was plotted as a histogram, and the area under each curve plotted. Total Alexa 
Fluor 488 fluorescence was normalised against the Coomassie stain fluorescence within the 
same lane, and presented as a ratio. 
 
 
4.4.9 Deglycosylation of metabolically labelled glycoproteins using PNGase F 
 
Metabolically labelled membrane protein fractions reacted with alkyne-Alexa Fluor 488 or 
horseradish peroxidase (Pierce) were deglycosylated with PNGase F from Elizabethkingia 
miricola (Sigma). Briefly, lysates (5 μg) were adjusted to a final volume of 35 μl with Milli-Q 
18.2 Ω water and denatured at 100oC for 5 minutes in a solution of 250 mM phosphate 
buffer (pH 7.5), 2% SDS and 1M 2-mercaptoethanol. Samples were cooled for 5 minutes at 
4oC and incubated with PNGase F in Triton X-100 (15% v/v) for 3, 24, 72 or 96 hours.  
 
PNGase F-treated samples were loaded on precast 4-12% 1mm Bis-Tris gels (Thermo Fisher 
ScientificTM) and resolved in 1x NuPAGE MOPS buffer (Invitrogen) (30 min 60 V, 120 min 120 
V). Alexa-488 fluorescence (Cy2; 489 nm maximum excitation wavelength, 506 nm maximum 
emission wavelength) was imaged in-gel with a Typhoon scanner (GE Healthcare). Gels were 
stained subsequently with Instant Blue™ Coomassie (Expedeon) and imaged using an 
Odyssey CLx Infrared Imaging System (LI-COR Biosciences).  
 
 
4.4.10 2D western blot analysis of azidosugar labelled glycoproteins 
 
35 μg of metabolically labelled protein reacted with alkyne-biotin were reacted with 0.2 mM 
Cy3 dye (200 pmoles/μl) at room temperature for 30 minutes. Reactions were quenched 
with an equal volume of 1 mM lysine. Samples were processed using the 2-D Clean-Up Kit 
(GE Healthcare), according to the manufacturer’s protocol. Briefly, up to 100 μl of sample 
was mixed with 300 μl Precipitant Solution, incubated on ice for 15 minutes, mixed with 300 
μl Co-precipitate Solution, and incubated on ice for an additional 15 minutes. The 
precipitated protein was pelleted at maximum speed (21, 000 x g) for 5 minutes, and the 
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supernatant removed. Without disturbing the pellet, 40 μl Co-precipitate Solution was 
added to the protein pellet and incubated on ice for 5 minutes. The mixture was centrifuged 
at maximum speed (21, 000 x g) for 5 minutes, the supernatant removed, and the protein 
pellet washed in a solution of 25 μl Milli-Q 18.2 Ω water, 1 ml ice-cold Wash Buffer and 5 μl 
wash additive for 1 hour (including vortexing of the solution for 30 seconds, every 10 
minutes). The mixture was pelleted at maximum speed (21, 000 x g) for 5 minutes, the 
supernatant removed, and the pellet air dried briefly for 5 minutes. 
 
The dried pellets were resolubilised in 250 μl rehydration buffer (7M urea, 2M thiourea, 2% 
ASB-14, 2 mg/ml DTT (fresh), 1% IPG buffer pH 3-10 non-linear (GE Healthcare (fresh)), 
heated at 37oC for 10 minutes, vortexed for 30 seconds, and centrifuged at maximum speed 
(21, 000 x g) for 5 minutes to remove insoluble precipitates. Samples were loaded onto pre-
cast 13 cm pH 3-10 non-linear IPG strips (GE Healthcare) and isoelectric focusing carried out 
using the Ettan™ IPGphor™ 3 Isoelectric Focusing System (GE Healthcare) (20oC, 50 µA/strip, 
3 hr rehydration, 20V for 10 hr, 500V for 1 hr, 1000V for 1 hr, 5000V for 5hr). 
 
On completion, IPG strips were immediately equilibrated for 20 minutes at room 
temperature in a reducing equilibration solution (75 mM Tris pH 8.8, 30 % v/v glycerol, 6 M 
Urea, 2 % w/v SDS, 5mg/ml DTT (fresh)) on an orbital shaker. Equilibrated strips were rinsed 
in SDS running buffer (25 mM Tris pH 8.3, 192 mM glycine, 0.1% SDS) and placed on the top 
of manually cast 0.1 x 16 x 18 cm 12% poly-acrylamide gels (Milli-Q 18.2 Ω water, 12% 
acrylamide (29:1 acrylamide:bis-acrylamide), 0.375 M Tris-HCl pH 8.8, 0.1% SDS, 0.1% 
ammonium persulphate, 1:250 TEMED). Gels were sealed with an agarose-dye (0.5 % 
Agarose in SDS running buffer (29 mM Tris pH 8.3, 192 mM Glycine, 0.1% SDS) + 0.002% w/v 
bromophenol blue), placed in the Se600 X-15-1.5 Chroma Vertical Electrophoresis unit 
(Hoefer) and separated in SDS running buffer (29 mM Tris pH 8.3, 192 mM Glycine, 0.1% 
SDS) until the dye front reached the bottom of the gel (20 min at 25 mA/gel, ~5 hours at 40 
mA/gel, 15 °C).  
 
After electrophoresis, Cy3 fluorescence (548 nm maximum excitation wavelength, 561 nm 
maximum emission wavelength) was imaged in-gel using a Typhoon Scanner (GE 
Healthcare), and proteins transferred to 0.45 µm pore nitrocellulose membranes (Bio-Rad) 
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overnight in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 10% methanol) using a 
Hoefer TE62 tank (4oC, 100 mA, 16-17 hours). Blots were imaged for Cy3 fluorescence (548 
nm maximum excitation wavelength, 561 nm maximum emission wavelength) on a Typhoon 
Scanner (GE Healthcare) post-transfer to assess transfer efficiency. Biotinylated proteins 
were detected by treating blots with 1x Odyssey® PBS block buffer (LI-COR) for 1 hour and 
1:5000 IRDye 800CW Streptavidin (LI-COR) in PBS block buffer for 15 minutes. Blots were 
washed 6 times in PBS (0.1% Tween) for 5 minutes, once in PBS for 5 minutes, and imaged 
on an Odyssey CLx Infrared Imaging System (LI-COR Biosciences). 
 
 
4.4.11 Statistical analysis  
 

















Chapter 5: Identification of bioorthogonally labelled 






5.1.1 Glycans as biomarkers 
 
Glycans are the complex carbohydrate structures formed when monosaccharides link 
together via glycosidic bonds. Glycans act as cellular decorations with roles in intracellular 
signalling, hormone regulation, cell migration, plasma membrane structuring, immunity, 
host-pathogen recognition, and drug sensitivity (Pinho and Reis 2015; Varki 2017). In cancer, 
alterations in the expression of glycoenzymes and their location within the Golgi 
compartments, alterations to the tertiary conformation of peptide backbones and nascent 
glycan chains, as well as fluctuations in the abundance of acceptor substrates, sugar 
nucleotide donors and cofactors (Pinho and Reis 2015; Adamczyk et. al. 2012), cause the 
generation of aberrant cancer-associated antigens (Chapter 1: Figure 1.7). Aberrant 
glycosylation can affect growth factor signalling, cell proliferation, adhesion, and migration, 
and promote tumour progression through enhanced cell-matrix interactions, invasion, 
angiogenesis, and metastasis (Moremen et. al. 2012).  
 
Based on the role of glycosylation in cancer progression, several studies have gone on to 
characterise glycome differences between healthy individuals and cancer patients (Abelev 
et. al. 1963; Springer et. al. 1975; Chan et. al. 1984; Turner et. al. 1985; Ng et. al. 1987), 
leading to the identification of aberrantly glycosylated glycoproteins or oligosaccharide 
signatures, known as biomarkers in tissue or serum (Nimse et. al. 2016). Cancer biomarkers 
are used in clinical practice for cancer diagnosis, therapeutic monitoring, detecting disease 
recurrence, and examining tumour burden (Peracaula et. al. 2003) (Chapter 1: Figure 1.12). 
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However, the utility of biomarkers has been challenged in recent years due to low cancer 
specificity and high false-positive rates (Mayeux 2004). 
 
 
5.1.2 Identification of new glycosylated biomarkers using bioorthogonal chemistry 
 
Several technologies exist to study the structure, distribution, abundance, and function of 
glycans in cancer, within cells and tissues, and their variation during cancer (Bertozzi and 
Sasisekharan 2009; Bennun et. al. 2016), such as glycan-binding lectin and antibody arrays, 
carbohydrate stains, deglycosylation enzymatic cleavage, genetic mutation models, 
hydrazide chemistry oxidation of sugars, liquid chromatography–mass spectrometry, 
hydrophilic interaction chromatography and boronate affinity chromatography (Springer and 
Gagneux 2016; Pan et. al. 2012; Pan et. al. 2016; Cieniewski-Bernard et. al. 2014). 
 
In recent years, more novel methods of capturing glycoproteins have involved the use of 
bioorthogonal monosaccharide analogues containing a functional azide group or “chemical 
reporter” not normally present in the cell (Laughlin et. al. 2009), which are incorporated 
metabolically into cellular glycan structures, and detected subsequently by covalent ligation 
of imaging probes or affinity reagents that rapidly react with the azide group (Saxon and 
Bertozzi 2000; Saxon et. al. 2002) (Chapter 1: Figure 1.20). In the search for new and 
improved biomarkers, bioorthogonal azide-based chemical reporters, generally called 
azidosugars, have been combined with mass spectrometry analysis to capture and identify 
glycosylated proteins, which are overexpressed in small lung cell carcinoma tissue (Pan et. al. 
2012), and prostate cancer tissue (Spiciarich et. al. 2017), that were previously missed using 
less sophisticated lectin- or antibody-based glycoprotein capture methods.  
 
Pan and colleagues incubated A549 lung cell adenocarcinoma, Hela cervical carcinoma, and 
SW1990 pancreatic adenocarcinoma cell lines, with Ac4ManNAz (Pan et. al. 2012). 
Incorporated azide groups were covalently ligated to biotin-SS-alkyne, using copper-
catalysed chemistry, and the azidosugar labelled proteins enriched using streptavidin-
coupled beads. Purified azidosugar labelled proteins were identified by mass spectrometry, 
leading to the identification of neural adhesion molecule, which was uniquely expressed in 
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A549 lung cell adenocarcinoma, and subsequently shown to be overexpressed in small lung 
cell carcinoma tissue using immunohistochemistry (Pan et. al. 2012). Similarly, Spiciarich and 
colleagues metabolically labelled prostate tissue slices derived from radical prostatectomy 
specimens with Ac4ManNAz, captured the azidosugar labelled glycoproteins using biotin-
alkyne and streptavidin-coupled beads, and then identified the azidosugar labelled proteins 
using mass spectrometry (Spiciarich et. al. 2017). Legumain was shown to be glycosylated 
and significantly overexpressed in lysates extracted from normal tissue slice cultures (TSC) in 
comparison to cancer TSC’s (Spiciarich et. al. 2017). These studies highlighted bioorthogonal 
chemistry as a novel strategy for glycoprotein enrichment and biomarker discovery based on 
the identification of azidosugar labelled proteins uniquely identified in cancer tissue, or 
overexpressed in cancer tissues in comparison to normal healthy tissue. 
 
Using bioorthogonal chemistry (Chapter 1: Figure 1.24), flow cytometry (Chapter 3) and gel 
electrophoresis (Chapter 4), we have previously shown a correlation between increases in N-
azidoacetylmannosamine (Ac4ManNAz)-specific sialyation and N-azidoacetylgalactosamine 
(Ac4GalNAz)-specific glycosylation of plasma membrane glycoconjugates and increases in the 
metastatic potential of cell lines representing the stages of cancer progression (Chapter 2). 
The data illustrated the utility of bioorthogonal labelling in detecting patterns of aberrant 
glycosylation associated with progressive disease, and was consistent with a growing body of 
evidence implicating increased protein glycosylation as a driver in tumourigenesis 
(Christiansen et. al. 2014). Whilst this trend formed the basis for monitoring tumour 
glycosylation in vivo (Chapter 3: Figures 3.5-3.8), differential azidosugar labelling may also be 
useful for identifying biomarkers indicative of cancer progression. The strong labelling of the 
glycoprotein fraction, observed using 1D (Chapter 4: Figure 4.2-4.4) and 2D gel 
electrophoresis (Chapter 4: Figure 4.6 and 4.7), suggested that differential glycosylation, 
specifically within the glycoproteins, may have prognostic value. Therefore, we endeavoured 
to identify prognostic biomarkers from the prostate cancer membrane proteome using 







The metastatic potential of the established prostate cancer cell lines used in the study was 
confirmed in the scratch wound (Chapter 2: Figure 2.2), Boyden chamber migrations assays 
(Chapter 2: Figure 2.3a and b) and by demonstrating a correlation with the expression of 
known invasion biomarkers (Chapter 2: Figures 2.3d). Collectively, the data validated the 
LNCAP panel of prostate cancer cell lines as a suitable in vitro model of prostate cancer 
progression. However, given the heterogeneity of human cancers of the same type, we 
investigated if there were other differences in the prostate cancer cell lines, apart from 
migration and invasion.  
 
Comparison of the genetic sequences of each cell line revealed vast differences in the 
consensus profiles of the PNT1A and PC3 cell lines (Figure 5.1a). Furthermore, previous data 
have shown the PNT1A cell line to be highly motile (Chapter 2: Figure 2.2) and invasive 
(Chapter 2: Figure 2.3a-c). We deemed the PNT1A cell to be an unsuitable model for normal 
prostate epithelium and unsuitable for mass spectrometry analysis. As well as being 
genetically divergent, the PC3 cell line did not express markers commonly associated with 
prostate cancer in humans, such as prostate-specific antigen (PSA) and prostate-specific 
membrane antigen (PSMA) (Figure 5.1b). Therefore, only the LNCAP lineage of cell lines 
(LNCAP, LNCAP C4, LNCAP C4-2, and LNCAP C4-2B), were taken forward for further analysis. 
They were genetically related (Figure 5.1a) and most representative of the clonal evolution 






Figure 5.1: Selection of prostate cancer cell lines for mass spectrometric analysis. (a) Gene 
sequences from the prostate cancer cell lines were compared, against the LNCAP cell line. (b) 
Immunohistochemistry staining (in brown), was used to measure relative protein expression 
of known markers of prostate cancer progression: prostate-specific antigen (PSA, column 2), 
and prostate-specific membrane antigen (PSMA, column 3). Sections were also stained with 




5.2.1 Preparation of azidosugar-labelled proteins for mass spectrometry analysis. 
 
The LNCAP lineage of prostate cancer cell lines was incubated with precursors of sialic acid 
and N-acetylgalactosamine that had been labelled with an azide group (N-
azidoacetylmannosamine (Ac4ManNAz) and N-azidoacetylgalactosamine (Ac4GalNAz)), and 
which are incorporated biosynthetically into cell surface glycans. The membrane proteome 
was isolated, and the incorporated azide groups covalently ligated to alkyne-biotin using 
copper-catalysed chemistry. Proteins were enriched using streptavidin-coupled beads 
(Figure 5.2a) and resolved by 1D western blot. Specific capture of metabolically labelled 
proteins was confirmed using Streptavidin-800 fluorescence (Figure 5.2b). 
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Biotinylated proteins were detected in samples treated with Ac4ManNAz or Ac4GalNAz, 
confirming specific enrichment of azidosugar labelled proteins within the membrane 
proteome. The detection of proteins by silver stain, in samples treated with vehicle, 
indicated some non-specific binding of unlabelled proteins to the streptavidin beads, 
although this was minimal in comparison to the specific enrichment of proteins treated with 
the azidosugars (Figure 5.2b). We anticipated detecting more protein from cells treated with 
Ac4GalNAz, due to labelling of the core structure (serine/threonine-N-acetylgalactosamine) 
present in all O-glycosylated proteins. As expected, strong Streptavidin-800 fluorescence and 
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Figure 5.2: Work flow for the enrichment of azidosugar-labelled proteins using 
streptavidin-coupled magnetic beads. (a) Azidosugar-labelled proteins were enriched from 
35 μg of alkyne-biotin labelled extract, using streptavidin-coupled beads. Specific capture of 
azidosugar-labelled proteins was confirmed by western blot and Streptavidin-800 
fluorescence. (b) Representative western blots and silver stains are shown from the LNCAP 
C4-2B prostate cancer cell line. Elutions were conducted twice. Background controls were 
included to account for non-specific protein enrichment. Abbreviations: M = Ac4ManNAz 
treated, G = Ac4GalNAz treated. 
 
 
Next, azidosugar-labelled proteins were enriched using streptavidin-coupled beads, resolved 
by 2D gel electrophoresis in duplicate, and subjected to western blot analysis or silver 
staining (Figure 5.3a). Metabolically labelled proteins were visualised using Streptavidin-800 
fluorescence. Parallel 2D gels were silver stained. Protein spots on the silver stain which co-
registered with spots of Streptavidin-800 fluorescence on the western blot were picked, and 
processed for mass spectrometric analysis (Figure 5.3a, black arrowheads). Streptavidin-800 
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white arrow heads), which was attributed to the sensitivity of bioorthogonal chemistry and 
its ability to detect low abundance glycoproteins. Traditional mass spectrometry approaches 
require proteins to be visible by Coomassie or silver staining so that protein spots can be 
picked manually and analysed (Meleady 2011). Therefore, spots of Streptavidin-800 
fluorescence on western blot that could not be co-registered with silver-stained protein 
spots (Figure 5.3a, white arrowheads) were excluded from the analysis. 
 
To allow all azidosugar-labelled proteins to be identified, including low abundant proteins 
undetectable by standard protein stains (Figure 5.3a, white arrowheads), an alternative 
approach was adopted where enriched elutes were analysed directly using mass 
spectrometry. Leakage of streptavidin monomers from the beads was observed in the 
eluents (Figure 5.3b) as a result of the high heat and agitation needed to break the 
streptavidin-biotin binding and maximise elution of the azidosugar-alkyne-biotin labelled 
glycoproteins from the magnetic beads. Several attempts were made to minimise leakage of 
streptavidin from the beads such as reducing elution temperatures from 100° C to room 
temperature or using detergent-free buffers (data not shown). Gentler elution conditions 
resulted in negligible elution of the azidosugar-labelled proteins from the beads. Therefore, 
we used high heat and agitation to maximise elution of the azidosugar-labelled proteins 
from the magnetic beads, resolved the elutes by 1D gel electrophoresis (Figure 5.3c), and 
then cut the streptavidin bands from the silver-stained gels (Figure 5.3d, red box), excluding 
them from the analysis. The remaining lanes were segmented and tryptically digested, 
followed by protein identification using liquid chromatography-tandem mass spectrometry 
(LCMS) (Savaryn et. al. 2016; Glish and Vachet 2003). This approach was used to identify 
prognostic biomarkers from the prostate cancer membrane proteome using bioorthogonal 


































































     


























Figure 5.3: Preparation of azidosugar-labelled proteins for mass spectrometry analysis. 
Azidosugar labelled proteins were enriched from 35 μg of azidosugar-alkyne-biotin labelled 
extract using streptavidin-coupled beads and prepared for mass spectrometry using a variety 
of approaches. (a) Representative 2D western blot and silver stain of proteins from the 
LNCAP C4-2B cell line labelled with Ac4GalNAz. Regions, where streptavidin 800 fluorescence 
could be correlated with the silver stain (black arrowheads), were picked and identified by 
mass spectrometry. Silver-stained protein spots that co-registered with spots of Streptavidin-
800 fluorescence on the western blot were picked, and processed for mass spectrometry 
analysis (black arrowheads). Spots of Streptavidin-800 fluorescence on western blot that 
could not be co-registered with silver-stain protein spots were excluded from the analysis 
(white arrowheads). (b) Representative chromatograph of the streptavidin bead elute from 
the LNCAP C4-2 cell line labelled with Ac4ManNAz. The abundant peak caused by streptavidin 
monomers is highlighted (black arrowheads). (c) Elutes were resolved by 1D gel 
electrophoresis prior to mass spectrometric analysis. (d) Representative silver stain of a gel 
submitted for mass spectrometric analysis of a membrane protein extract from LNCAP C4-2B 
cells. Lanes were segmented into 10 pieces, and subjected to tryptic digestion, followed by 
protein identification by liquid chromatography-tandem mass spectrometry.  The strongly 
stained region due to streptavidin contamination was removed (red box). Abbreviations: M = 
Ac4ManNAz treated, G = Ac4GalNAz treated. 
 
 
5.2.2 Identification of azidosugar-labelled proteins using liquid chromatography-tandem 
mass spectrometry 
 
Spectra representing individual peptides generated from in-gel tryptic digestion (Figure 5.3c 
and d) were searched against databases of known primary peptide sequences using the 
Mascot software (http://www.matrixscience.com/search_intro.html, 2019), leading to the 
identification of 3555 unique proteins. Identified proteins were subsequently classified by 
their cellular location using gene ontology (GO) analysis (www.pantherdb.org) (Figure 5.4a). 
Of the designated membrane proteins, 67% were classified as plasma membrane proteins 
(Figure 5.4b), confirming specific azidosugar labelling and glycosylation-dependent 
enrichment of cell surface proteins. This was consistent with a previous study where 51% of 
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proteins identified from Ac4ManNAz treated human prostate cancer tissue slices, were 






Figure 5.4: Cellular distribution of proteins identified using mass spectrometry. Azidosugar 
labelled proteins were enriched from the LNCAP lineage of prostate cancer cell lines (LNCAP, 
LNCAP C4, LNCAP C4-2, and LNCAP C4-2B). Proteins identified with Mascot were classified by 




Using the Scaffold proteomic software, proteins were filtered by plasma membrane GO 
terms. For each of the filtered membrane proteins, the ratio of spectral counts identified 
from Ac4ManNAz- (AzM) (Figure 5.3d, lane 3) or Ac4GalNAz-treated (AzG) (Figure 5.3d, lane 
4) samples, and the untreated control samples (U) (Figure 5.3d, lane 2) were calculated. The 
distribution of Az/U ratios within each cell line was then represented as histograms to 
distinguish between Ac4ManNAz-specific (Figure 5.5a, i), Ac4GalNAz-specific (Figure 5.5a, ii) 
and non-specific streptavidin bead enrichment. Ac4ManNAz-labelled proteins (Figure 5.5b, i) 
or Ac4GalNAz-labelled proteins (Figure 5.5b, ii) with a relative abundance 4-fold and greater 
than the untreated control samples (Haun et. al. 2015; Spiciarich et. al. 2017), were selected 
for further analysis.  
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For each cell line, the frequency of proteins identified as having an AzM/U ratio (Figure 5.5c, 
i) or AzG/U ratio (Figure 5.5c, ii) of 4 and above was summarised. A general increase in the 
number of azidosugar-labelled proteins meeting the threshold correlated with an increase in 
the metastatic potential of the cell lines. This was consistent with previous data which has 
shown a correlation between an increase in metabolic labelling and metastatic potential 
using flow cytometric analysis (Chapter 3: Figure 3.2) and gel electrophoresis (Chapter 4: 
Figure 4.2-4.5). Furthermore, more azidosugar labelled proteins were detected in samples 
treated with Ac4GalNAz. This is due to the labelling of the core structure (serine/threonine-
N-acetylgalactosamine) present in all O-glycosylated proteins, as seen with 2D gel 
electrophoresis (Chapter 4: Figure 4.4). 
 
A subclass of fifteen proteins was created with an AzM/U ratio (Figure 5.5d, i) or AzG/U 
(Figure 5.5d, ii) ratio of 4 and above, in two or more of the prostate cancer cell lines. Of 
these proteins, five were labelled with both azidosugars (denoted with * in Figure 5.5d). 
These represent glycoproteins with sialic acid and N-acetylgalactosamine within their glycan 
structures, which are replaced metabolically with Ac4ManNAz and Ac4GalNAz respectively. It 
was reassuring to see that proteins known to be involved in cancer progression met these 
stringent shortlisting criteria, such as epidermal growth factor (Chang et. al. 2015) and 
lysosome-associated membrane protein 1 (Okato et al. 2016). Other proteins, currently 
being investigated as biomarkers for monitoring prostate cancer progression were also 
identified such as filamin B (Ravipaty et al., 2017). Interestingly, such proteins were enriched 
based on their overexpression in human prostate cancer tissue, as opposed to their 
differential glycosylation, which is the method adopted here. Four proteins in our list have 
not previously been implicated in prostate cancer: 45 kDa calcium-binding protein, serpin 
B12 (isoform 2), plasma membrane calcium-transporting ATPase 1 (isoform B), and Leucyl-
cystinyl aminopeptidase. Collectively, the data highlights the utility of bioorthogonal 
















































































































Figure 5.5: Identification of azidosugar-labelled proteins in prostate cancer cell lines. 
Azidosugar-labelled proteins were enriched from the LNCAP lineage of prostate cancer cell 
lines using streptavidin-coupled beads. For each protein identified by liquid chromatography-
tandem mass spectrometry, the ratio of spectral counts identified from N-
azidoacetylmannosamine- (Ac4ManNAz or AzM) or N-azidoacetylgalactosamine-labelled 
(Ac4GalNAz or AzG) samples, and the untreated control samples (U) were calculated. (a) 
Representative histogram illustrating the distribution of AzM/U (i) and AzG/U ratios (ii) from 
the highly metastatic LNCAP C4-2B prostate cancer cell line. (b) Ac4ManNAz-labelled proteins 
(i) and Ac4GalNAz-labelled proteins (ii) with an Az/U ratio of 4 and above were selected for 
further analysis. (c) For each cell line, the frequency of proteins identified as having an 
AzM/U ratio (i) or AzG/U ratio (ii) of 4 and above is summarised. (d) The characteristics of 
proteins identified as having an AzM/U ratio (i) or AzG/U (ii) ratio of 4 and above, in at least 
two of the prostate cancer cell lines, are summarised. *denotes dual labelled proteins with 
both AzM/U and AzG/U ratios of 4 and above. (Chen et. al. 2017; Li et. al. 2008; Berthois et. 
al. 2003); Okato et. al. 2016; Bauman et. al. 2015; Evans et. al. 1997; Wilson et. al. 2000; 
Chang et. al. 2015; Ravipaty et. al. 2017; Zalcberg et. al. 2000; Yasmin-Karim et. al. 2014). 
 
 
Next, the Az/U ratios from each of the shortlisted proteins (Figure 5.5) were compared 
across each of the LNCAP cell lines. We selected azidosugar-labelled proteins exhibiting a 
general increase in AzM/U ratio (Figure 5.6.a, i) or AzG/U ratio (Figure 5.6a, ii), which 
correlated with an increase in the metastatic potential of the cell lines. To confirm if 
increases in azidosugar labelling were due to increases in the overall expression of the 
proteins, we used a label-free approach based on spectral counts obtained from the whole 
membrane enriched proteome (Figure 5.3d, lane 1). Normalised spectral abundance factors 
(Zybailov et. al. 2006; Byrum et. al. 2013) were calculated to estimate the relative abundance 













Figure 5.6: Comparison of differential azidosugar-specific glycosylation and relative protein 
expression. Azidosugar-labelled proteins were identified using mass spectrometry. For each 
protein, the ratio of spectral counts identified from N-azidoacetylmannosamine- (Ac4ManNAz 
or AzM) or N-azidoacetylgalactosamine-labelled (Ac4GalNAz or AzG) samples, and the 
untreated control samples (U) were calculated. Proteins with an AzM/U ratio or AzG/U ratio 
of 4 and above in at least two of the prostate cancer cell lines, were compared across the 
LNCAP lineage of prostate cancer cell lines. (a) Proteins exhibiting a general increase in 
AzM/U ratio (i) or AzG/U ratio (ii), which correlated with an increase in the metastatic 
potential of the cell lines are summarised. (b) Normalised spectral abundance factors (NSAF) 
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membrane antigen were included for comparison with established markers of prostate 
cancer progression.  
 
 
Normalised Spectral Abundance Factors, showed, as expected, a relative increase in the 
expression of total PSA, but also an increase in Ac4ManNAz and Ac4GalNAz glycan labelling of 
PSA, which correlated with an increase in the metastatic potential (Figure 5.6). Glycoprofiling 
of PSA may reveal prognostic markers of disease aggressiveness, a concept already 
extensively reviewed in the literature (Tkac et. al. 2019; Llop et. al. 2016). More interesting 
was the case of basigin (Figure 5.7a) and 45 kDa calcium-binding protein (Figure 5.7b), which 
showed a general increase in Ac4ManNAz and Ac4GalNAz labelling, despite their total 
expression decreasing across the panel of cell lines. Decreased expression of basigin has 
been reported in prostate cancer in comparison to non-malignant prostate tissue and 
proposed as a predictor of progression and recurrence after prostatectomy (Bauman et. al. 
2015). The molecular weight of basigin ranges between 29 – 64 kDa, based on the extent of 
b1,6- branched polylactosamine at its three N-glycosylation sites (Tang et. al. 2004). Whilst 
the low and high molecular weight glycoforms of basigin are well documented in the 
literature, little is known about the prognostic value of differentially glycosylated basigin in 
prostate cancer (Figure 5.7a, i). The relative abundance of 45 kDa calcium-binding protein 
decreased across the panel of LNCAP cell lines, and was low in comparison to prostate-
specific antigen (Figure 5.7b, ii). This, once again, highlighted the sensitivity of bioorthogonal 






Figure 5.7: Differential glycosylation of basigin and 45 kDa calcium-binding protein. (a) A 
general increase in N-azidoacetylmannosamine (Ac4ManNAz) and N-
azidoacetylgalactosamine (Ac4GalNAz) labelling of basigin was observed (i) despite the 
expression of basigin decreasing across the panel of cell lines (ii). (b) A general increase in 
Ac4ManNAz and Ac4GalNAz labelling of 45 kDa calcium-binding protein was observed (i) 










lines (ii). Ratios and NSAF’s for prostate-specific antigen and prostate-specific membrane 
antigen are included for comparison with established markers of prostate cancer 
progression. The darker shades in the arrow’s greyscale represent an increase in the 
metastatic potential of the prostate cancer cell lines.  
 
 
5.2.3 Glycoprofiling of membrane bound and secreted basigin using lectin blotting  
 
Basigin was selected as a candidate of interest as it had a similar abundance to prostate-
specific antigen (Figure 5.7b), and was classified as a secreted protein (Figure 5.5d, ii). The 
expression of membrane-associated basigin in whole-cell lysates and secreted basigin in 
conditioned media was analysed in the panel of prostate and breast cancer cell lines in order 
to investigate whether it may have significance as a prognostic biomarker. 
 
Whole-cell lysates were obtained from prostate and breast cancer cell lines grown in 
complete media. In parallel, conditioned media was collected from cells grown in serum-
starved conditions for 24 hours. No significant reduction in cell viability was observed as a 
result of growing the prostate (Figure 5.8a, i) or breast (Figure 5.8a, ii) cells under serum-free 
conditions. To show concentrations of proteins in the conditioned media were a result of 
secretion and not cell death, expression of tubulin was analysed by western blot (Dowling 
and Clynes 2011) (Figure 5.8b). The low abundance of tubulin in the conditioned media, 
relative to the whole-cell lysate indicated intact cell membranes (Figure 5.8b, i and ii). 
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Figure 5.8: Preparation of whole-cell lysates and conditioned media from prostate and 
breast cell lines. (a) Viability of prostate (i) and breast (ii) cells grown in complete media and 
serum-free media was compared. (b) The abundance of tubulin in the whole-cell lysate and 
conditioned media prepared from the prostate (i) and breast (ii) cell lines were compared by 
western blot (10 μg protein loaded per lane). Equal loading was confirmed by total protein 
Coomassie stain. All data represent the average ± S.D. of two independent experiments, each 
with 3 replicates. p values represent significance assessed by one-way ANOVA. The darker 
shades in the arrow’s greyscale represent an increase in the metastatic potential of the panel 
of prostate and breast cell lines.  
 
 
Next, the relative expression of high-glycosylated (~40-60 kDa) and low-glycosylated (~32 
kDa) basigin (Huang et. al. 2013; Tang et. al. 2004) was analysed by western blot (Figure 
5.9a, i).  A greater level of basigin expression was observed in the prostate cancer cell lines 
compared to the breast cancer cell lines. Increased expression of basigin has been 
demonstrated in the progression from the non-tumourigenic MDA MB 453 cell line, 






































metastatic MDA MB 231 cell line (Kong et. al. 2014), although we could not clearly observe 
this in 30 μg of lysate prepared from the breast cancer cell lines used in this study. 
 
Decreased expression of basigin (Figure 5.9a, ii) across the panel of prostate cancer cell lines 
was observed in whole-cell lysates, validating the relative expression observed using liquid 
chromatography-mass spectrometry (Figure 5.7a, ii).  Minimal secreted basigin was detected 















Figure 5.9: Expression of basigin in conditioned media and whole-cell lysates from prostate 
cancer cell lines. (a) Relative expression of high-glycosylated and low-glycosylated basigin (i) 
in whole-cell lysates prepared from prostate and breast cancer cell lines analysed by western 
blot. A decrease in basigin expression (ii, Black arrow head) was observed, validating the 
decrease in normalised spectral abundance factors (NSAF) observed with mass spectrometry. 
Actin was used as a loading control. (b) Relative expression of basigin (i) in conditioned media 
prepared from prostate and breast cancer cell lines. Minimal secreted basigin was detected 
in the conditioned media (ii, Black arrow head). Equal loading was assessed by total protein 
Coomassie stain. (30 μg loaded per lane). 
 
 
Capturing aberrantly glycosylated basigin in patient liquids such as serum or urine, using the 
techniques adopted in this project (Chapter 1: Figure 1.24), would require biorthogonal 
labelling of live tissue by administering azidosugars directly to patients in vivo or conducting 
metabolic labelling of tissue biopsies ex vivo. Tissue explants from subcutaneous xenografts 
derived from the LNCAP C4-2B prostate cancer cell line, have been previously maintained on 
dental sponges (Centenera et. al. 2013), and metabolically labelled ex vivo, although cell 
death and loss of tissue architecture were observed (Kuo 2015, PhD thesis, unpublished). 
Spiciarich and colleagues successfully metabolically labelled prostate tissue slices derived 
ii. 
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from radical prostatectomy specimens, followed by identification of Ac4ManNAz labelled 
proteins using mass spectrometry (Spiciarich et. al. 2017). However, neither of these ex vivo 
bioorthogonal metabolic labelling techniques have been translated into clinical practice. 
Lectins provide an alternative approach to detecting changes in glycosylation. Therefore, we 
endeavoured to detect the differential glycosylation of basigin, observed with bioorthogonal 
metabolic labelling (Figure 5.7a), using lectins. This could provide the preliminary data 
needed to support the development of a clinical assay, which would use sialic acid 
recognising lectins such as Maackia Amurensis Lectin II and Elderberry bark lectin, or N-
acetylgalactosamine recognising lectins such as Vicia Villosa Lectin and Dolichos Biflorus 
Agglutinin, to capture aberrantly glycosylated basigin, similar to the aberrantly fucosylated 
alpha fetoprotein (AFP-LC3) capture assay developed by FUJIFILM Wako Diagnostics U.S.A 
(http://www.wakodiagnostics.com/afpl3test.html, 2019; Block et. al. 2005; Meany and Chan 
2011; Adamczyk et. al. 2012; Pinho and Reis 2015) (Chapter 1: Figure 1.16). 
 
Sialylated glycoproteins were detected with fluorescein-conjugated Elderberry bark lectin 
(EBL; also known as Sambucus nigra lectin) in whole-cell lysates obtained from the panel of 
prostate and breast cancer cell lines (Figure 5.10a, i). Few glycoproteins were detected with 
fluorescein-conjugated Maackia amurensis lectin I (MAL I), which recognises galactose, sialic 
acid at the 3 position of galactose, and lactose (Figure 5.10a, ii). Next, lectin blotting was 
used to detect a human recombinant glycosylated basigin standard using EBL and MAL I 











Figure 5.10 Detection of glycoproteins using a lectin blot. (a) Whole-cell lysates (30 μg/lane) 
prepared from the prostate and breast cancer cell lines were resolved by 1D western blot and 
probed with 5μg/ml or 10μg/ml of Elderberry bark lectin (EBL) to detect sialic acid (i) or 
Maackia amurensis lectin I (MAL I) to detect galactose, sialic acid at the 3 position of 
galactose, and lactose (ii). Equal loading was confirmed by total protein Coomassie stain and 
by using actin as a loading control (iii). (b) Glycosylated recombinant proteins (10μg) 
horseradish peroxidase (HRP), soybean trypsin inhibitor (STI) and human basigin (BSG) 
produced in Sf9, Baculovirus cells were resolved by 1D western blot and probed with 10μg/ml 





5.2.4 Immunoprecipitation of PSA 
 
Next, we endeavoured to immunoprecipitate basigin from whole-cell lysates prepared from 
our panel of cell lines for lectin blot analysis (Figure 5.7a). We selected PSA to optimise 
immunoprecipitation protocols due to the availability of optimised antibodies and lectin 
glycoprofiling studies (Tkac et. al. 2019). We could not detect PSA using an anti-PSA antibody 
(Abcam) (Figure 5.11a) or biotin-conjugated anti-PSA antibody (Abcam) (Figure 5.11b) in 
whole-cell lysates prepared from the prostate cancer cell lines. Non-specific bands were 
detected in lysates prepared from the prostate cell lines and a selection of breast cancer cell 
lines, which do not express PSA (Figure 5.11b, white arrowheads). The expression of PSA in 
prostate cancer cell lines has previously been confirmed by immunohistochemistry (Chapter 
2; Figure 2.3d), and extensively documented in the literature (Chapter 1: Table 2.1a). 
Therefore, the negative immunoblots were attributed to low immunoreactivity of the 
antibodies. 
 
We used the direct immunoadsorption approach (Peter et. al. 1999) to pull down PSA from 
whole-cell lysates obtained from the LNCAP and LNCAP C4-2B prostate cancer cell lines, 
which express PSA, and the PC3 prostate cancer cell line, which does not express PSA (Figure 
5.1b). Generally, streptavidin magnetic beads were blocked with an anti-PSA-biotin antibody 
(Abcam), followed by addition of the whole-cell lysates for immunocapture of PSA. Captured 
PSA was eluted by incubation in 2% SDS and 1x LDS loading buffer (NuPAGE) for 2 hours at 
room temperature. Elutes were resolved by 1D western blot followed by detection of PSA 
using an anti-PSA primary antibody (Abcam). Two faint bands were observed on the anti-PSA 
blot following immunoprecipitation, which corresponded to the denatured heavy (50 kDa) 
and light (25 kDa) chains of the biotinylated anti-PSA antibody (Lal et. al. 2005) (Figure 5.11c, 
black arrowheads). This is a common problem with immunoprecipitation protocols and 
would mask visualisation of immunoprecipitated basigin in future experiments, as its most 











Figure 5.11: Western blot analysis of PSA. (a) Detection of PSA in whole-cell lysates prepared 
from the prostate and breast cancer cell lines using an Abcam antibody. (b) Detection of PSA 
in whole-cell lysates prepared from the prostate and breast cancer cell lines using an Abcam 
biotin-conjugated antibody, which was detected using streptavidin-800 fluorescence. Bands 
of non-specific streptavidin-800 fluorescence were observed (white arrowheads). (c) Whole-
cell lysates prepared from the LNCAP, LNCAP C4-2B, and PC3 prostate cancer cell lines were 
immunoprecipitated using an Abcam biotin-conjugated anti-PSA antibody and streptavidin-
coupled beads. Precipitates were resolved by gel electrophoresis and analysed by anti-PSA 
immunoblot. Denatured heavy (50 kDa) and light (25 kDa) chains of the biotinylated anti-PSA 
antibody were observed (black arrowheads). (30 μg/lane).  
 
 
We faced challenges obtaining suitable anti-PSA antibodies to optimise the 
immunoprecipitation protocol. The anti-PSA antibody has now been shown to have variable 
efficiency in LNCAP cell line lysates (https://www.abcam.com/prostate-specific-antigen-




ab182031.html, 2019). Therefore, we were unable to conduct immunoprecipitation of 
basigin with an optimised protocol to conduct lectin based glycoprofiling within the 





Previously, we assessed the complex changes in glycoprotein populations and azidosugar 
incorporation in membrane enriched extracts from prostate cancer cell lines using 1D and 
2D-gel electrophoresis (Chapter 4). Using 1D gel electrophoresis analysis, an increase in the 
sialyation (Ac4ManNAz) and N-acetylgalactosamine glycosylation of proteins correlated with 
an increase in the metastatic potential of panels of prostate (Chapter 4: Figure 4.2b, i and c, 
i), breast (Chapter 4: Figure 4.3b, i and c, i) and pancreatic (Chapter 4: Figure 4.4b) cancer 
cell lines. Using 2D gel electrophoresis analysis, eight spots exhibiting an increase in both 
Ac4ManNAz and Ac4GalNAz labelling were observed (Figure 4.6b and c, white arrowheads), 
despite the expression of proteins within the eight spots, appearing similar. This suggested 
that differential glycosylation may be a more sensitive and specific marker for monitoring 
cancer progression, than increases in total protein expression alone. In this study, we used 
mass spectrometry to identify differentially azidosugar labelled proteins across the LNCAP in 
vitro model of prostate cancer progression, which it was anticipated might lead to the 
discovery of new prognostic biomarkers.  
 
LNCAP cell lines (Chapter 2: Table 2.1a) were treated with Ac4ManNAz or Ac4GalNAz. 
Metabolically labelled cell-surface glycoproteins were extracted, covalently tagged with an 
alkyne-biotin bifunctional-biotin probe, and the resulting biotin-tagged azidosugar-labelled 
proteins enriched using streptavidin-coupled beads. Proteins were then identified using 
liquid chromatography-tandem mass spectrometry.  
 
We identified a subclass of fifteen differentially glycosylated proteins (Figure 5.5d). Within 
this subclass, we identified proteins known to be involved in cancer progression, such as 
epidermal growth factor (Chang et al. 2015) and lysosome-associated membrane protein 1 
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(Okato et al. 2016), and proteins currently being investigated as biomarkers for monitoring 
prostate cancer progression such as filamin B (Ravipaty et al. 2017). Most interesting was the 
identification of two proteins, basigin (CD147) and 45 kDa calcium-binding protein, which 
showed a general increase in Ac4ManNAz and Ac4GalNAz labelling, despite their total 
expression decreasing across the panel of prostate cancer cell lines (Figure 5.9). Decreased 
expression of basigin (Figure 5.9a, ii) across the panel of prostate cancer cell lines was 
observed in whole-cell lysates, validating the relative expression observed using liquid 
chromatography-mass spectrometry (Figure 5.7a, ii). 
 
Basigin is a transmembrane glycoprotein, which activates monocarboxylate transporters, 
facilities Plasmodium falciparum erythrocyte invasion during the pathogenesis of malaria, 
and induces the production of metalloproteases and vascular endothelial growth factor 
(VEGF) in cancer cells during tumour invasion (Muramatsu 2016). Decreased expression of 
membrane-bound basigin has been reported using immunohistochemistry (IHC) in prostate 
cancer tissues in comparison to non-malignant prostate tissue and proposed as a predictor 
of progression and recurrence after prostatectomy (Bauman et. al. 2015). Basigin has been 
shown to be highly expressed in normal prostate tissue using IHC, with expression levels 
decreasing in prostatic intraepithelial neoplasia (PIN) lesions, reducing further in prostate 
cancer (Pértega-Gomes et. al. 2011). Furthermore, decreased expression of basigin has been 
strongly associated with ERG (ETS (erythroblast transformation-specific)-related gene) 
positive prostate cancer (Grupp et. al. 2013), a subclassification characterised by the 
presence of the TMPRSS2 (transmembrane protease, serine 2) and ERG fusion gene, which 
are detected in approximately 50% of prostate cancers (Ayala et. al. 2015). In contrast, 
elevated basigin expression in prostate cancer tissue, in comparison to benign prostatic 
hyperplasia, has been observed and correlated with poor prognosis (Han et. al. 2009). Meta-
analyses and systematic reviews studying the association of basigin expression with prostate 
cancer have confirmed the conflicting results in the literature, reporting both increases and 
decreases in basigin expression (Peng et. al. 2016). However, little is known about the 
prognostic value of differentially glycosylated basigin in prostate cancer. Similarly, neither 
the glycosylation or total expression of 45 kDa calcium-binding protein has been implicated 
in prostate cancer.  
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Bioorthogonal azide-based chemical reporters have been combined with mass spectrometry 
analysis to capture and identify glycosylated proteins, which are overexpressed in small lung 
cell carcinoma tissue (Pan et. al. 2012), and prostate cancer tissue (Spiciarich et. al. 2017). In 
this study, we challenge the traditional approach to biomarker discovery, commonly based 
on identifying proteins that are overexpressed in cancer, instead, giving deliberate attention 
to proteins exhibiting an increase in glycosylation, despite showing a decrease in total 
protein expression across an in vitro model of prostate cancer progression. This was based 
on the observation of eight protein spots on 2D gel western blot, exhibiting an increase in 
both Ac4ManNAz and Ac4GalNAz labelling, which correlated with an increase in the 
metastatic potential of two prostate cancer cell lines, despite the total expression of 
proteins within the eight spots, appearing similar (Chapter 4: Figure 4.6b and c, white 
arrowheads). Overall, our data suggest that differential glycosylation may be a more 
sensitive and specific marker for monitoring cancer progression, than increases in total 
protein expression.  
 
 
5.4 Materials and Methods 
 
5.4.1 Cell lines 
 
The PNT1A, LNCAP, and LNCAP C4-2B human prostate cell lines were obtained from the 
Cancer Research UK Cambridge Institute Biorepository, based on stocks made available by 
Joe Kuo. The LNCAP C4, LNCAP C4-2, and PC3 human prostate cancer cell lines were 
purchased from ATCC. All prostate cell lines were cultured in RPMI with L-glutamine (Gibco®, 
InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories).  
 
The MDA MB 453, MCF-7, MDA-MB-468, and MDA MB 231 human breast cancer cell lines 
were obtained from the Cancer Research UK Cambridge Institute Biorepository, based on 
stocks made available by Joe Kuo. All breast cell lines were cultured in DMEM with L-
glutamine (Gibco®, InvitrogenTM) and 10% Foetal bovine serum (FBS Gold, PAA Laboratories). 
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Cell lines were genotyped and authenticated by Short Tandem Repeat (STR) DNA profiling 
and comparison with available databases from ATCC or DSMZ. All cell lines tested negative 
for Mycoplasma using the MycoProbe™ Kit (R&D Systems). 
 
 
5.4.2 Tissue culture 
 
Cell lines were maintained in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) in 5% CO2, 
in 37 °C humidified incubators, and cultured to 80% confluence. Briefly, cells were washed 
once with warm Phosphate Buffered Saline (PBS; 20 ml/flask; 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4 per litre, pH 7.4), and trypsinised. Prostate cancer cell lines were 
trypsinised for 4 minutes at 37oC, apart from the PC3 cell line, which was trypsinised for 7 
minutes. Breast cancer cell lines were trypsinsed for 7 minutes at 37oC. Trypsinised cells 
were added to equal volumes of media, centrifuged at 700 x g for 4 minutes (4oC), and 
resuspended in fresh media. Viable cell counts were obtained by Trypan blue dye exclusion 




5.4.3 Bioorthogonal metabolic labelling of cell lines in vitro for mass spectrometry 
 
N-azidoacetylmannosamine (Ac4ManNAz), N-azidoacetylgalactosamine (Ac4GalNAz) and 
TMDIBO-PEG3-biotin were synthesised by Henning Stöckmann, Department of Chemistry. 
 
LNCAP, LNCAP C4, LNCAP C4-2, and LNCAP C4-2B cell lines were seeded at 1.75 x 104 
cells/cm2 in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM) and maintained at 5% CO2, in 
37 °C humidified incubators for 3 days before metabolic labelling experiments. Flasks were 
then washed once with 20 ml warm Phosphate Buffered Saline (PBS; 8 g NaCl, 0.2 g KCl, 1.44 
g Na2HPO4, 0.24 g KH2PO4 per litre, pH 7.4), and cells trypsinised for 4 minutes at 37oC. 
Trypsinised cells were added to equal volumes of media, centrifuged at 700 x g for 4 minutes 
(4oC) and resuspended in fresh media. Viable cell counts were obtained by Trypan blue dye 
exclusion using a LUNA™ Automated Cell Counter (Logos Biosystems), and cells seeded at 3 x 
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104 cells/cm2 in NuncTM 175 cm2 flasks (Thermo Fisher ScientificTM). Plates were incubated in 
5 % CO2, 37 °C for 24 hours. After 24 hours, the media was replaced with fresh media only 
(0.1% DMSO, vehicle control) or fresh media supplemented with 50 μM Ac4ManNAz or 
Ac4GalNAz, using a surface:area volume ratio equivalent to a 6 well plate (52.5 ml). Cells 
were incubated in 5 % CO2 at 37 °C for 24 hours. After 24 hours, cells were harvested by 
trypsinisation and counted, as described previously. 
 
5 x 106 cells were transferred into Nostick® hydrophobic microcentrifuge tubes (Scientific 
Specialties, Inc.), washed twice in 2 ml ice-cold PBS, and fractionated using a Qproteome® 
Cell Compartment kit (Qiagen), according to the manufacturer’s protocol. Briefly, washed 
cells pellets incubated in 1 ml Extraction Buffer CE1 for 10 minutes at 4oC on an end-over-
end shaker (30 rpm). Lysates were centrifuged at 1000 x g for 10 minutes at 4oC. The 
supernatant, primarily containing cytosolic proteins, was transferred into a fresh Nostick® 
hydrophobic microcentrifuge tubes (Scientific Specialties, Inc.) and stored at -20oC. The 
remaining pellet was resuspended in 1 ml Extraction Buffer CE2 and incubated for 30 
minutes at 4oC on an end-over-end shaker (30 rpm). Lysates were centrifuged at 6000 x g for 
10 minutes at 4oC. The supernatant, primarily containing membrane proteins, was 
transferred into a fresh Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, 
Inc.). Samples were stored at -20oC. 
 
Four volumes of ice-cold acetone were added to the membrane protein-enriched fractions 
and incubated for 1 hour on ice. Precipitated proteins were pelleted by centrifugation at 12, 
000 x g for 10 minutes (4oC). The supernatant was discarded and the protein pellets air-dried 
for 15 minutes. Dried proteins pellets were resuspended in 100 μl Tris-HCL buffer (50mM, pH 
8, 0.5% SDS). Residual acetone was removed by the sequential addition of 600 μl methanol, 
150 μl chloroform, and 400 μl Milli-Q 18.2 Ω water, with vortexing. After centrifugation at 
18, 000 x g for 10 minutes (4oC), the upper aqueous phase was removed and the precipitated 
proteins washed twice with 450 μl methanol. The pellets were air-dried for a minimum of 15 
minutes and resuspended in 100 μl Tris-HCL buffer (50 mM, pH 8, 0.5% SDS). The total 




Up to 200 μg of metabolically labelled protein was chemoselectively reacted with alkyne-
biotin (Life Technologies) using the Click iT Protein Reaction Kit (Life Technologies), according 
to the manufacturer’s protocol. Residual reactants were removed by 
methanol/chloroform/Milli-Q 18.2 Ω water precipitation, as described previously. Protein 
pellets were dried for a minimum of 15 minutes, and resuspended in 200 μl Tris HCL buffer 
(50 mM, pH 8, 0.5% SDS) and sonicated for 30 seconds (3 cycles of 10 seconds ON and 5 
seconds OFF) using the Biorupter ® Plus (Diagenode). The total protein concentration was 
determined using the DC™ Protein Assay (BIO-RAD), using BSA as a standard. Samples were 
stored at -20oC.  
 
 
5.4.4 Enrichment of metabolically labelled glycoproteins using Streptavidin Mag Sepharose 
beads  
 
35 μg of metabolically labelled protein reacted with alkyne-biotin were incubated with 50 μl 
of Streptavidin Mag Sepharose beads (GE Healthcare), in binding buffer (Tris Buffered Saline 
(TBS), 50mM Tris-HCL, 150Mm NaCl, pH 7.5), for 2 hours at room temperature with end-
over-end mixing (30 rpm). Beads were washed with wash buffer (3x; TBS, 2M Urea, pH 7.5) 
and transferred to fresh Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, 
Inc.). Biotinylated proteins were eluted from the beads with 50 μl elution buffer (2% SDS) at 
100oC, for 10 minutes with agitation (1000 rpm). Based on Bradford protein quantification 
analysis (Bio-Rad) of eluted samples, the average amount of eluted proteins was between 
11-13 μg of protein.  
 
Elutions (50 μl) were loaded onto on precast 4-12% 1mm Bis-Tris gels (Thermo Fisher 
ScientificTM). Gels were resolved in 1x NuPAGE MOPS buffer (Invitrogen) (30 min 60 V, 120 
min 120 V) and silver stained (Pierce Kit). Silver stained gels were stored in acetic acid (5%) 






5.4.5 Sample preparation for LCMS/MS 
 
Each gel lane was cut into 10 bands and was transferred into a 96-well PCR plate. Bands 
were cut into 1 mm2 pieces, destained, reduced (DTT) and alkylated (iodoacetamide) and 
subjected to enzymatic digestion with sequencing grade trypsin (Promega, Madison, WI, 
USA) overnight at 37°C. After digestion, the supernatant was pipetted into a sample vial and 
loaded onto an autosampler for automated LC-MS/MS analysis. 
 
 
5.4.6 LC-MS/MS  
 
All LC-MS/MS experiments were performed using a Dionex Ultimate 3000 RSLC nanoUPLC 
(Thermo Fisher Scientific In, Waltham, MA, USA) system and a Q Exactive Orbitrap mass 
spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA). Separation of peptides was 
performed by reverse-phase chromatography at a flow rate of 300 nL/min and a Thermo 
Scientific reverse-phase nano Easy-spray column (Thermo Scientific PepMap C18, 2 μm 
particle size, 100A pore size, 75 μm i.d. x 50 cm length). Peptides were loaded onto a pre-
column (Thermo Scientific PepMap 100 C18, 5 μm particle size, 100A pore size, 300 μm i.d. x 
5mm length) from the Ultimate 3000 autosampler with 0.1% formic acid for 3 minutes at a 
flow rate of 10 μL/min. After this period, the column valve was switched to allow elution of 
peptides from the pre-column onto the analytical column. Solvent A was water + 0.1% 
formic acid and solvent B was 80% acetonitrile, 20% water + 0.1% formic acid. The linear 
gradient employed was 2-40% B in 30 minutes.  Further wash and equilibration steps gave a 
total run time of 60 minutes. 
 
The LC eluant was sprayed into the mass spectrometer using an Easy-Spray source (Thermo 
Fisher Scientific Inc.). All m/z values of eluting ions were measured in an Orbitrap mass 
analyzer, set at a resolution of 70000 and was scanned between m/z 380-1500. Data-
dependent scans (Top 20) were employed to automatically isolate and generate fragment 
ions by higher-energy collisional dissociation (HCD, NCE:25%) in the HCD collision cell and 
measurement of the resulting fragment ions was performed in the Orbitrap analyser, set at a 
resolution of 17500. Singly charged ions and ions with unassigned charge states were 
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5.4.7 Database searching 
 
Post-run, all MS/MS data were converted to mgf files and the files were then submitted to 
the Mascot search algorithm (Matrix Science, London UK, version 2.6.0) and searched 
against the UniProt human database (93609 sequences; 37041084 residues) and common 
contaminant sequences containing non-specific proteins such as keratins and trypsin (115 
sequences, 38274 residues). Variable modifications of oxidation (M) and deamidation (NQ) 
were applied as well as a fixed modification of carbamidomethyl (C). The peptide and 
fragment mass tolerances were set to 20 ppm and 0.1 Da, respectively. A significance 
threshold value of p<0.05 and a peptide cut-off score of 20 were also applied.  All data (DAT 
files) were then imported into the Scaffold program (Version_4.5.4, Proteome Software Inc, 




5.4.8 Quantitative analysis of protein levels 
 
A label-free approach based on spectral counts was used to estimate the relative abundance 




Figure 5.12: Calculation of Normalised Spectral Abundance Factor (NSAF). Normalised 
Spectral Abundance Factors (NSAFs) were calculated based on the notion that increases in 
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the abundance of a protein are reflected in increases in proteolytically released peptides. 
Abbreviations: Protein (k), spectral count (SpC), molecular weight (MW), number of proteins 
in the gel lane (N). (Liu et. al. 2004; Zybailov et. al. 2006; Byrum et. al. 2013). (Figure taken 
from Byrum et. al. 2013). 
 
 
The entire spectral count data set was shifted by +0.1, to enable analysis of proteins with 
zero spectral counts, and log-transformed. Normalised Spectral Abundance Factors (NSAFs) 
for each protein within a given lane were then calculated. For a given protein (k), the 
number of spectral counts (SpC) was divided by its molecular weight (MW) and divided again 
by the sum of SpC/MW for all proteins (N) within a given lane (Liu et. al. 2004; Zybailov et. al. 
2006; Byrum et. al. 2013). 
 
 
5.4.9 Preparation of whole-cell lysates and conditioned media 
 
Prostate and breast cancer cell lines were cultured in phenol red-free media and counted as 
described previously, seeded at 3 x 104 cells/cm2 in 100 mm cell culture dishes (15 ml 
media/dish) (Corning), and incubated in 5 % CO2, at 37 °C for 24 hours. After 24 hours, dishes 
were washed twice with warmed PBS and replaced with fresh phenol red-free, serum-free 
media (15 ml media /dish). 
 
After 24 hours, media from each dish was transferred in to 15 ml Falcon tubes and 
centrifuged at 1000 x g for 10 minutes to pellet cells from the conditioned media. The 
supernatants were transferred to Amicon Ultra-15 centrifugal filter tubes (Merck Millipore; 3 
kDa MWCO) and centrifuged at 3500 rpm for 30 minutes. Centrifugation was repeated, 
concentrating the supernatants to 200-250 μl volume. Concentrated conditioned media 
were transferred to fresh Nostick® hydrophobic microcentrifuge tubes (Scientific Specialties, 
Inc.). 
 
In parallel, the cells from which the conditioned media was obtained were harvested by 
trypsinisation and centrifugation, as described previously. Cell viability was measured by 
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Trypan blue dye exclusion using a LUNA™ Automated Cell Counter (Logos Biosystems). Cells 
were incubated with 1 ml RIPA buffer (Thermo Fisher ScientificTM) supplemented with 1x 
HaltTM Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher ScientificTM) and 1x 0.5 M 
EDTA solution (Thermo Fisher ScientificTM), for 30 minutes at 4oC on an end-over-end shaker 
(30 rpm). Lysates were centrifuged at maximum speed (21, 000 x g) for 20 minutes at 4oC 
and the supernatant transferred into a fresh Nostick® hydrophobic microcentrifuge tubes 
(Scientific Specialties, Inc.).  
 
The total protein concentrations were determined using the DC™ Protein Assay (BIO-RAD), 




5.4.10 Western blot  
 
Whole-cell lysates or conditioned media were resolved on precast 4-12% 1 mm Bis-Tris gels 
(Thermo Fisher ScientificTM) in 1x NuPAGE MOPS buffer (Invitrogen) (10 μg/lane, 30 min 60 
V, 120 min 120 V), and 1D gels transferred onto nitrocellulose membranes using an iBlot 2 
(Life). Blots were incubated in 1x Odyssey® PBS block buffer (LI-COR) for 1 hour, followed by 
an overnight incubation at 4oC with the following primary antibodies in PBS blocking buffer 
(0.1% tween, 0.1% SDS): rabbit polyclonal anti-basigin (1 μg/ml; Abcam), rabbit monoclonal 
anti-PSA (1:10,000; Abcam), mouse monoclonal biotin conjugated anti-PSA (1:5000; Abcam), 
rabbit monoclonal anti-vimentin (1:1000; Cell Signalling Technologies), rabbit monoclonal 
anti-b-tubulin (1:1000; Cell Signalling Technologies), and rabbit monoclonal anti-b-actin 
(1:1000; Cell Signalling Technologies)  
 
After overnight incubation, primary antibodies were removed, and the blots washed 3 times 
(PBS + Tween (0.1%), 5 minutes). Blots were incubated for 1 hour at room temperature with 
a goat anti-rabbit IRDye 680 RD secondary antibody (1:15, 000; LI-COR) in PBS blocking 
buffer (0.1% tween, 0.1% SDS). Blots treated with rabbit antibodies were washed 3 times in 
PBS (0.1% Tween) for 5 minutes, once in PBS for 5 minutes, and imaged on an Odyssey CLx 
Infrared Imaging System (LI-COR Biosciences). Blots treated with mouse monoclonal biotin 
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conjugated anti-PSA (1:5000; Abcam) were washed 3 times in PBS (0.1% Tween) for 5 
minutes, incubated in Streptavidin-800 (1:5000; LI-COR) for 15 minutes, washed 6 times in 
PBS (0.05% Tween) for 5 minutes, once in PBS for 5 minutes, and imaged on an Odyssey CLx 
Infrared Imaging System (LI-COR Biosciences). 
 
 
5.4.11 Lectin blotting 
 
Whole-cell lysates, recombinant glycosylated basigin produced in Sf9 Baculovirus cells 
(Prospec-Tany Technogene), horseradish peroxidase (HRP) (Pierce) and soybean trypsin 
inhibitor (STI) (Pierce), were resolved on precast 4-12% 1mm Bis-Tris gels (Thermo Fisher 
ScientificTM) in 1x NuPAGE MOPS buffer (Invitrogen) (5-30 μg/lane, 30 min 60 V, 120 min 120 
V), and 1D gels transferred onto nitrocellulose membranes using an iBlot 2 (Life). 
Membranes were blocked in 3% Bovine Serum Albumin (BSA) (Sigma) in PBST (0.05% Tween) 
overnight at 4oC. After overnight incubation, the BSA block buffer was removed, and the 
blots washed 3 times (PBS + Tween (0.05%) for 10 minutes). Blots were incubated for 30 
minutes at room temperature with 5 or 10 μg/ml of fluorescein labelled Elderberry Bark 
Lectin (EBL; Vector Labs) or fluorescein labelled maackia amurensis lectin I (MAL I; Vector 
Labs). Blots were washed 6 times (PBS + Tween (0.05%), 5 minutes), and once in PBS for 5 
minutes.  Cy2 fluorescence (489 nm maximum excitation wavelength, 506 nm maximum 
emission wavelength) was imaged using a Typhoon scanner (GE Healthcare)  
 
 
5.4.12 Immunoprecipitation of PSA  
 
0.4 mg/ml of mouse monoclonal, biotin conjugated, anti-PSA antibody (Abcam) was 
incubated with 50 μl of Streptavidin Mag Sepharose beads (GE Healthcare), in binding buffer 
(Tris Buffered Saline (TBS), 50mM Tris-HCL, 150Mm NaCl, pH 7.5), for 30 minutes at room 
temperature with end-over-end mixing (30 rpm). Beads were washed with wash buffer (3x; 
TBS, 2M Urea, pH 7.5) and incubated with 35 μg of unlabelled membrane-enriched protein 
lysates diluted in binding buffer, for 2 hours at room temperature. Captured proteins were 
eluted by incubation in 2% SDS and 1x LDS loading buffer (NuPAGE) for 2 hours at room 
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temperature. Elutions were resolved on precast 4-12% 1mm Bis-Tris gels (Thermo Fisher 
ScientificTM)) in 1x NuPAGE MOPS buffer (Invitrogen) (30 min 60 V, 120 min 120 V), and 1D 
gels transferred onto nitrocellulose membranes using an iBlot 2 (Life). Blots were incubated 
in 1x Odyssey® PBS block buffer (LI-COR) for 1 hour, followed by an overnight incubation at 
4oC with a rabbit monoclonal anti-PSA antibody (1:10,000; Abcam) in PBS blocking buffer 
(0.1% tween, 0.1% SDS). 
 
After overnight incubation, the primary antibody was removed, and the blots washed 3 
times (PBS + Tween (0.1%), 5 minutes). Blots were incubated for 1 hour at room 
temperature with a goat anti-rabbit IRDye 680 RD secondary antibody (1:15, 000; LI-COR) in 
PBS blocking buffer (0.1% tween, 0.1% SDS). Blots were washed 3 times in PBS (0.1% Tween) 
for 5 minutes, once in PBS for 5 minutes, and imaged on an Odyssey CLx Infrared Imaging 
System (LI-COR Biosciences). 
 
 
5.4.13 Statistical analysis  
 















Chapter 6: Conclusion 
 
 
The link between aberrant glycosylation and cancer progression has formed the basis for the 
detection of cell surface glycans and glycoproteins in the clinical management of cancer. 
However, the utility of biomarkers, such as PSA for prostate cancer, and MUC1 for breast 
cancer, have been challenged in recent years due to low cancer specificity and high false-
positive rates. The aim of this study was to use synthetic analogues of monosaccharides, 
called azidosugars, to monitor dynamic changes in cell surface glycosylation in models of 
prostate, breast and pancreatic cancer progression, in order to identify novel biomarkers. 
 
We combined bioorthogonal azide-based chemical reporters with mass spectrometry 
analysis to capture and identify differentially glycosylated proteins. Our studies led to the 
identification of basigin (CD147), a transmembrane glycoprotein, which showed a strong 
increase in sialyation and N-acetylgalactosamine glycosylation, despite its total expression 
decreasing across a panel of prostate cancer cell lines with increasing metastatic potential. 
Based on total protein expression alone, basigin, which would become less abundant during 
cancer progression and consequently more difficult to detect in aggressive disease, 
appeared to have no clinical value. But in the context of elevated glycosylation, our data 
suggest that differential glycosylation may be a more sensitive and specific marker for 
monitoring prostate and breast cancer progression, than increases in total protein 
expression alone. Differentially glycosylated basigin may be a prognostic marker of prostate 
cancer progression. 
 
The power of aberrant glycosylation in improving biomarker specificity has already been 
observed in prostate and liver cancers. Immunoprecipitation of differentially N-glycosylated 
and sialylated PSA subforms from urine or tissue has been shown to distinguish patients with 
prostate cancer from those with benign prostate hyperplasia and to improve the cancer 
specificity of the PSA test (Sarrats et. al. 2010; Pihikova et. al. 2016; Tabarés et. al. 2007; Jia 
et. al. 2017; Li et. al. 2015; Hsiao et. al. 2016; Meany et. al. 2009; Saldova et. al. 2011). In 
2006, the FDA approved the use of alpha fetoprotein (AFP)-L3 for detecting hepatocellular 
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carcinoma. AFP-L3 is an aberrantly fucosylated version of AFP, generated by the 
overexpression of fucosyltransferase FUT 8 (Meany and Chan 2011). AFP-L3 levels are 
significantly elevated in hepatocellular carcinoma patients in comparison to benign liver 
diseases such as cirrhosis, providing a marker for the onset of hepatocellular carcinoma 
(Block et. al. 2005; Meany and Chan 2011; Adamczyk et. al. 2012; Pinho and Reis 2015). 
 
Capturing aberrantly glycosylated basigin in liquid patient samples, such as serum or urine, 
using the techniques adopted in this project, would require biorthogonal labelling of live 
tissue by administering azidosugars directly to patients in vivo or conducting metabolic 
labelling of tissue biopsies ex vivo. We believe that translating bioorthogonal labelling 
techniques to a clinical setting will pose some challenges, requiring extensive clinical trials, 
azidosugar dose optimisation, safety studies, and ethical approval. Lectins provide an 
alternative approach to detecting changes in glycosylation. Their binding specificities are 
well characterised, they are abundant in nature, inexpensive, stable under a range of 
experimental conditions, and bind a variety of human tissues (van Kooyk 2008; Bird-
Lieberman et. al. 2012). Lectins have been used to detect differential sialyation of PSA 
(Meany et. al. 2009) and increased glycosylation of basigin across the stages of 
hepatocellular carcinoma using Phaseolus vulgaris leucoagglutinin lectin, which recognises 
galactose and complex β1,6-branched N-glycans (Cui et. al. 2018; Huang et. al. 2013). Lectin-
based fluorescence imaging has also revealed a link between glycosylation and cancer 
progression within mucosal surfaces (Bird-Lieberman et. al. 2012; Kuo et. al. 2016) (Chapter 
1: Figure 1.17, Figure 1.19 and Figure 1.23).  
 
We were unable to use glycan-binding lectins to confirm differential glycosylation of basigin, 
within the timeframe of this project. Therefore, future experiments would involve 
immunoprecipitating basigin from whole-cell lysates prepared from our panel of prostate 
cancer cell lines to confirm differential glycosylation using lectin blot analysis. This could 
provide the preliminary data needed to support the development of a clinical assay, similar 
to the AFP-LC3 capture assay developed by FUJIFILM Wako Diagnostics U.S.A, which uses the 
Lens culinaris agglutinin (LCA) lectin to capture aberrantly fucosylated AFP-L3 
(http://www.wakodiagnostics.com/afpl3test.html, 2019; Block et. al. 2005; Meany and Chan 
2011; Adamczyk et. al. 2012; Pinho and Reis 2015) (Chapter 1: Figure 1.16). Glycosylated 
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basigin has been observed in prostate, breast (Kong et. al. 2014), liver (Cui et. al. 2018; 
Huang et. al. 2013) and pancreatic cancers (Haun et. al. 2015). Therefore, aberrantly 
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